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ABSTRACT 
 
Primary Epstein-Barr virus (EBV) infection causes infectious mononucleosis (IM) in 50% of 
infected adolescents and young adults. It has long been known that IM is associated with 
the aberrant expansion of EBV-specific CD8+ T cells and can cause rare but serious 
complications, including airway obstruction, splenic rupture, and haemolytic anaemia. IM is 
also associated with an increased incidence of EBV-associated Hodgkin’s Lymphoma and 
autoimmune diseases like multiple sclerosis. Despite significant research, it is not clear 
why some individuals are more likely than others to develop clinical symptoms. In seeking 
an explanation, we studied immune control during the early stages of EBV infection, before 
cell-mediated immune responses come into play. We hypothesized that there is a defect in 
immune control during the early stages of EBV infection.  EBV infection induces a strong 
humoral immune response and the antibodies produced against EBV are used as 
diagnostic markers in the detection of EBV infection. While considerable knowledge has 
been accumulated on T cell response during acute IM, we have little understanding of 
virus-specific B cell immunity during primary EBV infection. Cross-sectional and 
longitudinal analyses of humoral immune responses in this project revealed that patients 
with acute IM have a severe deficiency of anti-EBV neutralizing antibodies, which was 
associated with a lack of gp350-specific B cell responses and a significant reduction in 
total memory B cells in peripheral blood. Furthermore, these patients also showed 
dysregulation of tumour necrosis factor (TNF)-family members BAFF and APRIL and 
increased expression of FAS on circulating B cells.  This impairment of anti-viral B cell 
responses was coincident with a dramatic loss of circulating myeloid and plasmacytoid DC 
numbers during acute IM, which recovered to baseline following convalescence. The loss 
of plasmacytoid dendritic cells was found to be much greater than that of myeloid DCs, 
with slower recovery upon disease resolution.  This is consistent with earlier published 
findings of an absence of IFN-αin the plasma of IM patients, since plasmacytoid dendritic 
cells are the main producers of IFN-α A number of possible causes for the loss of blood 
DCs were also explored in this project. Finally, using in vitro studies, we demonstrated that 
the loss of circulating DCs is intrinsically linked to the impaired activation and maturation of 
antibody-secreting B cells. These observations delineate new mechanistic insight into 
immune dysregulation during acute IM and its impact on anti-viral B cell responses that will 
help us to design better therapeutic/prophylactic strategies to prevent acute IM symptoms. 
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CHAPTER 1. INTRODUCTION 
1.1. EPSTEIN-BARR VIRUS – GENERAL INTRODUCTION 
Herpesviruses are large DNA viruses with 100—200 kb genome size. There are at 
least 25 viruses in the herpesviridae family, of which eight are known to infect humans and 
establish life-long persistence in their hosts (Murphy 1995). However, while an estimated 
90% of humans carry multiple types of herpesvirus from childhood, not everyone shows 
signs of infection. Herpesviruses are notorious for the many mechanisms they employ to 
evade the immune system (Hill, Jugovic et al. 1995, Ahn, Angulo et al. 1996, Abendroth, 
Slobedman et al. 2000). The virus may remain latent for long periods of time, causing 
infection only occasionally. Infection is usually mild in immunocompetent individuals, but 
can be severe in individuals whose immune systems are compromised (Babcock, Decker 
et al. 1999). 
Herpesviridae are divided into three families—alpha, beta and gamma (Roizman, 
Carmichael et al. 1981). Alpha herpesviruses are neurotropic viruses. They include herpes 
simplex virus types I and II (HSV-I and HSV-II) and varicella-zoster virus. Beta 
herpesviruses include human herpesvirus types 6 and 7 (HHV-6 and HHV-7) and 
cytomegalovirus, which has the largest genome among herpesviruses. The gamma 
herpesvirus family is lymphotropic and includes Epstein-Barr virus (EBV), also called 
human herpes virus 4 (HHV4), and Kaposi’s sarcoma-associated herpesvirus (KSHV or 
HHV8). These, in turn, are divided into lymphocryptovirus and rhadinoviruses. EBV is a 
member of the lymphocryptovirus family.  
Denis Burkitt, a surgeon working in Africa in the 1950s, was instrumental in the 
discovery of EBV. He studied a cancer of the jaw that affects children in East Africa 
(Burkitt 1958), which subsequently came to be named Burkitt’s lymphoma (BL). EBV was 
isolated and documented in 1964 by Anthony Epstein and colleagues using cell lines 
derived from BL (Epstein, Achong et al. 1964). EBV was the first identified case of a 
human tumour virus (de-Thé, Geser et al. 1978). Subsequently, EBV has been associated 
with a number of human non-malignant and malignant diseases of both lymphoid and 
epithelial origin (Epstein, Achong et al. 1964, Wolf, zur Hausen et al. 1973, Rickinson, 
Jarvis et al. 1975, Weiss, Movahed et al. 1989).  
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1.2. GENOME STRUCTURE 
Like all herpesviruses, EBV is an enveloped icosahedral virus. It has a protein core 
with double stranded DNA surrounded by a nucleocapsid with 162 capsomers, the protein 
tegument, and an outer envelope with glycoprotein spikes (Epstein, Barr et al. 1965). EBV 
was the first herpesvirus to be sequenced. The complete DNA sequence of the EBV B95-8 
strain was first published in 1984 (Baer, Bankier et al. 1984). A reference sequence for the 
wild type EBV genome was created using the sequence from two viral genomes, the B95-
8 and Raji strains of EBV (de Jesus, Smith et al. 2003). The genome is composed of linear 
double-stranded DNA of about 172kb. It includes highly repetitive terminal repeats, as well 
as internal repeats that divide the genome into short and long sequence domains. The 
genes are known according to their position on a BamH1 restriction endonuclease map of 
the genome (Cheung and Kieff 1982).  
Different strains of EBV have been identified, with variations at the DNA level 
(Bornkamm, Delius et al. 1980). The main strains of EBV are broadly classified under two 
distinct types, type I and type II, also known as type A and type B. They show sequence 
homology, except for changes in DNA sequence of mostly latent genes (Sample, Young et 
al. 1990). EBV type I is more common in Western societies and both types are found 
equally in the African population (Apolloni and Sculley 1994). A clinical study based on 
university students in the UK found that infection with type I strain of EBV is more likely to 
cause infectious mononucleosis (IM), a clinical manifestation of EBV primary infection 
(Crawford, Macsween et al. 2006). Multiple strains of EBV have also been detected in IM 
patients (Tierney, Edwards et al. 2006).  
1.3. LIFE CYCLE 
EBV is usually transmitted orally, through saliva, and establishes infection within the 
oropharynx. Although early studies indicated that primary infection occurs in epithelial 
cells, more recent studies have suggested that circulating B cells in the oropharynx, and 
not epithelial cells, are the primary site of infection (Allday and Crawford 1988, Niedobitek, 
Agathanggelou et al. 1997). Absence of EBV infection in B cell-deficient patients, as well 
as the requirement that B cells be in co-culture with epithelial cells in order for efficient 
infection of epithelial cells in vitro, proves that EBV has a clear preference for B-
lymphocytes (Gratama, Oosterveer et al. 1988, Faulkner, Burrows et al. 1999, Faulkner, 
Krajewski et al. 2000). Preferential binding to B cells is mediated through the interaction of 
the major viral envelope glycoprotein gp350 with complement receptor CD21 on the B cell 
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surface (Fingeroth, Weis et al. 1984). Janz and colleagues showed that even though 
gp350 is not absolutely necessary for EBV infection, it is required for efficient EBV 
infection of B cells (Janz, Oezel et al. 2000). 
Although B cells remain the preferred site of EBV infection, the presence of 
replicating virus in epithelial cells suggests that epithelial cells, too, play an important role 
in EBV infection and transmission. Shannon-Lowe and colleagues showed that EBV is 
transferred from the surface of infected B cells to epithelial cells (Shannon-Lowe, Neuhierl 
et al. 2006, Shannon-Lowe and Rowe 2011). In this way, EBV can infect both the lymphoid 
and epithelial compartments simultaneously. 
There are two distinct stages in the EBV life cycle, the latent and lytic cycles. In B 
cells, infection is predominantly latent, whereas in oropharyngeal epithelial cells the 
infection is mostly lytic (Greenspan, Greenspan et al. 1985). Latency in epithelial cells is 
found in EBV-positive epithelial tumour cells (Raab-Traub, Hood et al. 1983, Brooks, Yao 
et al. 1992). In latent infection, only a limited number of genes are expressed that are 
required for maintenance, proliferation and survival. In the lytic cycle, viral DNA is 
replicated and mature virions are produced, which are then released to infect new cells 
(Wang and Hutt-Fletcher 1998, Laichalk and Thorley-Lawson 2005). 
1.3.1. Latent Cycle 
The EBV viral genome resides as an episome in EBV-infected B cells (Decker, 
Klaman et al. 1996). The episome, which is circularized EBV DNA, does not integrate into 
the host genome. In vitro generated EBV-transformed lymphoblastoid cell lines (LCLs) are 
similar to EBV-transformed B cells in vivo and proliferate indefinitely in cell culture (Pope, 
Horne et al. 1968). These LCLs are used to study EBV-encoded genes expressed during 
latent infection of B lymphocytes. EBV-immortalized B-lymphoblasts express nine virus-
encoded latent antigens, including six nuclear antigens (EBNA 1–6), three latent 
membrane proteins (LMP1, 2A and 2B), two non-coding RNAs (EBERs) (Lerner, Andrews 
et al. 1981, Hennessy, Fennewald et al. 1985, Dillner, Kallin et al. 1986, Longnecker and 
Kieff 1990) and non-translated viral miRNAs (Pfeffer, Sewer et al. 2005). Primary infection 
is followed by the expression of EBNA2 and EBNA5 (ENBA-LP). The other nuclear 
antigens, membrane proteins and RNAs are expressed soon afterwards (Alfieri, 
Birkenbach et al. 1991). 
Three types of latency are found in B cells in vivo (Qu and Rowe 1992, Tierney, 
Steven et al. 1994, Joseph, Babcock et al. 2000). Depending on the type of infected cells, 
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the virus uses different expression patterns for each latency programmes (Babcock, 
Hochberg et al. 2000):  
 Latency programme: This refers to either Latency 0, where the virus persists in 
circulating memory B cells with no viral gene expression, or Latency I, where transient 
expression of LMP2A, alone or together with the expression of EBNA1, is seen. The 
expression of these viral proteins is necessary for maintaining persistent infection of 
EBV in memory B cells. The latency programme in which EBNA1 is transcribed from 
the Qp promoter (Nonkwelo, Skinner et al. 1996) is found in EBV-positive BL (Rowe, 
Rowe et al. 1987, Chen, Zou et al. 1995, Bell, Groves et al. 2006). 
 Default or Latency II programme: EBNA1, along with latent membrane proteins LMP1 
and 2, is expressed from the Qp promoter. Latency II gene expression can be found in 
nasopharyngeal carcinoma (NPC), an epithelial carcinoma, and Hodgkin’s lymphoma 
(HL) (Fåhraeus, Fu et al. 1988, Brooks, Yao et al. 1992, Deacon, Pallesen et al. 1993).  
 Growth programme: Also known as the latency III and this expression pattern is seen 
in LCLs in vitro, latency III expresses all of the latent EBV genes. Expression is 
initiated from the Wp promoter following infection and later from the Cp promoter 
(Woisetschlaeger, Yandava et al. 1990, Shannon-Lowe, Adland et al. 2009). Latency 
III infection can be found in IM and post-transplant lymphoproliferative disorder 
(PTLD). 
1.3.2. Latent Gene Expression 
EBNA1 is a multifunctional DNA-binding viral protein, which binds to the latent origin 
of replication (oriP) on the viral episome (Yates, Warren et al. 1985). This allows EBNA1 to 
control replication of the viral DNA during cell division (Sample, Brooks et al. 1991, 
Nonkwelo, Skinner et al. 1996). EBNA1 is the only viral protein that is expressed in all 
three latency stages and continues to express when cells undergo lytic infection (Hsiao, 
Lin et al. 2006, Malik-Soni and Frappier 2012, Sivachandran, Wang et al. 2012, Pinzon-
Charry, Woodberry et al. 2013). It is required for the efficient growth transformation of 
primary B cells and for transactivation from the Cp viral promoter (Speck, Pfitzner et al. 
1986). EBNA1 ensures the maintenance of the EBV episome in order to establish latency 
(Rawlins, Milman et al. 1985). The absence of EBNA1 in an EBV mutant has been shown 
to result in integration of the complete viral genome into the host genome (Humme, 
Reisbach et al. 2003).  
EBNA2 is one of the first nuclear antigens to be expressed after B cells are infected, 
and it is essential for cellular transformation (Rooney, Howe et al. 1989, Alfieri, Birkenbach 
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et al. 1991). EBNA2 is a transcriptional activator of several viral genes, including LMP1 
and LMP2, as well as cellular genes CD23 and CD21 that are B cell antigens (Abbot, 
Rowe et al. 1990). EBNA2 differs more extensively between type1 and type 2 strains of 
EBV (Aitken, Sengupta et al. 1994, Cancian, Bosshard et al. 2011). EBNA5 is one of the 
first nuclear antigens expressed, along with EBNA2, following infection (Alfieri, Birkenbach 
et al. 1991). It enhances EBNA2-dependent transcription (Harada and Kieff 1997, Peng, 
Zhao et al. 2004). EBNA5 and EBNA2 transcripts are encoded from the same primary 
transcript, differing only in their second exon. The transcript also includes other EBNA 
proteins (Dillner, Kallin et al. 1986, Rogers, Woisetschlaeger et al. 1990). 
EBNA3A, 3B and 3C or 3, 4 and 6 are encoded by three adjacent genes and have 
similar genomic organization (Sample, Young et al. 1990). EBNA3A and 3C are found to 
be essential for virus-mediated growth transformation (Tomkinson, Robertson et al. 1993). 
They may also be involved in transcriptional regulation, checkpoint control, LCL 
proliferation, protein folding and cell cycle regulation (Robertson, Grossman et al. 1995, 
Krauer, Kienzle et al. 1996, Parker, Touitou et al. 2000, Anderton, Yee et al. 2008). 
LMP1 is essential for B cell transformation and it is involved in EBV-associated 
malignancies (Kaye, Izumi et al. 1993, Cader, Vockerodt et al. 2013). LMP1 prevents 
apoptosis by activating the NF-B pathway, which contributes to high-level expression of 
anti-apoptotic proteins like Bcl-2, Bcl-XL, Bfl-1 and Mcl-1 (Finke, Fritzen et al. 1992, Wang, 
Rowe et al. 1996, D'Souza, Edelstein et al. 2004). LMP1 is a homolog of CD40, which is a 
B cell-activating surface molecule (Gires, Zimber-Strobl et al. 1997, Rastelli, Hömig-Hölzel 
et al. 2008). Cells infected with EBV express LMP1 along with LMP2A, which can mimic B 
cell receptor (BCR) signalling, and together they provide the necessary survival signal for 
EBV-infected B cells to progress into the long-lived memory B cell population (Caldwell, 
Wilson et al. 1998, Uchida, Yasui et al. 1999).  
LMP2A and 2B are transcribed from the same strand by a bidirectional promoter 
(Laux, Perricaudet et al. 1988). LMP2A blocks BCR signalling by latently-infected B cells 
and induction of lytic EBV infection, thus promoting the survival of EBV-infected B cells. It 
also mimics the presence of BCR and provides signals for B cell survival (Caldwell, Wilson 
et al. 1998, Kilger, Kieser et al. 1998). LMP2A expression is consistently detected in EBV-
associated malignancies (Brooks, Yao et al. 1992, Busson, McCoy et al. 1992, Stewart, 
Dawson et al. 2004). The specific function of LMP2B is not known, but recent studies have 
reported that LMP2B can modulate the effect of both LMP1 and LMP2A (Rivailler, Quink et 
al. 1999, Rovedo and Longnecker 2007, Rechsteiner, Berger et al. 2008).  
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EBV encodes two non-coding RNAs—EBER1 and EBER2—which are abundantly 
expressed in latently-infected cells and constitute a reliable marker for the detection of 
EBV infection (Swaminathan, Tomkinson et al. 1991, Chang, Chen et al. 1992). EBERs 
are not expressed during lytic infection (Greifenegger, Jager et al. 1998).They have been 
shown to induce the production of IL-10, which stimulates B cell growth and suppresses 
cytotoxic T lymphocytes (CTLs) (Kitagawa, Goto et al. 2000). EBERs provide resistance to 
interferon-(IFN-)-induced apoptosis and are involved in the maintenance of 
oncogenesis in BL cells (Komano, Maruo et al. 1999, Ruf, Lackey et al. 2005). Conversely, 
EBER released from EBV-infected B cells also has been found to contribute to the 
immunopathology during EBV infection by activating immune response and inducing pro-
inflammatory cytokines (Iwakiri, Zhou et al. 2009). 
EBV encodes 44 mature microRNAs. They belong to two gene clusters, BHRF1 
(miR-BHRF1) and BART (miR-BART) (Dölken, Malterer et al. 2010). BHRF1 miRNA is 
expressed during latency III, and BART miRNA is expressed at low levels during latent 
and lytic infections (Pfeffer, Sewer et al. 2005, Amoroso, Fitzsimmons et al. 2011). Recent 
studies have shown that miRNAs are expressed at a higher level during the initial stages 
of infection, which suggests that miRNA is involved during initial infection by EBV (Seto, 
Moosmann et al. 2010). miRNAs inhibit apoptosis in newly-infected B cells and help 
maintain BL cells in the absence of other viral gene expression (Vereide, Seto et al. 2014). 
1.3.3. Lytic Cycle 
All types of latency can be activated into a productive lytic cycle by the expression 
of the BZLF1 gene, which acts as a switch between the lytic and latent cycles (Sinclair 
2006). During the lytic cycle, about 80 genes are expressed that support replication of viral 
DNA and synthesis of viral proteins (Pearson 1986). Lytic proteins are divided into 
immediate early (IE), early (E) and late antigens (L). The IE genes, encoding the BZLF1 
and BRLF1 proteins, are transcribed following infection, even when inhibitors of protein 
synthesis are present (Biggin, Bodescot et al. 1987, Amon, Binne et al. 2004). IE proteins 
are involved in transcriptional regulation, but they are not found in the mature virion. 
BZLF1 acts as a switch to activate the lytic cycle, while BRLF1 is involved in the 
expression of viral lytic genes (Feederle, Kost et al. 2000, Sinclair 2006). IE proteins also 
are involved in the control of early protein synthesis. IE proteins regulate the expression of 
E proteins BMLF1 and BMRF1, which may transactivate other E genes (Quinlivan, Holley-
Guthrie et al. 1993). The E proteins are involved in DNA replication and are divided into 
EA-R (restricted) and EA-D (diffused) (Henle, Henle et al. 1970). Late proteins are the 
 7 
 
virus’s structural components and required for the packaging of viral DNA. They are the 
viral capsid antigen (BNRF1) and the membrane antigen complex, the BLLF1(gp350), 
BALF4 (gp110), BXLF2 (gH), BKRF2 (gL), BZLF2 (gp42) and BDLF3 (gp150) (Hummel, 
Thorley-Lawson et al. 1984, Gong, Ooka et al. 1987, Heineman, Gong et al. 1988, 
Mackett, Conway et al. 1990, Nolan and Morgan 1995, Johannsen, Luftig et al. 2004). 
During the late stage, EBV episomes are replicated into linear concatemers which are then 
cleaved and packaged into infectious virions (Gong and Kieff 1990, Papworth, Van Dijk et 
al. 1997). 
1.4. EBV-ASSOCIATED DISEASES 
EBV is the causative agent of BL in Africa, NPC in China, and IM and HL in 
Western societies. It has also been linked to PTLD, oral hairy leukoplakia, X-linked 
lymphoproliferative syndrome, gastric carcinoma, NK/T cell lymphoma, some T cell 
lymphomas, and carcinoma of the salivary glands. 
1.4.1. Infectious Mononucleosis (IM) 
IM was given the name glandular fever in the late 1800s. It was renamed Infectious 
Mononucleosis in 1920 by Sprunt and Evans after they discovered the atypical 
lymphocytes that are associated with this disease (Sprunt and Evans 1920). The causative 
agent, EBV, was discovered in 1964 and the association between EBV and IM was first 
made in1968 by Gertrude and Werner Henle (Henle, Henle et al. 1968). 
Primary EBV infection often occurs within the first few years of life and stays 
asymptomatic. IM is the result of delayed infection by EBV. In adolescents, about 50% of 
those who contract EBV develop symptoms of IM (Pereira, Blake et al. 1969, Fleisher, 
Henle et al. 1979). The characteristic symptoms are fever, lymphadenopathy and 
pharyngitis. Additional symptoms include sore throat, headache, nausea, fatigue and 
abdominal pain (Straus, Cohen et al. 1993). Although seen most commonly in young 
adults, IM may sometimes manifest in children or older adults. In children, the symptoms 
are not distinguished from many other childhood diseases, while in older adults the 
symptoms are different from the typical disease (Horwitz, Henle et al. 1976, Kanegane, 
Kanegane et al. 1997, Chan, Chiang et al. 2003, Cheng, Chang et al. 2007). Older adults 
have prolonged fever and liver abnormalities without pharyngitis or lymphadenopathy 
(Auwaerter 1999). 
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The atypical lymphocytes commonly seen with IM are CD8+ T cells that are mostly 
directed against lytic EBV antigens. The vigorous immune response by T cells contributes 
to the symptoms of IM but at the same time is thought to be responsible for eliminating 
most EBV-infected cells (Hislop, Annels et al. 2002). Confirmation of the clinical symptoms 
of IM is carried out with serological testing, either for heterophile antibodies or specific 
EBV antibodies (Sumaya and Ench 1985). IM patients show high titres of IgM and IgG 
antibodies for viral capsid antigen (VCA) and EA. Antibodies for EBNA1 develop late after 
EBV infection and remain at a constant detectable titre for life. IgG for VCA also persists 
for life (Henle, Henle et al. 1974) . EBV is shed in oral secretions continually and at a high 
concentration for months after acute infection (Fafi-Kremer, Morand et al. 2005). However, 
the amount of virus shed is found to be unrelated to the severity of the illness (Balfour, 
Holman et al. 2005). A study of IM during convalescence and the establishment of 
persistent infection revealed that the majority of patients carry multiple strains of EBV 
(Tierney, Edwards et al. 2006) that were found in three distinct compartments – the oral 
cavity, the peripheral blood lymphocytes, and the cell-free fraction of blood plasma (Sitki-
Green, Edwards et al. 2004).  
Clinical Complications during IM  
Although complications during IM are not common among healthy individuals, some 
have been reported. Splenic hemorrhage or splenic rupture, commonly related to trauma, 
has been reported during the second week of infection (Smith and Custer 1946, Rutkow 
1978, Maki and Reich 1982). Tonsillar swelling, if substantial, may cause upper airway 
obstruction (Chan and Dawes 2001). Fulminant or fatal IM, hemolytic anemia and some 
neurologic conditions also have been reported (Jenson 2000, Cohen 2003). 
1.4.2. X-Linked Lymphoproliferative Disorder (XLP) 
XLP is a rare, inherited, immunodeficiency disease that affects young males 
(Sullivan, Byron et al. 1983, Grierson and Purtilo 1987). It is a fatal form of IM, in which the 
immune system is unable to control primary EBV infection, even while it is able to resolve 
other common viral infections like influenza. The defective gene is SH2D1A, which is an 
important regulator of T and NK cells (Sayos, Wu et al. 1998). This defect results in 
uncontrolled T cell activation and cytokine release in response to EBV infection, which 
leads to extensive organ damage throughout the body. More than 50% of XLP patients 
die, while the longevity of survivors is not known (Seemayer, Gross et al. 1995).  
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1.4.3. Oral Hairy Leukoplakia (OHL) 
OHL is a nonmalignant lesion of the tongue epithelium. It is an opportunistic 
infection found in immunocompromised AIDS patients (Lau, Middeldorp et al. 1993). This 
disease is an example in which the lytic cycle of EBV can be seen in the epithelial cells 
localized to the sides of the tongue (Greenspan, Greenspan et al. 1985).  
1.4.4. Burkitt’s Lymphoma (BL)  
Endemic BL is a cancer that affects children in equatorial Africa and New Guinea 
where there is high prevalence of malaria. This is usually a tumour in the jaw and shows 
evidence of EBV DNA. Patients have a high titre of EBV-specific antibodies (Geser, Lenoir 
et al. 1983). Sporadic BL is common in South America and North Africa and is mostly an 
abdominal tumour. The tumour cells show a very characteristic translocation between 
chromosomes 8 and 14 in Ig heavy chain locus and in some cases on chromosomes 2 or 
22 on Ig light chain locus. This brings the c-myc gene from its usual regulatory position to 
the constitutively expressed immunoglobulin (Ig) gene in B cells, which results in elevated 
expression of the oncogene c-myc (Bernheim, Berger et al. 1983, Li, Van Calcar et al. 
2003). 
1.4.5. Nasopharyngeal Carcinoma (NPC) 
NPC is a tumour of the epithelium and is found mostly in southern China and 
Southeast Asia and less commonly in Northern Africa (Pagano, Huang et al. 1975, 
Shanmugaratnam 1978). High titres of EBV-specific antibodies are found in the serum of 
NPC patients (Henle and Henle 1976). NPC tumour cells express latency II antigens 
EBNA1, LMP1 and LMP2 (Fåhraeus, Fu et al. 1988). It has been found that, besides EBV, 
genetic and environmental factors contribute to the development of NPC (Ho, Ng et al. 
1978, Armstrong, Armstrong et al. 1983).  
1.4.6. Hodgkin’s Lymphoma (HL) 
HL is most common in Western societies, where 40—50% of cases are positive for 
EBV (Jarrett, Gallagher et al. 1991). The tumour shows prevalence in the age group of 25 
to 30 (Gutensohn and Cole 1980). Studies have shown a three-fold to four-fold increase in 
likelihood for individuals with a history of IM to also develop HL (Hjalgrim, Askling et al. 
2000). HL and IM are characterized by the presence of mononuclear Hodgkin and 
multinuclear Reed-Sternberg (HRS) cells. In HL the latency II program is observed 
(Pallesen, Hamilton-Dutoit et al. 1991).  
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1.4.7. Post-Transplant Lymphoproliferative Disorder (PTLD) 
PTLD is a potentially fatal complication due to immunosuppression in transplant 
patients (Crawford, Thomas et al. 1980). Polyclonal B cell lymphomas arise in individuals 
with impaired T cell responses, resulting in uncontrolled proliferation of EBV-infected cells 
(Babcock, Decker et al. 1999). EBV seronegative transplant recipients, especially pediatric 
recipients, are more at risk of developing PTLD. Different manifestations of PTLD exist, 
depending on factors including type of transplant and age. Latency III or growth program is 
expressed during PTLD (Thomas, Hotchin et al. 1990).  
1.5. EBV INFECTION OF B CELLS 
Three patterns of latency are established after EBV infects B cells, based on the 
type of cells infected in vivo. It also results in the transformation of B cells into 
lymphoblasts in vitro (Babcock, Hochberg et al. 2000). EBV preferentially targets resting 
memory B cells for latency and persists as an episome, circular virus DNA in the nuclei of 
infected cells, thereby establishing lifelong persistence (Decker, Klaman et al. 1996, 
Thorley-Lawson and Gross 2004).  
Research on EBV infection and the mechanisms by which it activates B cells is 
essential for understanding the virus and its associated diseases. Most EBV infections are 
considered non-pathologic threats and they stay undetected by the host immune system 
(Babcock, Hochberg et al. 2000). After infection, EBV-infected cells follow the normal B 
cell development pathway. The virus activates the proliferation of newly-infected B cells by 
expressing the latency III program, enters the germinal centre (GC) using the more 
restricted latency II program, and persists in long-lived memory B cells by expressing the 
latency I program (Thorley-Lawson and Babcock 1999, Souza, Stollar et al. 2005). In 
some cases, EBV-infected GC B cells are found in the B cell lymphomas of HL, PTLD and 
BL (Küppers, Klein et al. 1999). 
GC B cells accumulate mutations during the process of somatic hypermutation 
(SHM) and Ig class switching (CSR), which are required for the formation of a B cell with 
high affinity BCR. The mutations are caused by genomic instability during double-stranded 
DNA break required for SHM and CSR (Pasqualucci, Migliazza et al. 1998). These non-
functional B cells are usually eliminated in the GC by apoptosis (Lam, Kühn et al. 1997). 
However, B cells carrying defective BCR in the malignant cells of HL, PTLD and BL are 
not eliminated (Kanzler, Hansmann et al. 1996). Lymphoma cells in most of these 
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malignancies are believed to be derived from these defective GC B cells that are rescued 
from apoptosis (Brauninger, Spieker et al. 2003, Timms, Bell et al. 2003). EBV infection 
has been found to be a likely event that rescues these pro-apoptotic B cells, since EBV-
positive cases of lymphoma show the accumulation of these GC B cells with harmful 
mutations (Bechtel, Kurth et al. 2005). Studies from different groups have shown that, in 
vitro, BCR-deficient GC B cells may be saved from apoptosis by EBV infection (Chaganti, 
Bell et al. 2005, Mancao, Altmann et al. 2005).  
EBV latent membrane proteins LMP1 and LMP2A, which can mimic CD40 and BCR 
respectively, are thought to be responsible for the rescue of defective B cells both in vivo 
and in vitro (Lalmanach-Girard, Chiles et al. 1993, Gires, Zimber-Strobl et al. 1997). Since 
these two proteins are expressed in the later stages of EBV infection, two additional viral 
proteins (BHRF1 and BALF1)—homologs of anti-apoptotic BCL-2—were found to be 
transiently expressed in newly-infected B cells (Altmann and Hammerschmidt 2005). Both 
LMP1 and LMP2A are expressed in EBV-positive HL and PTLD and could play a role in 
lymphomagenesis. Conversely, a characteristic feature of BL is the translocation of the 
proto-oncogene myc from its regulated position to the constitutively active immunoglobulin 
position in B cells. The translocation event is suspected to occur during the Ig class switch 
recombination, which is a destabilizing cellular event that occurs in GC B cells (Goossens, 
Klein et al. 1998).  
Analysis of EBV-infected cells from the tonsils of IM patients showed that EBV uses 
two different strategies to spread in the B cell compartment, namely direct infection of 
different subsets of B cells and clonal expansion of GC or memory B cells (Kurth, Spieker 
et al. 2000). During IM, around 1% of peripheral B cells can be infected by EBV (Klein, 
Svedmyr et al. 1976, Hochberg, Souza et al. 2004). The normal architecture of tonsillar 
tissue is disrupted by proliferating EBV-infected B cells and cytotoxic T cells (CTLs) that 
are responding to the virus (Anagnostopoulos, Hummel et al. 1995, Niedobitek, 
Agathanggelou et al. 1997). It has also been reported that during IM EBV-positive B cells 
undergo clonal expansion, without somatic hypermutation as in a normal GC (Kurth, 
Spieker et al. 2000). Thus, EBV-infected B cells located in GC do not follow a normal GC 
reaction to generate memory B cells during IM (Kurth, Hansmann et al. 2003). A study led 
by Siemer found that EBV infection of B cells causes dysregulation of surface marker 
expression required for the identity of different B cell subsets. Thus, EBV infection seems 
to influence various factors and process of B cell differentiation (Siemer, Kurth et al. 2008). 
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1.6. IMMUNE RESPONSE TO EBV 
The immune system’s response to EBV is usually successful in limiting the primary 
infection and controlling the lifelong latency state of the virus, which is why in most 
instances the infection is asymptomatic. That is, immune control of EBV results in a 
balance where host and virus coexist without disease in most carriers. Different branches 
of immune response coordinate to achieve control at different points in the life cycle of 
EBV. Host immune response is initiated by the innate immune system when it comes in 
contact with the virus. Innate immunity is primarily mediated by dendritic cells (DCs) and 
natural killer (NK) cells (Biron, Nguyen et al. 1999, Mocikat, Braumüller et al. 2003), with 
macrophages, neutrophils, NKT cells and γδ T cells also playing a role (De Paoli, Gennari 
et al. 1990, Martorelli, Muraro et al. 2012, Chung, Tsai et al. 2013). 
1.6.1. Innate Immune Response 
Dendritic cells are professional, antigen-presenting cells that are involved in the 
innate activation of NK cells and in the induction of the adaptive immune response 
(Lanzavecchia and Sallusto 2001, Ferlazzo, Pack et al. 2004). They accomplish this by 
cross-presenting EBV antigens, which results in the priming of CD8+ and CD4+ T cells 
(Bickham, Goodman et al. 2003). DCs are involved, directly and indirectly, in the 
development of the humoral immune response by presenting antigens, providing 
cytokines, and activating CD4+ T follicular helper cells (Wykes, Pombo et al. 1998, 
Litinskiy, Nardelli et al. 2002, Cucak, Yrlid et al. 2009). There are two main subsets of 
blood DCs, namely myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) (Romani, Gruner 
et al. 1994, Grouard, Rissoan et al. 1997). EBV can infect subsets of DCs and monocytes, 
and EBV infection prevents the conversion of monocytes to DCs (Li, Liu et al. 2002). It 
also has been reported that EBV infection induces IFN- production by pDCs in in vitro 
culture and in the humanized NOD-SCID mouse model (Lim, Kireta et al. 2007, Quan, 
Roman et al. 2010). Furthermore, depletion of pDCs promotes EBV infection and 
associated diseases in the humanized NOD-SCID mouse model, while enrichment of 
pDCs results in better control of EBV infection (Lim, Kireta et al. 2007).  
NK cells are able to reduce EBV transformation of B cells both in vitro and in vivo 
(Thorley-Lawson, Chess et al. 1977, Baiocchi, Ward et al. 2001). Studies have also 
reported a correlation between NK cell numbers, EBV viral load, and severity of symptoms 
during IM (Williams, McAulay et al. 2005, Balfour, Odumade et al. 2013). A defect in NK 
cell response during early EBV infection may contribute to the inability of individuals with 
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X-linked lymphoproliferative disease (XLP) to control EBV infection (Parolini, Bottino et al. 
2000). XLP patients also lack invariant NKT cells, which suggest that this subset of innate 
immune cells could have a role in the early control of EBV infection (Chung, Tsai et al. 
2013). 
Among other immune cells, while macrophages play a role in clearing the virus 
EBV-infected macrophages have reduced phagocytic ability (Lin and Li 2009). Neutrophils 
also provide innate immunity to EBV infection as there is an increase in blood neutrophils 
during initial infection and a transient neutropenia is observed in IM patients. The 
interaction between EBV and neutrophils produces an opposing influence, with EBV 
infection causing increased apoptosis of neutrophils while also causing enhanced antiviral 
activity like respiratory burst and production of cytokines (Savard and Gosselin 2006).The 
γδ T cell population expands during acute IM and remains elevated during convalescence, 
which suggests a function in the control of primary EBV infection (De Paoli, Gennari et al. 
1990). 
1.6.2. Cell-Mediated Immune Response  
The more common occurrence of EBV-associated diseases in T cell-
immunocompromised patients suggests that cell-mediated immune response is important 
for the control of EBV infection (Khanna, Bell et al. 1999). The first evidence of virus-
specific T cell memory was provided by in vitro assays, where B cell proliferation from 
seropositive individuals was found to regress after infection with the virus (Moss, Rickinson 
et al. 1978, Rickinson, Moss et al. 1979). This response was primarily mediated by EBV-
specific MHC class I restricted CD8+ T cells (Moss et al., 1979), although MHC class II 
restricted CD4+ T cells also are involved (Misko, Sculley et al. 1991).  
The cellular events following EBV infection can either be asymptomatic, with no 
evidence of major expansion of virus-specific T cells, or, in the case of IM, with massive T 
cell activation and expansion with cytotoxic effector functions. Interestingly, comparable 
high viral loads can be found in both types of infection (Silins, Sherritt et al. 2001). Both 
asymptomatic and acute primary infections are followed by persistent latent infection of 
memory B cells, which lasts for the lifetime of the host. If EBV-infected B cells receive the 
signal to differentiate into plasma cells, or experience another similar event, it may lead to 
reactivation of lytic EBV infection (Babcock, Decker et al. 1998, Laichalk and Thorley-
Lawson 2005). 
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Immune Responses during IM 
Clinical evidence from the study of IM patients, from the time of acute infection 
through recovery and carrier state, suggests a strong cell-mediated immune response, 
mainly involving CD8+ T cells (Callan, Tan et al. 1998). Most of what is known about CD8+ 
T cell response to EBV infection has been obtained from the study of IM patients. The 
atypical lymphocytes found in large numbers in the blood of IM patients consist mostly of 
EBV-specific CD8+ T cells (Tomkinson, Maziarz et al. 1989). This expanded population of 
CD8+ T lymphocytes has been found to be antigen-driven and mostly specific for EBV lytic 
antigens and to a lesser extent for EBV latent antigens (Steven, Annels et al. 1997). The 
acute phase of IM is followed by a sharp reduction in CD8+ T cell numbers during recovery 
(Callan, Fazou et al. 2000). 
Despite having a large number of lytic epitope-specific CD8+ T cells in the blood of 
IM patients, virus shedding from the oropharynx remains high for several months (Fafi-
Kremer, Morand et al. 2005). Comparative studies of blood and tonsil samples during 
acute IM, recovery and long-term carrier states have shown that there is poor recruitment 
of EBV-specific effectors in tonsils during acute IM (Hislop, Kuo et al. 2005). This was 
found to be due to the lack of homing markers on the effector cells during IM. Latent 
infection of the B cell pool is quickly controlled as latent epitope-specific CD8+ T cells 
acquire homing markers more rapidly than the lytic epitope-specific memory T cells. In the 
long-term carrier state, both latent and lytic antigen specific cells are enriched within the 
tonsillar CD8+ T cells and both forms of infection are tightly controlled. 
Immune Response by CD8+ T cells 
Memory CTL responses in long-term virus carriers are highly focused on select 
epitopes from EBV latent and lytic cycle antigens. During convalescence from acute 
infection, the number of CD8+ T cells contracts, and a fraction are selected as long-term 
memory T cells and are maintained thereafter for life (Dunne, Faint et al. 2002). These 
memory T cells show marked immunodominance, in which epitopes from a particular 
subset of latent or lytic antigens preferentially induce a strong response from CD8+ T cells, 
while other antigens are subdominant targets and recognized less efficiently (Hislop, 
Gudgeon et al. 2001). 
Among EBV-latent antigens, the EBNA3 subset of nuclear antigens displays a 
marked degree of immunodominance over other latent antigens (Khanna, Burrows et al. 
1992, Murray, Kurilla et al. 1992). This preference for EBNA3 proteins and their derived 
peptide epitopes was observed even during primary infection. CTL responses to other 
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latent antigens were less frequently detected (Khanna, Burrows et al. 1992). Among the 
epitopes that are presented during primary infection by CTLs, only a fraction is recognized 
by memory CTL. So the makeup of long-term memory CTLs differs greatly from that 
observed for CTLs following primary infection (Steven, Leese et al. 1996). The majority of 
the CTL population—that is produced during a primary response—is heavily culled during 
the establishment of memory (Catalina, Sullivan et al. 2001). This is particularly evident for 
CTL-recognizing lytic cycle epitopes that are more heavily culled, relative to CTL-specific, 
for latent cycle antigens (Hoshino, Morishima et al. 1999, Callan, Fazou et al. 2000). This 
likely reflects the critical role of CD8+ T cells specific for latent epitopes in limiting the 
expanding pool of latently infected B cells (Hislop, Annels et al. 2002). 
CD8+ T cells specific for epitopes from EBV IE and E lytic antigens have been 
detected in the blood of IM patients, and these responses, were shown to restricted 
through a variety of HLA-A, B and C (Steven, Annels et al. 1997). Using tetrameric HLA-
peptide complexes, it has been found that a majority of the peripheral blood CD8+ T cells 
targeting EBV can be specific for epitopes encoded by BZLF1 (Callan, Tan et al. 1998). 
While T cells specific for lytic cycle antigens contract during convalescence, they can be 
retained as long-lived memory T cells. Although T cells targeting lytic cycle antigens are 
less in number for most individuals, they can still dominate over responses to EBV latent 
antigens in some individuals (Tan, Gudgeon et al. 1999). CTLs from patients with acute IM 
also show reactivity to late EBV antigens, such as the viral structural antigens gp350 and 
gp85. These gp350 and gp85 specific memory CTLs are maintained at low levels following 
recovery (Khanna, Moss et al. 1999). In vitro assays of CD8+ T cell response to EBV lytic 
antigens show different levels of immunodominance, with IE the most abundant, followed 
by E and then late proteins, indicating that the efficiency of epitope presentation decreases 
with the advance of the lytic cycle (Pudney, Leese et al. 2005). These observations are 
indicative of the strong immunodominance of IE-derived epitopes and E proteins whose 
expression is directly activated by the IE proteins. 
Immune Response by CD4+ T cells 
Unlike CD8+ T cells, the CD4+ T cell pool remains relatively constant in the blood of 
IM patients (Maini, Gudgeon et al. 2000). The response to EBV by CD4+ T cells has been 
studied less than the response by CD8+ T cells. Even though the control of EBV infection 
is mainly managed by MHC class I restricted CD8+ T cells, MHC class II restricted CD4+ T 
cells have also been reported to play a role (Tomkinson, Maziarz et al. 1989, Precopio, 
Sullivan et al. 2003). A number of CD4+ T cell epitopes from the viral glycoprotein gp350 
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have been identified (Wallace, Wright et al. 1991). In addition, ex vivo studies have 
identified multiple EBNA and LMP derived MHC class II epitopes, which have much lower 
cognate T cell frequencies than MHC class I epitopes from the same antigens (Leen, Meij 
et al. 2001, Long, Haigh et al. 2005). CD4+ T cells specific for epitopes from IE, E and also 
several L lytic cycle proteins have been found in healthy carriers (Amyes, Hatton et al. 
2003, Woodberry, Suscovich et al. 2005). Recent studies by Long et al. found that in 
contrast to CD8+ T cells, CD4+ T cell responses to EBV lytic antigens are broadly 
distributed across IE, E and L protein targets (Long, Leese et al. 2011). Adhikary et al. 
have shown, using in vitro studies, that recognition of lytic structural protein by CD4+ T 
cells could result in the detection of newly infected B cells before viral latency is 
established (Adhikary, Behrends et al. 2006). Participation of CD4+ T cells during the early 
stages of EBV infection has also been reported by other studies (Nikiforow, Bottomly et al. 
2001). This suggests that such responses could probably control a recent B cell infection 
event in vivo.  
Using a dox-regulated expression system, in which antigen expression can be 
controlled, Mackay and colleagues looked at antigen presentation to CD4+ and CD8+ T 
cells. They found that newly synthesized antigens are readily presented by MHC class I 
and recognized by CD8+ T cells, while MHC class II presentation and recognition by CD4+ 
T cells was delayed (Mackay, Long et al. 2009). This suggests that CD8+ T cells are more 
effective during primary infection, while CD4+ T cells are important in controlling persistent 
infection. In this scenario, CD8+ and CD4+ T cells would work together to control EBV by 
targeting different stages of the EBV life cycle.  
1.6.3. Humoral Response to EBV Infection  
EBV infection causes a humoral immune response to a large number of virus-
encoded antigens. This response is prominent during the acute phase of IM, where the 
initial humoral response is directed towards lytic antigens EA-R, EA-D, and the VCA. At a 
later stage the response targets latent antigens such as EBNA1 (Henle, Henle et al. 1968). 
Primary infection is characterized by the presence of IgM and IgG antibodies specific for 
VCA and EA, detectable IgM and weak IgG against MA (Hewetson, Rocchi et al. 1973), 
and an absence of antibodies against EBNA1. EBNA1-specific antibodies are not detected 
until convalescence. The long-term virus carrier state leads to the persistence of IgG 
against VCA, MA and EBNA1 for life (Henle, Henle et al. 1970). 
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1.7. VACCINE DEVELOPMENT 
The idea for a vaccine against EBV, to reduce clinical symptoms of acute IM and 
control the more severe EBV-associated diseases, was first proposed by M.A. Epstein in 
1976 (Epstein 1976, North, Morgan et al. 1982). The many diseases and malignancies 
associated with EBV make the virus an important candidate for vaccine development. The 
EBV structural antigen gp350 was considered from the beginning as a potential target, 
based on the observation that this glycoprotein is the principal target for the virus-
neutralizing antibody response in vivo (Pearson, Dewey et al. 1970). Epitopes from gp350 
has also been shown to induce a CTL response (Khanna, Bell et al. 1999). Peptide 
epitopes from other lytic cycle antigens and latent antigens have also been investigated as 
candidates for an epitope-based vaccine. An HLA-B8 restricted epitope from EBNA3 has 
recently been used in a Phase I clinical trial. It was found to be well-tolerated and safe, 
and the vaccine recipients seroconverted asymptomatically without IM (Elliott, Suhrbier et 
al. 2008). One hurdle for peptide-based vaccines is the wide range of HLA types in 
different individuals. The construction of recombinant or synthetic polyepitopes linking 
minimum CTL epitopes in a continuous string has been shown to be highly effective in 
inducing a protective CTL response (Thomson, Khanna et al. 1995, Thomson, Elliott et al. 
1996) and offers one strategy for an epitope-based vaccine that provides broad HLA 
coverage. 
The EBV membrane protein gp350 is the best characterized vaccine target antigen 
from EBV. This protein has been used in pre-clinical vaccine trials in animal models and in 
clinical trials in humans. Vaccination with gp350 protected cottontop tamarins against 
lymphoma and in common marmoset, vaccination reduced the viral load when compared 
to the control (Morgan, Finerty et al. 1988, Mackett, Cox et al. 1996). The gp350 protein 
was found to be highly immunogenic when complexed with immune stimulating complexes 
(ISCOMS) or Adjuvant System 04 (AS04) from GlaxoSmithKline. Recombinant vaccinia 
virus-expressing gp350 has also been tested in common marmosets and in a human trial 
in China (Gu, Huang et al. 1995). Recent Phase I/II and Phase II studies using 
recombinant gp350 complexed with AS04 demonstrated optimal immunogenicity after 
three doses. All forms of gp350 were found to be safe and well tolerated. While no 
protection from primary EBV infection was detected, recombinant gp350 in AS04 was 
effective in reducing the symptoms of IM (Moutschen, Léonard et al. 2007, Sokal, 
Hoppenbrouwers et al. 2007).  
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1.8. IMMUNE EVASION 
Viruses have developed various strategies to avoid detection and elimination by the 
host’s immune system (Jackson, Nilsson et al. 1990, Gilbert, Riddell et al. 1993, York, 
Roop et al. 1994, Lorenzo, Jung et al. 2002). Herpesviruses use their ability to establish 
latency as a means to avoid detection. EBV achieves latency by regulating the expression 
of latent genes in B cells and activating virus replication in lymphoid and epithelial cells 
only occasionally. In order to accomplish this, the virus has developed mechanisms to 
interfere with different levels of immune clearance. Down-regulation of viral genes, 
inhibition of antigen processing and presentation and resistance to apoptosis are some of 
the mechanisms employed by EBV for immune evasion (Vossen, Westerhout et al. 2002, 
Ressing, van Leeuwen et al. 2003, Desbien, Kappler et al. 2009, Wycisk, Lin et al. 2011). 
The most obvious strategy used by EBV to escape detection is to limit the number 
and levels of viral proteins it expresses. EBV only expresses a few genes during latency. 
The EBV nuclear antigen, EBNA1, is present in all latent and lytic cycles and in EBV-
associated malignancies. EBNA1 can limit its own synthesis to prevent proteasomal 
degradation and antigen presentation. This is achieved by the glycine-alanine (GAr) repeat 
domain in its N-terminus (Levitskaya, Coram et al. 1995, Tellam, Sherritt et al. 2001, Yin, 
Manoury et al. 2003, Tellam, Smith et al. 2008). Further studies have shown that GAr 
mRNA forms a G-quadruplex structure that prevents EBNA1 synthesis and presentation of 
EBNA1 epitopes to CD8+ T cells (Murat, Zhong et al. 2014, Tellam, Zhong et al. 2014). 
EBV also interferes with antigen presentation by down-regulating peptide 
transporters (TAP) that are required for MHC class I presentation with BNLF2a protein 
(Croft, Shannon-Lowe et al. 2009, Horst, Favaloro et al. 2011). EBV-encoded BILF1 
protein functions by down-regulating cell surface expression of the MHC class I molecule. 
It does so by binding to the molecule, internalizing and degrading it using lysosomes (Zuo, 
Quinn et al. 2011). EBV-encoded BGLF5 is an exonuclease enzyme which inhibits cellular 
protein synthesis (Knopf and Weisshart 1990, Rowe, Glaunsinger et al. 2007), causing 
reduced cell surface expression of both MHC class I and class II molecules, which lowers 
recognition of antigens by EBV-specific CD8+ and CD4+ T cells (Rowe, Glaunsinger et al. 
2007, Zuo, Thomas et al. 2008, Croft, Shannon-Lowe et al. 2009, Horst, Favaloro et al. 
2011). 
Bim (Bcl-2 interacting mediator of cell death) regulates apoptosis during lymphocyte 
development and the level of Bim is a critical factor in B cell survival. EBV is found to 
repress the expression of Bim in EBV-infected B cells by down-regulation of Bim mRNA 
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levels (Paschos, Smith et al. 2009). EBV also encodes two viral Bcl-2 proteins, BHRF1 
and BALF1, which are anti-apoptotic proteins. These are expressed during the initial 
stages of infection and also during the lytic phase (Henderson, Huen et al. 1993, Boya, 
Pauleau et al. 2004).  
BZLF2 encodes a glycoprotein, gp42, which is required for initial penetration and 
infection of B cells (Nemerow, Houghten et al. 1989). The gp42 additionally functions as 
an immune-modulator by binding directly to the chain of MHC class II molecules and 
preventing T cell receptors from interacting with MHC class II/peptide complexes (Ressing, 
Keating et al. 2005). EBV BARF1 blocks colony-stimulating factor CSF-1, which is required 
for the proliferation of monocytes. Furthermore, BARF1 inhibits mononuclear cells from 
producing IFN-, which is a key cytokine in the initiation of immune responses (Cohen and 
Lekstrom 1999). 
EBV subverts immune response by stimulating regulatory T cells through LMP1 to 
secrete IL-10, which inhibits T cell proliferation and IFN-γ secretion (Marshall, Vickers et al. 
2003). The viral homolog of cellular IL-10 is expressed by the BCRF1 gene and 
contributes to immune evasion during the early phase of EBV infection (Miyazaki, Cheung 
et al. 1993). LMP1 also functions as a constitutively active CD40 and aids in the survival of 
EBV-infected B cells. Expression of LMP1 promotes cell growth and confers apoptosis 
resistance (Henderson, Rowe et al. 1991, Middeldorp, Brink et al. 2003, Geiger and Martin 
2006).  
EBV-encoded miRNAs act as immune modulators. These miRNAs interfere in the 
expression of host miRNAs and viral genes to protect the infected cell from the immune 
response (Barth, Meister et al. 2011). EBV also uses miRNAs to regulate the expression of 
LMP1, which is toxic to the cell (Lo, To et al. 2007). EBV-encoded miRNAs protect the 
newly-infected B cells from apoptosis by down-regulating the pro-apoptotic Bim protein 
(Seto, Moosmann et al. 2010, Marquitz, Mathur et al. 2011). During latent EBV infection, 
the non-coding EBV-encoded RNAs, EBERs, confer resistance to apoptosis by IFN-, 
thereby facilitating B cell transformation (Nanbo, Inoue et al. 2002, Ruf, Lackey et al. 
2005). Thus, various strategies employed by the virus ensure the survival of EBV within 
the host immune cell by allowing it to remain undetected for the lifetime of the host. 
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1.9. MOLECULAR CHARACTERISATION OF EBV-SPECIFIC B CELL RESPONSE 
1.9.1. Project Background 
The B cell-dependent humoral immune response and the T cell-dependent cell-
mediated response have to work in concert to provide immunity against most pathogens. 
The role of CD4+ T cells in humoral immunity has long been acknowledged (Miller, De 
Burgh et al. 1965, Goodnow, Vinuesa et al. 2010). Recent research has shown that among 
the CD4+ T subsets, T follicular helper cells are required for the development of T cell 
dependent B cell responses (Breitfeld, Ohl et al. 2000, Schaerli, Willimann et al. 2000). It is 
not widely accepted that B cells are involved in cell-mediated immune responses. 
However, recent studies and clinical data from mice and humans have shown that B cells 
are not just recipients of T cell help but are active contributors to different aspects of 
cellular immunity (Cohen, Emery et al. 2006, Hauser, Waubant et al. 2008, Pescovitz, 
Greenbaum et al. 2009). B cells are found to influence T cell responses by presenting 
antigens, providing co-stimulatory molecules, and producing cytokines (Constant, 
Schweitzer et al. 1995, Crawford, Macleod et al. 2006, Lund and Randall 2010). 
Unlike T cells, which originate in the bone marrow and mature in the thymus, B cells 
originate in the foetal liver and migrate to bone marrow after birth. Once bone marrow 
develops B cells also originate in the bone marrow. B cells undergo selection and 
maturation in the bone marrow (Raff, Megson et al. 1976). They produce antibodies and 
activate the humoral immune response. The majority of B cells express MHC class II 
molecules on the cell surface and present antigens to T cells. After interaction with a T 
cell, the B cell divides and matures into antibody-producing plasma cells and memory B 
cells. Antibodies produced by plasma cells provide the main defence against extracellular 
pathogens by functioning in three ways: 1) Neutralization, in which antibodies bind to 
pathogens or their products and block access to host cells; 2) Opsonization, in which 
antibodies coat and tag pathogens, thereby promoting ingestion by phagocytes; and 3) 
Complement activation, where a group of about 20 serum proteins are sequentially 
activated and can directly lyse antibody-coated cells or enhance phagocytosis. Thus, 
antibodies also act to enhance the function of the innate immune system (Murphy 2008). 
Immunoglobulins (Ig) are glycoproteins that are either expressed on the surface of 
B cells or secreted by plasma cells in response to an immunogen. They are grouped under 
five classes (Berek, Berger et al. 1991): IgM, IgG, IgA, IgE and IgD, based on their heavy 
chain structure (Brack, Hirama et al. 1978). Any of these heavy chain structures can 
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combine with any of the two light chain structures ( or ) to form Ig or antibodies. Each Ig 
contains two antigen-binding sites encoded by two identical light chains and heavy chains 
linked by disulphide bonds. The heavy and light chains are coded by three different 
families of genes, each one on a different chromosome. A single constant (C) region can 
associate with many different variable (V) regions (Alt, Yancopoulos et al. 1984). The N 
terminal region, consisting of a heavy and light chain, binds the antigen and is known as 
the fragment antigen-binding (Fab). The C terminal region, consisting of a heavy chain 
pair, does not bind the antigen but interacts with cells of the immune system and is called 
fragment crystallizable (Fc). Therefore, the Fab contains the antigen-binding sites and Fc 
region mediates effector functions (Gathings, Lawton et al. 1977). The maturation of a B 
cell starts with the expression of the recombination activation genes RAG1 and RAG2, 
which activate the gene recombination for the production of Ig (Schatz, Oettinger et al. 
1989). The expression of IgM on the surface of a B cell leads to the progression of the 
maturation process, which results in the production of an antibody-secreting plasma cell 
(Fröland, Natvig et al. 1971).  
B cells are activated by one of two mechanisms: a T cell independent response, or 
a T cell dependent response. A T cell independent response is induced by antigens that 
are usually non-protein and have many repeating epitopes that interact with multiple BCRs 
and stimulate the production of IgM antibodies (Mond, Lees et al. 1995). This maturation is 
mainly caused by polysaccharides and does not involve GC formation or B cells 
undergoing affinity maturation and class switch recombination and generation of memory. 
An example of this response is how certain plant lectins, like pokeweed mitogen, induce 
proliferation and antibody production from mature B cells (Hammarstrom, Bird et al. 1979, 
Richards, Watanabe et al. 2008). The majority of antibody responses to proteins are T cell-
dependent, requiring the help of T cells. B cell activation mainly occurs in the GC and 
results in affinity maturation, class switching, and memory (Muramatsu, Kinoshita et al. 
2000).  
B cells play a crucial role in the host’s defence against infection, and this role is 
characterized by a series of coordinated processes that include antigen recognition and 
presentation, antibody secretion, and cytokine release. B cells mature and attain the ability 
to recognize antigens in the bone marrow. They undergo several distinct development 
stages in the bone marrow, including the elimination of auto-reactive cells from the 
population (Hartley, Crosbie et al. 1991, Brink, Goodnow et al. 1992). The maturation of B 
cells starts with somatic recombination, necessary for the production of Ig (Oettinger, 
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Schatz et al. 1990, Bassing, Swat et al. 2002). Through this somatic event, a finite set of 
genes produces a diverse array of gene recombination capable of recognizing a vast 
number of molecular structures. Each B cell has a unique Ig, the BCR, which is specific for 
a single antigen (Brack, Hirama et al. 1978, Rajewsky 1996, Murre 2007). Gene 
rearrangement in the bone marrow occurs at the beginning of B cell maturation and is 
completely independent of antigens (Tonegawa, Sakano et al. 1981, Lam, Kühn et al. 
1997). After developing in the bone marrow, B cells migrate to the secondary lymphoid 
organs, including the lymph nodes and the spleen, where circulating antigens from the 
blood and lymph are drained. Here, the B cells interact with foreign antigens with the help 
of T helper cells and DCs (Karrer, Althage et al. 1997, Junt, Moseman et al. 2007). 
Antigen-activated B cells migrate to the follicles of peripheral lymphoid tissue—
including the spleen, lymph nodes, Peyer’s patch, and the tonsils—where activated B cells 
start to divide and differentiate, forming GCs (Figure 1.1) (Hauser, Junt et al. 2007). B cells 
divide, mature and become centroblasts in these GCs (Küppers, Zhao et al. 1993). For GC 
response to be initiated it needs the interaction of BCR and CD40, two key receptors on B 
cells that provide growth and differentiation signals to those cells (Uchida, Yasui et al. 
1999). The initial interaction occurs at the margin between the primary follicles and T cell 
areas in secondary lymphoid tissues. Antigen-activated B cells undergo clonal expansion 
and somatic hypermutation in the dark zone of the GC. Somatic hypermutation modifies 
the immunoglobulin variable region, thereby generating antibodies with higher affinity for 
antigens (affinity maturation) (Li, Woo et al. 2004, Peled, Kuang et al. 2008). Centroblasts 
differentiate into centrocytes and move into the light zone of the GC, where the B cells with 
a functional BCR are selected by T helper cells and follicular dendritic cells (FDC). The 
survival of a B cell depends on a functional BCR (Kraus, Alimzhanov et al. 2004). The 
signals given by the T helper cells and FDCs result in the escape of the B cell from the 
apoptotic pathway of the GC and their release from GCs. GC B cells that do not receive 
signals through their BCR, or acquire mutations, are eliminated within the GC by apoptosis 
(Liu, Joshua et al. 1989). Ig class switching also occurs in the GCs in which the original 
IgM/ IgD heavy chain constant region is replaced by Ig isotype of IgG, IgA and IgE. The 
differentiated memory B cell or plasma cell is then released from the germinal centers 
(Kuppers 2003, Soulas-Sprauel, Le Guyader et al. 2007, Stavnezer, Guikema et al. 2008). 
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Figure 1. 1. Germinal Center (GC) 
Germinal centers provide the micro-environment inside the secondary lymphoid 
organs for the antigen activated B cells to develop into long lived plasma cells 
and memory B cells (Kuppers 2003).  
 
Interaction between B cells, CD4+ T helper cells and dendritic cells are required for 
the development of humoral immunity (Figure 1.2). CD4+ T follicular helper (TFH) cells are 
specialized T cells that help B cells differentiate into antibody producing plasma cells and 
memory cells. TFH cells also support germinal center formation and maintenance (Allen, 
Okada et al. 2007).TFH cells have recently been found to be a distinct effector subset from 
the other CD4+ T helper cells, the Th1, Th2, Th17 and regulatory T cells (Tregs). Bcl-6 is 
the key regulator of TFH differentiation, and the expression of the chemokine receptor 
CXCR5 guides TFH cells to the follicles (Haynes, Allen et al. 2007, Johnston, Poholek et al. 
2009, Yu, Rao et al. 2009, Baumjohann, Okada et al. 2011). Various studies have found 
that CD4+ T cells are important in the control of persistent viral infection (Battegay, 
Moskophidis et al. 1994, Zajac, Blattman et al. 1998). Fahey and colleagues have shown 
that viral persistence results in the redirection of CD4+ T cells from the Th1 response 
induced during acute infection to TFH cells (Fahey, Wilson et al. 2011). In addition acute 
viral infection has been found to generate both Th1 and TFH memory CD4
+ T cells (Hale, 
Youngblood et al. 2013).  
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Figure 1. 2. DC-B cell-T cell interaction 
Interaction of DC with T cells and B cells is important for humoral immune responses. DCs promote B cell differentiation 
into plasma cells by presenting antigens to B cells, providing cytokines and also by activating TFH cells. Signals from TFH 
cells are required for the differentiation of B cells into plasma cells and memory B cells. Adapted from Ueno et al (Ueno, 
Schmitt et al. 2010). 
 
Dendritic cells (DCs) were discovered by Ralph Steinman in 1973 and are derived 
from hematopoietic bone marrow stem cells (Steinman and Cohn 1973). Immature DCs 
exist in the circulation or as tissue resident cells monitoring the surroundings for foreign 
pathogens. They can sense pathogens through their pattern-recognition receptors (PRRs) 
and once activated, mature DCs migrate to lymphoid organs to initiate the immune 
response (Kadowaki, Antonenko et al. 2000, Jarrossay, Napolitani et al. 2001). DCs are 
required to mediate the initiation of innate and adaptive immune responses and establish 
immunity against pathogens. The two major blood DC subsets are pDCs and mDCs, and 
both subsets are efficient antigen presenting cells (Tel, Schreibelt et al. 2013). In addition, 
pDCs play a unique role in antiviral immunity by producing large amounts of type I 
interferons, especially IFN-, when activated by the presence of viral and bacterial 
components (Cella, Facchetti et al. 2000, Bauer, Redecke et al. 2001). 
Type I interferons not only interfere with viral replication but also initiate events that 
activate both innate and adaptive antiviral immune responses (Le Bon, Schiavoni et al. 
2001). It has also been reported that pDCs are required for the conversion of memory cells 
to plasma cells in a two-step process, with Type I interferons converting memory cells to 
plasmablasts followed by IL-6 converting plasmablasts to antibody-secreting plasma cells 
(Jego, Palucka et al. 2003). Type I interferons produced by pDCs also induce mDCs and 
monocytes to produce two membrane proteins, B cell activating factor (BAFF) and a 
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proliferation-inducing ligand (APRIL) which are required for B cell survival and proliferation 
(Litinskiy, Nardelli et al. 2002). The fate of DCs in primary and persistent EBV infections is 
not known. Decreased frequency and function of blood DC subsets have been reported 
during infections, including HIV, Hepatitis B and malaria (Pacanowski, Kahi et al. 2001, 
Duan, Wang et al. 2004, Pinzon-Charry, Woodberry et al. 2013). The reduced frequency of 
pDCs and impaired production of IFN- also are thought to be crucial factors responsible 
for viral infection in transplant patients (Lim, Kireta et al. 2006).  
While T cell response to EBV infection has been studied extensively, the B cell 
response during EBV infection has received less attention. It is known that EBV infection 
results in the production of antibodies to a variety of virus-encoded antigens. Antibodies to 
VCA, EA, as well as EBNA1, are used as diagnostic markers in the detection of primary 
and persistent EBV infection (Henle, Henle et al. 1970). Most of the information regarding 
EBV infection in vivo is from studies of IM patients. It is known that IM is caused by the 
uncontrolled expansion of CD8+ T cells in response to the virus and the cytokines it 
produces rather than by the virus itself. The reason for this aberrant expansion of CD8+ T 
cells in only some individuals, leading to symptoms of IM, is not known. So the aims for 
this project were to explore possible reasons for symptomatic EBV primary infection by 
investigating the role of humoral immunity during acute IM. Considering the important role 
of DCs in anti-viral immunity and in the development of humoral immune responses, the 
fate of DCs during EBV primary infection also was explored. 
Since B cells and antibody-secreting plasma cells are critical in providing protective 
immunity, this study was designed to investigate the B cell-specific immune response 
during EBV-associated infectious mononucleosis, and use this information towards 
developing a vaccine for IM. Long-lived plasma cells, memory B cells and memory CD8+ 
and CD4+ T cells make up the different arms of the immune system, that provide 
protective immunity. Quantitating memory B cell response is important for the successful 
design of a vaccine. Recent studies on B cells specific for influenza, malaria and HIV used 
B cell ELISpot for the quantification of antigen-specific memory B cells (Wrammert, Smith 
et al. 2008, Doria-Rose, Klein et al. 2009, Weiss, Traore et al. 2010). Detailed phenotypic 
analysis of the classification of B cells is possible by techniques including flow cytometry 
and the B cell ELISpot. While techniques like ELISA and flow cytometry measure antibody 
reactivity and specificity, ELISpot focuses on antibody-secreting cells and B cell responses 
at a cellular level. The method was described in 1983 and the assay was developed for 
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human memory B cells in 2003 by Crotty and colleagues (Czerkinsky, Nilsson et al. 1983, 
Sedgwick and Holt 1983, Crotty, Aubert et al. 2004).  
Using these techniques, this project studied B cell-mediated immune regulation 
during and post IM. EBV membrane protein gp350 is the best-characterized candidate 
protein for an anti-EBV vaccine. This is based on the observation that this glycoprotein 
produces a virus-neutralizing antibody response after natural infection (Thorley-Lawson 
and Poodry 1982). This protein was used to investigate the quality and quantity of virus-
neutralizing antibodies produced during primary and persistent EBV infection. The 
frequency and phenotype of B cell subsets were studied to see if there is a deregulation in 
the total B cell compartment as a result of IM.  
Acute IM causes the up-regulation of various inflammatory and immunosuppressive 
cytokines, as proven by various studies (Hornef, Wagner et al. 1995, Biglino, Sinicco et al. 
1996, Corsi, Ruscica et al. 2004). Recently, Balfour et al. assessed the plasma of IM 
patients for various cytokines that might contribute to disease symptoms, and found that 
most cytokines tested were elevated during acute IM (Balfour, Odumade et al. 2013). 
Consistently, IFN- was not detected in the plasma of IM patients. Since pDCs are the 
main producers of IFN-, the study aimed to determine the role of peripheral blood DC 
subsets during and post IM, to see whether lack of IFN- in the plasma of IM patients is 
due to a defect in the DC population during acute IM. 
1.9.2. Aims and Scope of Thesis 
The objective of this research project was to find out why primary EBV infection 
becomes symptomatic only in some individuals, resulting in Infectious Mononucleosis (IM). 
IM is seen in about 50% of infected adolescents and young adults who acquire EBV 
infection. IM is an immunopathological disease—symptoms arise because of an 
uncontrolled expansion of CD8+ T cells in response to the virus and the cytokines it 
produces. The reason behind this massive expansion of CD8+ T cells is not known. 
Therefore, the focus of this project was to study the immune control of EBV during the 
early stages of infection, before cell-mediated immune responses came into play. The 
main focus was on the study of the humoral immune response, which is not well 
understood. Various studies have described the involvement of DCs in the initiation of both 
the innate and adaptive immune responses and their importance in the development of the 
humoral immune response. Since DC function during EBV infection has received little 
attention, this project also studied peripheral blood DCs during acute IM. The study of the 
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humoral immune response focused on the virus-neutralizing antibody response, as well as 
global B cell function, during acute IM. 
1.9.3. Hypothesis 
Symptomatic EBV primary infection (IM) occurs due to defective control of innate and/or 
humoral immune responses during the early stages of EBV infection. 
1.9.4. Project Aims 
o To study the kinetics of different B cell subsets during primary and persistent 
EBV infection. 
o To investigate the B cell response against the EBV-membrane antigen gp350 
during IM. 
o To understand the role of peripheral blood DCs during EBV infection.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1. LIST OF CHEMICALS 
Acetic acid glacial BDH Chemicals, Poole, UK 
Acrylamide and bis-acrylamide Bio-Rad Laboratories, CA, USA 
Ammonium persulphate Bio-Rad Laboratories, CA, USA 
-D methyl glucoside ACROS Organics, NJ, USA 
Bromophenol blue Sigma-Aldrich, MO, USA 
2-Mercaptoethanol  Sigma-Aldrich, MO, USA 
5-Bromo-4 chloro-3-indolyl phosphate 
/nitroblue tetrazolium (BCIP/NBT)  
Sigma-Aldrich, MO, USA 
Concanavalin A sepharose GE Healthcare, Uppsala, Sweden 
Coomassie brilliant blue Bio-Rad Laboratories, CA, USA 
Carboxyfluoroescein diacetate succinimidyl ester 
(CFSE) 
Sigma-Aldrich, MO, USA 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, MO, USA 
Ethanol Sigma-Aldrich, MO, USA 
Ethylene diamine tetraacetic acid (EDTA) APS Chemicals Ltd, NSW, Australia 
Ficoll-PaqueTM Plus GE Healthcare, Uppsala, Sweden 
Glycerol APS Chemicals Ltd, NSW, Australia 
Glycine APS Chemicals Ltd, NSW, Australia 
Methanol  Fronine Pty Ltd, NSW, Australia 
Non-fat dry milk Bio-Rad Laboratories, CA, USA 
Paraformaldehyde Sigma-Aldrich, MO, USA 
Sodium carbonate BDH Chemicals, Poole, UK 
Sodium bicarbonate BDH Chemicals, Poole, UK 
Sodium dodecyl sulphate Bio-Rad Laboratories, CA, USA 
Streptavidin-alkaline phosphatase Sigma-Aldrich, MO, USA 
Tris Life Technologies, Vic, Australia 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) Sigma-Aldrich, MO, USA 
Trypan blue Sigma-Aldrich, MO, USA 
Trypsin CSL Ltd., Vic, Australia 
Tween 20 Sigma-Aldrich, MO, USA 
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2.2. EQUIPMENT 
Analytical balance    Sartorius AG, Gottingen, Germany 
Autoclave, Tomy ES-315   Tomy, Tokyo, Japan 
Bench top centrifuge, Sigma D-37520 Sigma, Osterode am Harz, Germany 
CO2 incubator-Steri-Cult 200  Forma Scientific, GA, USA 
Counting Microscope Olympus, CX41 Olympus, Tokyo, Japan 
Cryo 1°C freezing container  Nalgene, NalgeNunc, NY, USA 
ELISpot Reader System AutoimmunDiagnostica (AID), Strassburg, 
Germany 
Flow cytometry, FACS LSRII  Becton Dickinson, CA, USA 
Freezer -70°C    Thermo Forma, GA, USA 
Haemocytometer    Sigma-Aldrich, Stenheim, Germany 
Haemocytometer coverslips  Menzel-Glaser, Menzel, Germany 
Laminar Air Flow, Clyde Apac BH2000 Clyde-Apac, SA, Australia 
MACS Separator    Miltenyi Biotec, NSW, Australia  
Microcentrifuge, Eppendorf 5415D Eppendorf, Hamburg, Germany 
Milli-Q water supply    Millipore Corporation, MA, USA 
pH meter, Ionode    Denver Instruments, CO, USA 
Spectrophotometer    Thermo Fisher Scientific, NY, USA 
Vortex mixer     Ratek, Vic, Australia 
Water bath     Grant Instruments Inc., Shepreth, UK 
2.3. MEDIA AND BUFFERS 
 Foetal bovine serum (FBS) supplied by JRH Biosciences. FBS was heat-inactivated at 
56°C for 60 min, aliquoted and then stored at -20°C for use. 
 RPMI-1640 (R0) (Gibco, Life Technologies) prepared by the QIMR Berghofer media 
department, supplemented with L-glutamine and 100 U/mL of penicillin and 100 g/ml 
streptomycin (Gibco). 
 R10 medium containing R0 medium with 10% FBS. 
 Freezing medium containing R10 with 10% DMSO from Sigma-Aldrich. 
 Dulbecco’s Modified Eagle Medium (DMEM) from Gibco, supplemented with 10% 
FBS, 100 U/mL penicillin and 100 g/ml streptomycin sulphate. 
 F12 nutrient mixture from Gibco. 
 CTSTM OpTmizerTM serum free medium from Gibco 
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 Phosphate-buffered saline (PBS), prepared by the QIMR Berghofer Media 
Department. PBS contained 2.85 g of Na2HPO4.2H2O, 0.625g of NaH2PO4.2H2O and 
8.7 g of NaCl in 1L of Milli-Q water, with pH adjusted to 7.4. 
 Trypsin/versene with 0.5mM versene (EDTA) and 0.1% trypsin in Dulbecco’s PBS (80 
g NaCl, 2g KCl, 11.5 g NA2HPO4, 2 g KH2PO4, 40 ml 0.5% v/v phenol red and 10 L 
Milli-Q water). 
 Carbonate Buffer: 0.4 g of Na2CO3 and 0.73 g of NaHCO3 dissolved in 250 mL Milli-Q 
water and pH adjusted to 9.4. The buffer was autoclaved and stored at 4°C. 
 BCIP/NBT Sigma FASTTM tablets were used for spot development in ELISpot assays. 
One tablet per ELISpot plate was dissolved in 10 mL Milli-Q water just before use. The 
solution was filtered through a 0.22 m membrane prior to use. 
 Resolving buffer for autoMACS separator contains PBS with 0.5% FBS and 2mM 
EDTA. 
2.4. STUDY COHORT 
Blood was collected from volunteers from Brisbane (Australia) with informed consent 
and project approval by the Human Research Ethics Committee of QIMR Berghofer. 
Samples were obtained from 18 age-matched asymptomatic EBV carriers and 15 age-
matched EBV carriers with a history of IM. A cohort of 25 acute IM samples, which 
contained 16 longitudinal samples from acute IM (AIM) through recovery and long-term 
carrier state (post-IM), was obtained from collaborators in the USA and UK. The age range 
for acute IM patients was 16.1-32.1 years (median: 19.7; mean: 20.7) and for 
asymptomatic healthy carriers was 18-28 years (median: 24.0; mean: 24.7 years).   
2.5. CELL CULTURE TECHNIQUES 
2.5.1. Ficoll-Paque Separation of PBMC From Whole Blood 
Blood samples were donated by healthy EBV-positive and EBV-negative donors. 
EBV-positive donors included asymptomatic virus carriers, individuals with a history of IM, 
and individuals during and after acute IM. Peripheral blood mononuclear cells (PBMC) 
were isolated from fresh blood by density gradient centrifugation with Ficoll-Paque Plus. 
Two 9 mL Vacuette collection tubes of blood were combined in 50 mL Falcon tubes and 
diluted with R0. Diluted blood was then carefully overlaid onto 10 mL Ficoll-Paque, and 
centrifuged at 450 g, with low acceleration (level 2/10) and low brake (level 1/10), at room 
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temperature. The tubes were centrifuged for 20–30 min and the buffy coat at the interface 
was carefully collected using a Pasteur pipette. The PBMC collected were washed by 
centrifuging at 400 g for 10 min without brake, followed by washes with R0 and R10 at 200 
g for 10 min. Cells were counted using a hemocytometer and stored in liquid nitrogen in 
aliquots of 10 × 106 cells/vial.  
2.5.2. Cryopreservation and Thawing of PBMC  
Cells were pelleted by centrifugation at 200 g for 5 min. The supernatant was 
aspirated and the cells were resuspended at 10 × 106 cells per 1 mL in freeze mix (R10 
with10% DMSO). The cells were aliquoted into cryogenic storage vials and placed in a 
Cryo 1°C freezing container in a -80°C freezer overnight. Vials of cells were then moved 
into a liquid nitrogen dewar for long-term storage. Cells from liquid nitrogen were thawed in 
a 37°C water bath, washed once in 10 mL of R10 and centrifuged at 200 g for 10 min. The 
cells were then rested for a minimum of 1 h at 37°C in R10 and viable cells were counted 
using trypan blue.  
2.5.3. Serum Separation and Storage 
A total volume of 8 mL of blood was collected in a Vacuette serum tube. The tube 
was centrifuged at 1800 g with acceleration at level 7/10 and brake at level 2/10 for 10 
min. The separated serum was stored as small aliquots at -80°C. 
2.5.4. Plasma Separation and Storage 
A 9 mL collection tube (Vacuette) of blood per donor was centrifuged at 200 g for 10 
min at room temperature with acceleration of 5/10 and brake 3/10. The clear liquid, 
plasma, was collected and centrifuged again at 1800 g for 10 min at room temperature 
with low brake, and the plasma aliquoted and stored at -80°C. 
2.6. PREPARATION OF RECOMBINANT PROTEIN  
2.6.1. Protein Purification 
Cells expressing the protein of interest were grown to a high density in medium 
DMEM/F12 containing 10% heat-inactivated FBS, 100 U/mL of penicillin and 100 µg/mL of 
streptomycin. The cells were maintained in serum-free medium and the secreted protein 
was collected and concentrated using an Amicon Ultracel (Millipore) centrifugal filter. The 
concentrated protein was then purified using a concanavalin A sepharose 4B column. It 
was dialyzed using snake-pleated dialysis tubing in binding buffer (20 mM Tris–HCl pH 
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7.4, 0.5 M NaCl in water). The column was equilibrated overnight and washed with three 
times the column volume of binding buffer. The dialyzed protein in binding buffer was 
loaded onto the column and the flow-through was collected. The protein was reloaded onto 
the column three more times to facilitate maximum protein retention. The column was then 
washed with six times the column volume of wash buffer (binding buffer with 25 mM –D 
methyl glucoside) and eluted with increasing concentrations of –D–methyl glucoside. The 
concentrated protein was then visualised by dot-blot and/or western blot and the 
concentration estimated using the Bradford protein assay. The protein was then stored in 
PBS as aliquots at -70°C until use. 
2.6.2. Dot Blot 
The dot blot was used to determine the presence of protein after its expression and 
purification. On a strip of nitrocellulose membrane, the position of each different sample 
was marked with a circle using a pencil. Then, 10 l of different samples from the protein 
purification procedure (flow through, wash and elution samples), as well as positive and 
negative controls, were blotted on the nitrocellulose membrane. Using a narrow-mouth 
pipette tip, 1 l of sample was spotted in the centre of each circle. The membrane was 
allowed to dry for 1 h at room temperature and blocked using 5% dry milk in PBST (PBS 
with 0.05% Tween-20). After 1 h of blocking, the membrane was incubated with primary 
antibody against the protein (or GFP, if fused with GFP), at a 1:3000 dilution in PBST at 
room temperature on a rocker. The membrane was incubated with a secondary antibody 
after washing with PBST. Goat anti-mouse HRP (SouthernBiotech, USA) was added to the 
membrane at 1:3000 dilution and incubated for 1 h at room temperature. The protein was 
detected using western lightning plus-ECL (PerkinElmer Inc. USA) and exposed to X-ray 
film in the dark.  
2.6.3. Protein Concentration Estimation – Bradford Assay 
Protein concentration was estimated using Quickstart Bradford dye reagent (Bio-
Rad laboratories). Protein standards were made from 2 mg/mL BSA and PBS was used as 
a blank. In a 96-well flat-bottom plate, seven serial dilutions of protein standards were 
made in duplicate. The protein of interest and blank were also measured in duplicate, 
using a spectrophotometer. 
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2.7. IMMUNOLOGICAL ANALYSIS 
2.7.1. List of Antibodies Used in This Study 
Antibody Fluorochrome Supplier
a  Antibody Fluorochrome Supplier 
CD3 PE-Cy7 / Alexa Fluor 700 1 / 2  CXCR3 APC 1 
CD4 Pacific Blue 1  CXCR5 FITC 1 / 2 
CD8 PerCP-Cy5.5 2  Fas PE-Cy7 2 
CD11c APC 1  FasL PE 2 
CD19 eFluor 450 3  HLA-DR PerCP 1 
CD20 FITC 3  ICOS BV421 1 
CD24 PE 1  IFN-γ Alexa Fluor 700 1 
CD27 APC / APC-H7 1  IL-21 PE 3 
CD38 PerCP-Cy5.5 1  Lineage
b
 FITC 1 
CD123 BV421 / PE 1  PD1 APC 3 
BAFF-R FITC 1  TACI
 
APC 1 
BCMA PE 2  TNF APC 1 
CCR7 Alexa Fluor 700 1     
 
a
 Supplier codes:  1: Becton Dickinson, 2: BioLegend, 3: eBioscience. 
b
 Lineage antibody cocktail includes antibodies specific for CD3, CD14, CD19, CD20 and CD56. 
 
2.7.2. Flow Cytometric Analysis 
Phenotypic analyses of B cells and DCs were done using PBMC and flow 
cytometry. Frozen PBMC stored in liquid nitrogen were thawed at 37°C, washed once in 
R10 and rested for at least 1 h in a 37°C incubator. The cells were then counted and 
500,000 cells/well were used for surface antigen staining in a 96-well V-bottom plate. The 
cells were washed twice in PBS/2% FBS and incubated for 30 min at 4°C with 
fluorochrome-conjugated antibodies diluted in PBS/2% FBS. The cells were washed twice 
with PBS/2% FBS and fixed in 4% paraformaldehyde. Data were acquired on a 
FACSCanto II or LSRFortessa flow cytometer and analysed using FlowJo software 
(Treestar, USA).  
2.7.3. ELISpot 
Memory B cells in PBMC were quantified using the method developed by Crotty et 
al., in which the memory B cells are converted to antibody-secreting cells in vitro. PBMC 
were thawed and transferred to 24-well plates at 5 × 105 cells/well. The cells were 
incubated at 37°C for six days in R10 containing 50 µM β-mercaptoethanol and an 
optimized mix of polyclonal mitogens. This mix of polyclonal mitogens included pokeweed 
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mitogen extract (PWA) at 1/100,000 dilution, Protein A from Staphylococcus aureus, 
Cowan strain (SAC) at 1/10,000 dilution, CpG ODN 2006 at 2.5 g/mL (Sigma Aldrich) 
(Crotty, Aubert et al. 2004) and IL-10 at 25 ng/mL (BD Biosciences) (Weiss, Traore et al. 
2010). 
The antigen of interest was immobilized on a 96-well ELISpot plate (Millipore 
Multiscreen HTS IP) and incubated at 4°C overnight. Wells of the plate were coated with 
either 25 g/mL of gp350, recombinant EBV membrane antigen expressed from CHO cells 
(Hessing, van Schijndel et al. 1992), or control EBV non-neutralizing structural antigen 
VCA (GenWay Biotech). Positive control wells were coated with 10 g/mL of tetanus 
toxoid (CSL, Australia). To detect total IgG secreting cells, 15 g/mL capture anti-IgG 
(Mabtech) was used. The next day the plates were washed with PBS and blocked with 
R10 for 2–4 h at room temperature. For the detection of antigen-specific antibody-
secreting cells (ASC), the in vitro activated cells were washed and plated in triplicate in 
antigen coated wells at 3 × 105 cells/ well. For the detection of total IgG secreting cells 
3000 cells/well were plated in triplicate in wells containing capture anti-IgG. The plates 
were then incubated at 37°C overnight. 
The following day, excess cells were removed by washing wells with PBST. The 
plates were then incubated with 1:500 biotinylated anti-IgG (Mabtech) for 2 h at room 
temperature, followed by incubation with 1:1000 Streptavidin-AP (Sigma-Aldrich) for 1 h at 
room temperature. Sigma Fast BCIP/NBT was then added to the wells and incubated at 
room temperature until spots developed, at which time the reaction was stopped by 
washing with water. Spot quantification was done using an ELISpot reader system. 
2.7.4. Enzyme Linked Immunosorbent Assay (ELISA) 
 Protein in carbonate buffer pH9.4 was added to ELISA plates (EIA/RIA plate) and 
incubated overnight at 4°C. The coated plates were washed with PBST and blocked with 
PBS containing 5% non-fat dry milk (blotting grade blocker) for 2 h at room temperature. 
The plates were washed and 25 l of serially diluted samples were added in duplicate and 
incubated for 2 h at room temperature on a plate shaker. After further washing with 
PBSTs, 25 l of HRP-conjugated goat anti-human IgG (1:1000 dilution; Chemicon), or goat 
anti-human Ig (1:4000 dilution; Southern Biotech) was added and incubated for 1 h. After 
washing with PBSTs, 25 l of TMB ELISA substrate solution was added to each well and 
plates were incubated for 15 min at room temperature in the dark. Once the colour 
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developed, the reaction was stopped by the addition of 25 l of 1 M HCL. Absorbance was 
measured using a spectrophotometer at a wavelength of 450 nm.  
 
2.7.5. Cytometric Bead Array (CBA) analysis 
The supernatant from cell culture or plasma from donors was used to quantify 
cytokine levels present in the samples. A cytometric bead-based multiplex assay kit (BD 
Biosciences) was used to measure the different cytokines.The assay was done in 
accordance with the manufacturer’s instructions, with minor modifications. A lyophilised 
standard vial was reconstituted with 4 mL assay diluent and allowed to equilibrate for 15 
min before aliquoting and storing at -80°C. An aliquot of standard was used to set up eight 
2-fold dilutions of standard in assay diluent. The capture bead mix was made by adding 
0.1 l of each bead per test. Each capture bead stock vial was vortexed for 15 sec to 
resuspend beads thoroughly and resuspended using capture bead diluent for 
serum/plasma. Each assay was set up in a 96-well V-bottom plate by mixing 12 l of 
mixed capture beads and 10 l of standard or sample. The plate was then incubated at 
room temperature on a shaker for 1 h. During this time, a pool of PE-conjugated detection 
antibodies was made by combining 0.1 µl of each antibody with detection diluent. After the 
1 h incubation, 12 l of detection antibody pool was added to the plate and incubated for 
another 2 h at room temperature on a shaker. The beads were then washed with 175 l 
wash buffer per well and centrifuged at 200 g for 5 min, before being resuspended in 300 
l wash buffer for analysis. Data were acquired using a BD LSRFortessa flow cytometer 
and analysed using FCAP Array software (BD Biosciences)). 
2.7.6. Apoptosis Assay  
Annexin V binds to phophotidylserine, which is exposed on the plasma membrane 
off a cell when membrane integrity is lost during apoptosis. Annexin V detection kit from 
BD Biosciences was used in combination with a dead cell stain (Live/Dead Fixable Aqua 
Dead Cell Stain; Life technologies) to distinguish between dead and apoptotic cells. After 
labelling PBMC with the dead cell stain and antibodies specific for cell surface markers, 
the cells were washed with annexin binding buffer. Annexin V diluted in annexin binding 
buffer was then added and cells were incubated for 15 min at room temperature in the 
dark. The cells were then analysed by flow cytometry within 1 h of staining. 
 36 
 
2.7.7. Intracellular Cytokine Assay  
PBMC were thawed and rested for 1 h in R10 at 37°C before being counted and 
distributed in a 96-well V-bottom plate. The cells were stimulated by incubation with 
mitogen for 4-6 h at 37°C, in the presence of 1 µl/mL GolgiPlug (Brefeldin A; BD 
Biosciences). The cells were washed and stained with antibodies against cell surface 
markers and incubated at 4°C for 30 min. The intracellular staining was performed after 
fixing and permeabilizing the cells using Cytofix/Cytoperm solution. Permeabilizing 
solution, a 10× solution diluted to 1× with deionized water was used for subsequent 
washes and the cells were then incubated with antibodies specific for cytokines of interest 
at 4°C for 30 min. Data were acquired by flow cytometry and post-acquisition analysis was 
done using FlowJo software. 
2.7.8. Magnetic Bead Separation 
 PBMC were labelled with MACS microbeads (Miltenyi Biotech) for the magnetic 
separation of B cells and dendritic cells. Cells were counted and 1x106 PBMC were 
resuspended in resolving buffer and incubated with microbeads for 15 minutes at 4°C. The 
cells were washed and resuspended in 500l of resolving buffer and was used for 
magnetic separation. The autoMACS separator was prepared and primed according to the 
manufacturer’s instructions. Sample tubes were placed at the uptake port and the labelled 
and unlabelled fractions were collected from port pos1 for positive (labelled) fraction and 
port neg1 for the negative (unlabelled) fraction. Depending on the experiment, enrichment 
for B cells and deletion for dendritic cells, appropriate separation program was chosen on 
the separator.  
2.8. STATISTICAL ANALYSIS 
Statistical analysis was performed using Prism 6, GraphPad software. The data were 
presented as mean ± standard error of the mean (SEM) or as percentages. Statistical 
significance was determined using one way analysis of variance (ANOVA) for comparison 
of more than two groups. The Wilcoxon matched pairs test was used to compare 
measurements at two time-points for the same individual, and measurements for different 
groups were compared by non-parametric Mann-Whitney test. 
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CHAPTER 3. KINETICS OF B CELL SUBSETS DURING 
PRIMARY AND PERSISTENT EBV INFECTION 
3.1. ABSTRACT 
The humoral immune response to EBV infection is a less explored area of research 
that could provide insights into immune control during the early stages of EBV infection. 
Therefore, this study was designed to understand the humoral immune response during 
EBV infection, in particular during acute infectious mononucleosis (IM). Studies outlined 
under Aim 1 addressed global B cell function, specifically the kinetics of two main subsets 
of B cells - circulating memory B cells and long-lived plasma cells that provide protective 
immunity.  Analysis of the phenotype and frequency of B cell subsets from individuals at 
different stages of EBV infection showed a significant reduction in the total B cell 
population and in the memory B cell subset during acute IM. The frequency of circulating 
memory B cells remained low even after recovery when compared to samples from 
asymptomatic virus carriers. Moreover, the conversion efficiency of memory B cells to 
antibody-secreting plasma cells following in vitro activation was significantly compromised 
in individuals during and post-IM. Furthermore, IM patients also showed dysregulated 
expression of tumour necrosis factor family members BAFF and APRIL and increased 
FAS and FAS-L expression on circulating B cells and plasma respectively. Finally, in vitro 
studies showed that the upregulation of FAS on B cells was intrinsically linked to IL-12 
which is significantly elevated in the plasma of acute IM patients. These studies provide an 
important mechanistic insight on the global B cell immunity following primary EBV infection 
and may help us to design better prophylactic or therapeutic strategies to reduce the 
disease burden due to primary EBV infection.  
 38 
 
3.2. INTRODUCTION 
Humoral immune response plays a critical role in providing protection against 
infection with viral pathogens. Two subsets of B cell memory—long-lived plasma cells in 
bone marrow and memory B cells in the peripheral lymphoid systems—are essential for 
protective immunity. Along with CD8+ and CD4+ memory T cells, they constitute 
immunological memory. Following antigen encounter in secondary lymphoid organs, naïve 
B cells mature into both plasma cells and memory B cells. Plasma cells transit through the 
peripheral blood as plasmablasts and antibody-secreting cells (ASCs) then establish in the 
bone marrow. Memory B cells circulate in the peripheral lymphoid system. While long-lived 
plasma cells maintain high-affinity antibody levels in serum, memory B cells are capable of 
rapid response to a secondary infection, converting to plasma cells that secrete antibodies 
with high affinity (Slifka, Antia et al. 1998, Manz and Radbruch 2002, Purtha, Tedder et al. 
2011). Both plasma cells and memory cells are, therefore, critical mediators in the 
establishment of effective humoral immunity against viral challenge.  
Recent observations have also revealed that B cell survival and maturation are 
mediated by the B cell activation factor (BAFF) and its homolog APRIL (Schneider, 
MacKay et al. 1999). Both BAFF and APRIL are TNF-family ligands and are produced 
mostly by myeloid cells (Nardelli, Belvedere et al. 2001), including monocytes, 
macrophages and dendritic cells, as well as by some non-lymphoid cells (Mackay and 
Browning 2002). BAFF has three receptors on B cells—BAFF-R, TACI and BCMA—and it 
binds to them with varying degrees of affinity (Day, Cachero et al. 2005).  APRIL, however, 
binds only to TACI and BCMA. BAFF-R is expressed on most B cell subsets and is found 
to be the central receptor involved in B cell development, maturation and survival, while 
TACI and BCMA are expressed on mature B cells (Laabi, Gras et al. 1994, Ng, Sutherland 
et al. 2004, Darce, Arendt et al. 2007). Differential expression of BAFF-R has been shown 
to be associated with B cell dysfunction, increased susceptibility to apoptosis (FAS 
receptor expression) and reduced B cell numbers in a number of clinically important 
settings, including HIV-viremic patients and patients with acute malaria infection (Moir, 
Malaspina et al. 2004, Nduati, Gwela et al. 2011). Dysregulation in BAFF/BAFF-R 
expression has also been associated with some B cell-related autoimmune diseases, 
including Sjogren’s syndrome and systemic lupus erythematosus, both of which have been 
associated with EBV infection (Sellam, Miceli-Richard et al. 2007).  
Despite our thorough understanding of the role of B cell immunity in protection 
against most viral pathogens, research into the impact of EBV infection on the B cell 
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compartment has centred on B cells as the primary source of EBV infection, while little 
attention has been paid to the induction of B cell immunity during primary EBV infection, or 
the impact of EBV infection on the B cell compartment. The aim of this chapter is, 
therefore, to investigate the impact of acute symptomatic EBV infection on the peripheral B 
cell compartment. To explore the impact of acute EBV infection on B cells, longitudinal 
analysis of the phenotype and frequency of B cells in peripheral blood was investigated in 
a cohort of patients with acute IM, and in healthy latent virus carriers. This aim also studied 
the impact of acute EBV infection on the expression of the BAFF receptors and their 
ligands, and on the expression of FAS. Several cytokines are reported to be elevated 
during EBV primary infection, IM and contribute to the symptoms of IM (Balfour, Odumade 
et al. 2013). The influence of various cytokines on the survival of B cells was studied by in 
vitro assay.  
There was very little evidence of the activation of a strong B cell response in the 
peripheral blood of IM patients, as the frequency of ASC remained low during IM, unlike 
other acute viral infections (Doria-Rose, Klein et al. 2009, Lee, Falsey et al. 2010, 
Wrammert, Koutsonanos et al. 2011, Wrammert, Onlamoon et al. 2012). There was a 
reduction in the absolute number of peripheral B cells and in the proportion of memory B 
cells in the blood.  This loss of memory B cells in peripheral blood was associated with 
poor in vitro conversion of memory B cells into ASCs, and with apparent dysfunction in the 
expression of both BAFF-R and FAS on peripheral B cells.  
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3.3. MATERIALS AND METHODS 
3.3.1. Flow Cytometry Analysis of B Cells 
The phenotypic analysis of B cells in PBMC was performed ex vivo using Flow 
Cytometry. Specific human B cell markers for antibody-secreting cells (ASC) and memory 
cells conjugated to flurophores were used as previously reported (Crotty, Aubert et al. 
2004, Wrammert, Smith et al. 2008). The frequency and phenotype of ASCs and memory 
cells were analysed using the following surface markers: CD3-PE Cy7, CD27-APC and 
CD38-PerCp-Cy5.5, CD19–eFluor450 and CD20–FITC. The cells were washed with PBS 
2% FCS and incubated with surface markers for 30 min at 4oC. The cells were fixed with 
2% paraformaldehyde (Sigma Aldrich) in PBS. Data were acquired on a FACS Canto Flow 
cytometer and analysed using FlowJo software. 
To determine the differences in frequency of B regulatory cells in donors at various 
stages of EBV infection, phenotypic analysis of B regulatory cells was done using flow 
cytometry. The phenotype of Breg cells have been reported to be CD3-/CD19+ B cells that 
express high CD24 and CD38 surface markers (Blair, Norena et al. 2010).  The staining 
was done using surface markers CD3–PECy7, CD19–eFluor450, CD24- PE and CD38 
PerCpCy5.5 and data acquired and analysed by FACS Canto Flow cytometer and FlowJo 
software. 
Flow cytometric analysis was also used to study the expression of receptors of BAFF 
(B cell activation factor) on B cells, as well as the expression of death receptor FAS on B 
cells. BAFF binds to three receptors on B cells: BAFF-R, TACI and BCMA. PBMC were 
stained with CD3-Alexa Fluor 700, CD19-eFluor450, CD27-APC-H7, BAFF-R-FITC, TACI-
APC, BCMA-PE and Fas-PECy7. 
3.3.2. Conversion of Memory B Cells to Antibody-Secreting Cells 
PBMC (5x105 cells/well on a 24-well plate) were cultured in R10 with 50 uM –
mercaptoethanol for six days. The medium was supplemented with an optimized mix of 
polyclonal mitogens, which included pokeweed mitogen extract (PWA) at 1/100,000 
dilution, Protein A from Staphylococcus aureus, Cowan strain (SAC) at 1/10,000 dilution, 
CpG ODN 2006 at 2.5 ug/ml (Sigma Aldrich) (Crotty, Aubert et al. 2004) and IL-10 at 25 
ng/ml (BD Biosciences) (Weiss, Traore et al. 2010). 
The frequency and phenotype of antibody-secreting cells (ASCs) converted from 
memory B cells were analysed using the following surface markers: CD3-PE Cy7, CD27-
APC, CD38-PerCp-Cy5.5, CD19-eFluor450 and CD20-FITC. Cells were washed with PBS 
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2% FCS and incubated with surface markers for 30 min at 4oC. The cells were fixed with 
2% paraformaldehyde (Sigma Aldrich) in PBS before analysis. Data were acquired on 
FACS Canto Flow cytometer and analysed by FlowJo software. 
3.3.3. B Cell ELISpot  
Memory B cells in PBMC were quantified using the method developed by Crotty et al 
(2004), in which memory B cells are converted to antibody-secreting cells in vitro. PBMC 
were thawed and incubated at 37oC in a 24-well plate at 5x105 cells/ well for six days. The 
cells were suspended in R10 with 50 uM -mercaptoethanol).The medium was 
supplemented with an optimized mix of polyclonal mitogens, which included pokeweed 
mitogen extract (PWA) at 1/100,000 dilution, Protein A from Staphylococcus aureus, 
Cowan strain (SAC) at 1/10,000 dilution, CpG ODN 2006 at 2.5 µg/ml (Sigma Aldrich) 
(Crotty, Aubert et al. 2004) and IL-10 at 25 ng/ml (BD Biosciences) (Weiss, Traore et al. 
2010). 
The antigen was immobilized on a 96-well ELISpot plate (Millipore Multiscreen HTS 
IP) and incubated at 4oC overnight. The plate was coated with 5 µg/ml of capture anti-IgG 
(Mabtech) for measuring the frequency of total IgG-secreting B cells. On the next day, the 
plates were washed with PBS and blocked with R10 for 2–4 h at room temperature. The in 
vitro-activated cells were washed and 3000 cells/well were plated in triplicate in antigen-
coated wells for the detection of total IgG secreting cells. The plates were then incubated 
at 37oC overnight. The following day cells were washed with PBS containing 0.05% 
Tween–20 (PBST) and incubated with 1:500 biotinylated anti-IgG (Mabtech) for 2 h at 
room temperature followed by incubation with 1:1000 Streptavidin–AP (Sigma Aldrich) for 
1 h at room temperature. The plates were then incubated with Sigma Fast BCIP/NBT at 
room temperature until spots developed, following which the reaction was stopped by 
washing with water. Spot quantification was done using an ELISpot reader (AID 
Diagnostika). 
3.3.4. Enzyme Linked Immunosorbent Assay (ELISA) 
ELISA for BAFF/APRIL was done using ELISA kits (Human BAFF Quantikine ELISA 
kit from R&D Systems and LegendMax Human APRIL ELISA kit from Biolegend) 
according to manufacturer’s instructions. All reagents were brought to room temperature 
before the start of the assay.  Standards were prepared as per manufacturer’s instructions. 
The plates were washed with wash buffer four times. Assay buffer, standards and samples 
were added to their respective wells and sealed with adhesive strips and incubated at 
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room temperature on a microplate shaker for 2–3 h. The plates were washed and BAFF 
conjugate or APRIL detection antibody was added and the plates incubated at room 
temperature for 1 h with shaking. BAFF ELISA was continued by adding substrate solution 
and incubating for 30 min. APRIL ELISA was continued by incubating with Avidin–HRP 
solution for 30 min followed by substrate solution for 15 min, with washing between each 
step. The substrate reaction was stopped by the addition of stop buffer and the 
absorbance read at 450 nm immediately using a spectrophotometer. 
3.3.5. Cytometric Bead Array (CBA) Analysis 
The plasma samples from 10 longitudinal donors during and post-IM were used to 
quantify the cytokine levels present during EBV infection and compared with asymptomatic 
latent virus carriers. BD Cytometric bead-based multiplex assay kit (BD Biosciences) was 
used to measure FAS L in the plasma. The assay was done according to the 
manufacturer’s instructions, with minor adjustments. A lyophilised standard vial from the 
flex set was reconstituted with 4 ml assay diluents and allowed to equilibrate for 15 min 
before aliquoting and storing at –80oC. An aliquot of standard was used to set up 8x2–fold 
dilutions of standards in assay diluents. The capture bead mix was made by adding 0.1 µl 
of each bead per test. Each capture bead stock vial was vortexed for 15 s to resuspend 
the beads thoroughly and then resuspended using capture bead diluents for 
serum/plasma. The assay was set up in a 96–well V-bottom plate by mixing 12 µl of mixed 
capture beads and 10 µl of standard or sample. The plate was then incubated at room 
temperature on a shaker for 1 h. PE detection mix was also made similar to capture bead 
mix using detection diluents. After 1 h incubation, 12 µl of mixed PE detection reagents 
were added and incubated for another 2 h at room temperature on a shaker. The plate 
was washed with 175 µl wash buffer supplied in the kit and centrifuged at 200 g for 5 min. 
The beads were then resuspended with 300 µl wash buffer for analysis. The data were 
acquired on BD FACS LSRII flow cytometer and analysed on FCAP Array software. 
3.3.6. Annexin V Staining 
To determine the percentage of B cell apoptosis, Annexin V binding assays were 
performed using Annexin V kit (BD Biosciences). Annexin V was used in combination with 
a dead cell stain (Live/Dead Fixable Aqua Dead Cell Stain from Life Technologies) to 
distinguish between dead and apoptotic cells. PBMC were washed with 1X Annexin 
binding buffer (working concentration made by diluting one part of 10X Annexin V binding 
buffer provided in the kit with nine parts distilled water) following staining with B cell 
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markers. The B cell staining panel included CD3-Alexa Fluor 700, CD19- eFluor450, CD27 
APC-H7, BAFF-R–FITC, TACI–APC and Fas–PECy7. After staining with the dead cell 
stain and surface markers, the cells were incubated with 1 µl Annexin V (PE) in 100 µl 
Annexin binding buffer for 15 min at room temperature in the dark. The cells were then 
analysed using flow cytometry within 1 h of staining. 
3.3.7. Cytokine Influence and FAS/FAS L Killing 
To determine the mechanism responsible for reduced B cell numbers during acute 
IM, the possibility of FAS-mediated apoptosis was explored in vitro. The cells were 
cultured in serum free OpTmizer medium and various cytokines (R&D Systems) that were 
upregulated in infectious mononucleosis samples were added individually at 
concentrations of IL-4 (10 ng/ml), IL-6 (10 ng/ml), IL-10 (500 pg/ml), IL-12 (10 ng/ml), IFN- 
 (100 u/ml), TNF-(50 ng/ml) and TGF- (10 ng/ml). Culturing of cells with the addition of 
IL-12 resulted in an increased expression of FAS on B cells.  To induce cell death in vitro, 
FAS-upregulated B cells were incubated with soluble FAS L (R&D Systems), FAS-L 
aggregate made by incubating 100ng/ml of sFAS-L with N-terminal His tag with1g/ml of 
anti-His antibody (R&D Systems), or anti-CD3 stimulated T cells that express high 
membrane bound FAS-L. Cell viability was determined by flow cytometry. The cells were 
stained with CD3/CD19/ Live/Dead marker and Annexin V and the percentage of CD3-
/CD19+ B cells that were Annexin V positive were determined as apoptotic cells. 
Purified NA/LE mouse anti-human CD3 (BD Biosciences) at 2.5g/ml was coated on 
48-well plate overnight at 4oC. PBMC (1x106) were added the next day and incubated for 
three days for the activation of T cells. The activated T cells expressing high FAS-L was 
then mixed with an equal number of PBMC cultured in IL-12 for three days. The PBMC 
cultured with IL-12 were labelled with CFSE dye prior to culturing with IL-12 for three days 
to label cells expressing high FAS. The cells were then incubated for 6 h and CFSE 
labelled CD3-/CD19+ B cells were analysed for apoptotic cells by flow cytometry.   
3.3.8. Statistical Analysis 
Statistical analysis was performed using Prism 6, GraphPad Software. The data are 
presented as mean +/- SEM or as percentages. Statistical significance was determined 
using one way analysis (ANOVA) for comparison of more than two groups. The Wilcoxon 
signed-rank test was used to compare measurements at two time points for the same 
individual and comparison of different groups was done by the Mann Whitney test. 
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3.4. RESULTS 
3.4.1. Phenotype and Frequency of B Cell Subsets 
It has recently been observed in a number of clinical settings that there is 
perturbation in the peripheral blood B cell compartment during acute viral infections, and 
that this is often associated with an expansion in the number of ASCs that are mostly 
specific to the invading pathogen (Doria-Rose, Klein et al. 2009, Wrammert, Koutsonanos 
et al. 2011). Therefore, in order to explore the impact of acute EBV infection on the 
peripheral blood B cell compartment, the phenotype and frequency of B cell subsets were 
analysed at different stages of EBV infection.   
 
 
 
Figure 3. 1. Detection of circulating B cell subsets in ex vivo PBMC 
Representative dot blot showing the gating strategy for ex vivo B cell subsets using PBMC from a 
healthy virus carrier. Total B cells are gated as CD3
-
/CD19
+
 cells, memory B cells as CD3
-
/CD19
+
/CD20
+
/ CD27
+
 cells, and antibody-secreting cells (ASC) as CD3
-
/CD19
+
/CD20
lo
/CD27
hi
 and 
CD38
hi
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Peripheral blood mononuclear cells from a panel of 22 patients with acute EBV 
infection, 12 patients during the early recovery phase (20-50 days or > six months from the 
onset of symptoms), 30 long-term recovery patients (six months or more from the onset of 
symptoms) and 17 age-matched long term virus carriers were assessed for the frequency 
of total B cells, memory B cells (MBC) and antibody-secreting cells (ASCs).  
Representative analysis of the gating strategy for an individual is shown in Figure 3.1. 
Total B cells were defined as CD3-CD19+ cells, while MBC were identified by the co-
expression of CD20 and CD27 in CD19+ B cells.  ASCs were identified, as previously 
reported, based upon CD27 and CD38 expression in CD20lo B cells (Doria-Rose, Klein et 
al. 2009). Somewhat unexpectedly, this analysis revealed that although B cells are the 
primary source of EBV infection—and it has been reported that EBV-infected B cells 
constitute up to 1% of peripheral B cells during IM—there was a significant reduction in the 
proportion of CD3-CD19+ B cells (Figure 3.2A) during acute primary EBV infection.  
Although not significant, there was also a reduction in the absolute number of B cells in 
peripheral blood of the majority of IM patients during acute IM (Figure 3.2B).  
 
 
Figure 3. 2. Ex vivo 
characterization of total B 
cells in PBMC and whole 
blood 
Panel A: Analysis of 16 
longitudinal samples from donors 
during and post IM to study the 
frequency of total B cells as CD3-
/CD19+ cells. Statistical analysis 
was done by Wilcoxon matched 
pair test for comparison within 
group with significant p value as 
*** p<0.001.   
Panel B: Absolute count for total B 
cells is expressed as total PBMC 
count per litre of blood at time of 
harvest, 106cells/litre. 13 
longitudinal samples from donors 
during and post IM were analysed. 
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Following long-term convalescence, the proportion of peripheral B cells returned to 
normal (Figure 3.3A). Analysis of the proportion of MBC in the total B cell population also 
revealed a significant reduction during acute IM (Figure 3.3B). Interestingly, while MBC 
numbers gradually recovered during convalescence, they still remained significantly lower 
than the numbers for latent virus carriers, even after long-term recovery.  Although 
significant changes were evident in both total B cells and MBC populations during acute 
infection, unlike other primary infections there was no evidence of a change in frequency 
of ASCs in the peripheral blood of acute IM patients (Figure 3.3C). 
 
Figure 3. 3. Ex vivo 
characterization of B cell subsets 
in PBMC during EBV infection  
Panels A, B, C: Compilation of all data 
analysed from donors at different stages 
of EBV infection, with PBMC from 22 
acute IM donors, 12 recovering post IM 
donors (20–50 days after onset of 
symptoms, post IM < 6months), 30 post-
IM donors more than 6 months since 
start of symptoms, and 18 healthy virus 
carriers. PBMC were incubated with 
fluorescently labelled antibodies specific 
for CD3, CD19, CD20, CD27 and CD38 
then assessed for the frequency of total 
B cells, MBCs and ASCs by flow 
cytometry  
Panel A: ex vivo analysis of CD3-/CD19+ 
total B cells 
Panel B: CD3-/CD19+/CD20+/CD27+ 
Memory B cells  
Panel C: CD3-/CD19+/CD20lo/CD27hi 
and CD38hi antibody-secreting cells 
(ASCs).  
Data shows mean, range and data 
points; statistical analysis was done by 
one-way ANOVA, Tukey’s multiple 
comparison with **** p<0.0001, *** 
p<0.001, ** p<0.01 and * p<0.05 and ns 
not significant.  
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To characterise the memory B cells present in the blood of acute IM patients, PBMC 
from donors at different stages of EBV infection were cultured for six days in the presence 
of polyclonal mitogens that induce the differentiation of circulating memory B cells into 
ASCs. Figure 3.4 shows the gating strategy from a representative sample where the 
forward and side scatter plots for the lymphocyte gate were extended to include activated 
B cells (Doria-Rose, Klein et al. 2009).  
 
 
Figure 3. 4. Analysis of in vitro-activated PBMC  
Representative dots blot showing the gating strategy of in vitro-activated PBMC.  The PBMC were 
cultured with an optimized mix of polyclonal mitogens — pokeweed mitogen extract (PWA) at 
1/100,000 dilution, Protein A from Staphylococcus aureus, Cowan strain (SAC) at 1/10,000 
dilution, and CpG ODN 2006 at 2.5 µg/ml and IL-10 at 25 ng/ml — for six days. Using data 
gathered by flow cytometry, forward and side scatter plots for the lymphocyte gate are extended to 
include activated lymphocytes. Frequency of total B cells CD3-/CD19+ and antibody-secreting cells 
as CD3
-
/CD19
+
/CD20
lo
/CD27
hi
/CD38
hi
 are calculated.  
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The efficiency of conversion of MBC to ASCs was studied by comparing the PBMC of 
donors at different stages of EBV infection. Consistent with the ex vivo observations 
showing a lack of ASCs in the peripheral blood of IM patients, conversion of MBC to ASCs 
during acute EBV infection was significantly impaired (Figure 3.5A). To confirm these 
observations, in vitro activated B cells from IM patients and healthy virus carriers were 
assessed for the production of IgG using a B cell ELISpot assay. Consistent with the poor 
in vitro conversion into ASCs, B cells cultured from patients acutely infected with EBV, 
displayed a significant reduction in IgG production that recovered to normal levels 
following disease resolution (Figure 3.5B). These observations provide further support for 
significant perturbations in the B cell compartment during acute IM that result in low B cell 
numbers and reduced conversion efficiency of memory B cells to antibody-secreting cells.   
 
 
Figure 3. 5. Frequency of ASCs, total 
IgG-secreting cells and correlation with 
severity of infection 
Panel A: Accumulated data from the conversion 
of circulating memory B cells in blood to 
antibody-secreting cells after six days’ culture in 
the presence of polyclonal mitogens. Data from 
donors at different stages of EBV infection are 
compared. Data are represented as 
percentages and statistical analysis was done 
by one-way ANOVA, Tukey’s multiple 
comparison with **** p<0.0001, *** p<0.001, ** 
p<0.01 and * p<0.05. 
Panel B:  Using B cell ELISpot analysis, the 
frequencies of IgG-secreting cells per million 
PBMC are compared for donors during and post 
IM, and healthy virus carriers. The p value was 
obtained by one-way ANOVA, Tukey’s multiple 
comparison with **** p<0.0001. 
Panel C:  Correlation of frequency of IgG-
secreting cells with severity of infection. Severity 
of infection (SOI) scores assigned to acute IM 
patient donors ranged from zero to six, with 
asymptomatic infection being assigned a score 
of zero and severe symptoms with confinement 
to bed a score of six. The samples were 
grouped according to the severity of infection, 
with scores 0–3 being classified as mild 
infection and 4–6 as severe infection. 
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The severity of EBV-infection has been recently shown to correlate with a number of 
factors, including the viral load in peripheral blood and the peripheral CD8+ T cell numbers 
(Balfour, Odumade et al. 2013). To determine if the abovementioned B cell defects are 
associated with disease severity, a correlation between the severity of infection and 
frequency of total IgG-secreting B cells was explored. Acute IM samples were scored from 
mild to severe with scores ranging from 0 for asymptomatic infection, to 6 for severe illness 
requiring confinement to bed or hospitalization.  These samples were grouped, with scores 
0–3 classified as mild symptoms and 4–6 as severe symptoms, and the results were 
compared against the frequency of IgG-secreting B cells. Although not significant, likely 
due to the low cohort size in this analysis, a trend was observed where increasing severity 
of symptoms corresponded inversely with the incidence of IgG-secreting cells (Figure 
3.5C). 
In addition to assessing the frequency of memory B cells and ASC populations during 
IM, the frequency of a recently-discovered B cell subset—B regulatory cells—were also 
assessed for IM patients at different stages of acute EBV infection. B regulatory cells 
(Bregs: CD3-CD19+CD24hiCD38hi) are known to contribute to maintaining immune 
tolerance by balancing the Treg and Th1/Th17 populations (Flores-Borja, Bosma et al. 
2013). They also are known to play an important role in autoimmunity, allergy, cancer, and 
post transplantation (Blair, Norena et al. 2010, Newell, Asare et al. 2010, Schioppa, Moore 
et al. 2011, Carter, Rosser et al. 2012). Since EBV infection—and a history of IM in 
particular—have been implicated in various autoimmune diseases, a comparison was 
done of the frequencies of Bregs during different stages of EBV infection to understand 
their function during IM. Figure 3.6A shows the gating strategy for Breg cells as CD3-
/CD19+ B cells that express high levels of CD24 and CD38. A comparison of the frequency 
of these cells in patients during IM and after recovery, or in healthy virus carriers, showed 
no statistically significant differences (Figure 3.6B). These observations suggest that Bregs 
are unlikely to play a significant role during symptomatic primary EBV infection. 
  
 50 
 
 
 
 
Figure 3. 6. Frequency of B regulatory cells during EBV infection  
Panel A:  The difference in frequencies of B regulatory cells (Bregs) at different stages of EBV 
infection was measured by flow cytometry. Representative dot plot shows the gating strategy for 
Breg cells as CD3-/CD19+ B cells that express high CD24 and CD38. PBMC were incubated with 
fluorescently labelled antibodies specific for CD3, CD19, CD24 and CD38 and analysed.  
Panel B: Compilation of all data from donors with 13 acute IM samples, 12 recovering post IM 
samples (20–50 days after onset of symptoms), 11 post-IM samples more than six months since 
start of symptoms, and 10 healthy virus carriers are compared.  Data are represented as 
percentage of CD3-/CD19+ B cells and statistical analysis was done by one-way Anova, Tukey’s 
multiple comparisons, with ns meaning no significant difference between donor groups. 
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3.4.2. The Mechanism of Reduction of B Cell Frequency 
Data presented above suggested that acute EBV infection is associated with global B 
cell dysfunction. To explore the possibility whether direct infection of B cells with EBV 
impacts upon the conversion of memory cells to ASCs, PBMC from seven healthy 
volunteers were infected with EBV or mock infected for 6 h. These cells were washed and 
incubated with mitogens to convert memory B cells to antibody-secreting cells. ELISpot 
analysis of these donors was then performed to measure the IgG production and 
compared between infected and uninfected samples. ELISpot analyses showed 
comparable production of IgG between the two sets of samples, infected and mock treated 
(Figure 3.7).  
 
 
 
Figure 3. 7. Effect of EBV infection on conversion of MBC to ASC  
PBMC from healthy donors were infected with EBV B95-8 and used for conversion of memory B 
cells to antibody-secreting cells. The frequency of total IgG secreting cells was quantified and 
compared with mock treated PBMC by B cell ELISpot assay.   
 
To investigate other potential mechanism that results in reduced frequency of MBC 
and total B cells during IM, the concentration of BAFF and its homolog APRIL and 
expression of its receptors (BAFF-R, TACI and BCMA) on B cells were analysed. PBMC 
were stained with antibodies specific for BAFF-R, BCMA and TACI and its expression on 
CD3-/CD19+ B cells was assessed using flow cytometry. BAFF receptor expression on B 
cells was analysed using PBMC from donors undergoing acute IM and follow-up samples 
after six months of recovery. A longitudinal analysis of B cells from 12 IM patients showed 
that the expression of BAFF-R on B cells is significantly decreased during acute IM, with 
improved expression on disease resolution (Figure 3.8A). The percentage of B cells 
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expressing TACI on CD19+CD27+ memory B cells was found to be similar between 
different cohorts of EBV-infected individuals (Figure 3.8B). However, a significant increase 
in BCMA expression was observed on B cells from acute IM patients when compared to 
age-matched asymptomatic controls. Furthermore, the mean fluorescence intensity (MFI) 
of BCMA expression was found to be significantly higher during acute EBV infection when 
compared to latent infection (Figure 3.8C). This reversal in expression pattern of BAFF-R 
and BCMA during acute IM could also suggest defective BAFF signalling that could have 
an effect on the survival of B cells as no increase in ASCs was noticed during acute IM.  
 
 
Figure 3. 8. Expression of TNF 
receptor superfamily. 
BAFF/APRIL receptors, during 
EBV infection  
Panel A: Expression of the main B cell 
activation factor receptor (BAFF-R) on 
B cells measured as the mean 
fluorescence intensity MFI by flow 
cytometry. A total of 15 longitudinal 
samples from donors during and post 
IM, and 12 healthy virus carriers, were 
analysed and compared.  
Panel B: The expression of TACI, which 
is a common receptor for both BAFF 
and APRIL were measured on memory 
B cells (CD19+/CD27+ cells).  PBMC 
from 6 longitudinal IM samples and 12 
health carriers were analysed for TACI 
expression.  
Panel C: The expression of APRIL- 
specific receptor BCMA was measured 
as the mean fluorescence intensity 
MFI by flow cytometry. 9 longitudinal 
samples and 12 healthy virus carriers 
were analysed for BCMA expression. 
The data are presented as mean+/- 
SEM and statistical analysis for the 
same sample at different time points 
was done by Wilcoxon analysis, while 
comparison between different groups 
was done using Mann-Whitney 
analysis. The significant p values were 
** p<0.01 and * p<0.05. 
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In the next set of experiments, the plasma concentration of BAFF and its homolog 
APRIL were determined by ELISA using plasma samples from acute IM and age-matched 
individuals. Interestingly, plasma BAFF levels appeared to be inversely proportional in 
acute IM samples to the expression of BAFF-R. BAFF levels showed a significant increase 
during acute IM, with levels decreasing as the disease resolved (Figure 3.9A). Samples 
from post-IM and asymptomatic virus carriers showed similar concentration of BAFF in 
plasma. Conversely, plasma levels of APRIL were found to be significantly decreased 
during acute IM, with levels increasing after disease resolution (Figure 3.9B). Since APRIL 
is reported to be critical for the survival of plasma cells in bone marrow (Belnoue, Pihlgren 
et al. 2008), the reduced secretion of APRIL during acute IM could also impact upon the 
survival of blood ASCs during acute IM. These data provide further support for the 
dysregulation of BAFF signalling during acute IM. 
 
 
Figure 3. 9. Concentration of TNF-family members BAFF and its homolog APRIL  
Panel A:  Concentration of B cell activation factor (BAFF) as measured by ELISA. Nine longitudinal 
plasma samples from donors during and post IM were compared to plasma from 10 healthy virus 
carriers. 
Panel B: Concentrations of APRIL were measured by ELISA for 10 longitudinal plasma samples 
from donors during and post IM and compared to plasma from 11 healthy virus carriers.  
The data are presented as mean +/- SEM and statistical analysis for the same sample at different 
time points was done by Wilcoxon analysis, while comparison between different groups was done 
using Mann-Whitney analysis. The significant p values were *** p<0.001, ** p<0.01,* p<0.05 and 
ns as not significant. 
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To study whether the reduction in B cell numbers could be associated with an 
increased susceptibility to apoptosis, the expression of FAS on B cells was compared in 
IM samples and age-matched controls. A longitudinal analysis showed a significant 
increase in the expression of FAS on circulating B cells during acute IM with the level 
decreasing to reach level similar to age-match control upon disease resolution (Figure 
3.10A). Furthermore, the levels of FAS-L were found to be significantly higher in the 
plasma of acute IM patients when compared to asymptomatic latent virus carriers. 
Following resolution of acute IM symptoms, FAS-L levels reduced to the level observed in 
the plasma of asymptomatic latent virus carriers (Figure 3.10B). The increased level of 
soluble FAS-L in the plasma of IM patients could be an indication of increased expression 
of membrane-bound FAS-L on immune cells that could impact upon B cell survival. 
 
 
Figure 3. 10. FAS expression on B cells and FAS L concentration in plasma  
Panel A: FAS expression on CD19+ B cells from PBMC of 12 longitudinal IM donors and healthy 
virus carriers were analysed by measuring the mean fluorescence intensity MFI by flow 
cytometry.  
Panel B: FAS L concentration in the plasma of 10 longitudinal IM donors and 12 healthy virus 
carriers were measured by cytometric bead array from BD.  
The data are presented as mean +/_ SEM and statistical analyses for the same sample at different 
time points was done using Wilcoxon analysis and comparison between different groups using 
Mann-Whitney analysis. The significant p values correspond to * p<0.05, **p<0.01, *** p<0.001. 
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3.4.3. Influence of Cytokines and FAS-Mediated Killing 
One mechanism by which FAS expression might be up-regulated in B cells during IM 
is through cytokine mediated signalling. To assess this, PBMC from healthy donors were 
incubated with different cytokines shown to be elevated in the plasma of IM patients. 
These cytokines included IL-4, IL-6, IL-10, IL-12, IFN- , TNF- and TGF-Following 
incubation, FAS expression was assessed on B cells by flow cytometry. Of all the 
cytokines tested, exposure to IL-12 for 1-3 days resulted in the increased expression of 
FAS on B cells (Figure 3.11A, 3.11B). None of the other cytokines showed an increase in 
FAS expression. Next, the possibility of increased apoptosis by these B cells was tested 
by the addition of FAS-L. Three different forms of FAS-L was used in the experiments as 
monomeric soluble FAS-L was found to be less effective in triggering apoptosis when 
compared to FAS-L aggregate or membrane bound FAS-L. FAS upregulated B cells were 
incubated separately with soluble FAS-L (monomer or aggregated soluble FAS-L) or 
membrane-bound FAS-L and evaluated for apoptosis by annexin V staining. There was no 
noticeable increase in apoptotic cells when FAS upregulated cells were compared to 
mock-treated cells (data not shown). This suggests that increased expression of FAS 
alone is not enough to cause low B cell number, but that in combination with other factors 
like low BAFF-R expression, could also impact the survival of B cells during acute IM. 
 
 
Figure 3. 11. Cytokine influence in 
the reduction of B cells  
Various cytokines reported to be 
elevated during acute IM were 
incubated with PBMC from healthy 
virus carriers in an in vitro setting. The 
cells were grown in serum-free medium 
and incubated with individual cytokines 
at concentrations of IL-4 (10 ng/ml), IL-
6 (10 ng/ml), IL-10 (500 pg/ml), IL-12 
(10 ng/ml), IFN-  (100 u/ml), TNF- (50 
ng/ml) and TGF- (10 ng/ml). The cells 
were cultured for 1–3 days and the 
expression of FAS on B cells was 
calculated as mean fluorescence 
intensity MFI by flow cytometry.  
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3.5. DISCUSSION 
Global B cell function, and the frequency and phenotype of B cell subsets during EBV 
infection have not been well studied.  Understanding the kinetics of B cell subsets, MBCs 
and ASCs could provide significant insights into immune control in the early stages of EBV 
infection. The focus of studies outlined in this chapter was to quantify the two major B cell 
subsets that provide protective immunity. Besides studying the frequency and phenotype 
of B cell subsets, these studies also explored the various factors that could impact upon 
the survival and function of B cells during acute EBV primary infection. 
Symptomatic primary EBV infection is associated with a dramatic expansion of 
predominantly effector CD8+ T cells and to a lesser extent NK cells. The research reported 
here show that acute EBV infection is associated with a significant decrease in the number 
of B cells in the peripheral blood.  In this chapter, further evidence is provided 
demonstrating that this reduction in B cell numbers in the peripheral blood is associated 
with a reduction in the proportion of MBCs during acute IM, and is likely associated with 
dysregulation in BAFF/APRIL signalling. These changes are also associated with poor in 
vitro conversion of memory B cell populations into ASCs. This observation is 
complimented by the report by Svedmyr et al where PBMC from an acute IM patient 
showed severe reduction of Ig synthesis when activated by mitogen whilst response of B 
cells before the symptomatic infection and after recovery were normal (Svedmyr, Ernberg 
et al. 1984). Although it could be argued that the reduction in peripheral B cells is due to 
direct infection of B cells by EBV and loss of these B cells in the peripheral blood as a 
consequence of either EBV-induced lysis of infected B cells or clearing by EBV-specific T 
cells, it has been shown that EBV typically infects around 1% of peripheral B cells during 
acute IM (Klein, Svedmyr et al. 1976, Hochberg, Souza et al. 2004), suggesting that the 
significant changes in the B cell compartment during symptomatic infection are not likely 
due to EBV-induced specific recognition of EBV-infected B cells by EBV-specific CD8+ T 
cells. It is also unlikely that direct EBV infection of B cells contributed towards the 
inefficient in vitro conversion of MBCs into ASCs as in vitro infection of PBMC from healthy 
donors with EBV did not prevent IgG production and was comparable to mock infected B 
cells. 
In addition to a reduction in the number of B cells in the peripheral blood during acute 
EBV infection, there was also no evidence of an increase in the frequency of ASCs during 
IM. This is in contrast to elevated ASCs that are evident in the blood during infection with 
other viruses like influenza, dengue and respiratory syncytial virus (Lee, Falsey et al. 2010, 
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Wrammert, Koutsonanos et al. 2011, Wrammert, Onlamoon et al. 2012). While detection 
of antibody responses to EBV- antigens, particularly the viral capsid antigens, during IM 
suggests that early ASC formation during the 4-6 week incubation period does occur, 
dysfunction in the B cell compartment that is evident during IM suggests that continual 
plasmablast formation or their survival may be disrupted during symptomatic infection. 
This could potentially have a profound impact on the efficiency of EBV-specific antibody 
production following infection, resulting in the poor control of virus.   
While the direct mechanism that is leading to this global B cell dysfunction during IM 
is not absolutely evident, it is clear that the cytokine milieu may play a role, as was evident 
following in vitro observations showing that IL-12 can lead to the induction of FAS-
expression in B cells. Since IL-12 also plays a role in the promotion of B cell differentiation 
and plasmablast formation, other mechanisms, such as those inducing dysregulation in 
BAFF receptor signalling are also likely important mediators of B cell dysfunction during 
acute IM. BAFF-BAFF-R signalling was reported to provide survival signals to B cells in 
mice by inducing anti-apoptotic factor Bcl2 and together with B cell receptor (BCR) 
regulates B cell survival (Rauch, Tussiwand et al. 2009). Since dendritic cells and CD4 T 
cells play a direct role in the development of humoral immunity, these cells could influence 
the B cell development and function.  The function of these cells will be discussed in the 
following chapters so as to present an overall picture of the immune response during acute 
IM.   
Dysregulation in BAFF signalling have been associated with other diseases, 
including autoimmune disorders and primary antibody deficiencies that show a B cell 
dysfunction (Sellam, Miceli-Richard et al. 2007, Kreuzaler, Rauch et al. 2012). Some of 
these diseases show a strong correlation with EBV infection. Although highly speculative, 
it is possible that this B cell dysfunction during acute EBV infection could contribute to its 
potential role in B cell-associated autoimmune disorders. However, the role of EBV 
infection in these disorders is not absolutely definitive and requires significant further 
investigation to determine if the B cell dysfunction seen in both settings is related. It should 
also be noted that changes in BAFF signalling are also evident during acute malaria 
infection and in HIV infected individuals (Moir, Malaspina et al. 2004, Sellam, Miceli-
Richard et al. 2007, Nduati, Gwela et al. 2011). The reason for the inverse correlation in 
the expression of BAFF and its main receptor BAFF-R on B cells during acute IM is not 
clear.  It could be that high levels of BAFF in the serum of IM patients cause receptor 
endocytosis, or that reduced BAFF-R expression on B cells results in an increased BAFF 
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level. A decrease in BAFF-R expression and expression of BCMA on peripheral blood B 
cells is typically associated with the conversion of memory B cells into plasma cells (Avery, 
Kalled et al. 2003); so the reversal in expression pattern of BAFF-R and BCMA during 
acute IM could suggest premature maturation of B cells. Decreased expression of BAFF-R 
and increased expression of FAS found during acute IM has also been reported in HIV-
viremic patients and has been associated with reduced B cell number during HIV infection 
(Moir, Malaspina et al. 2004).  
The study of global B cell function during acute IM revealed a previously 
unappreciated defect in the peripheral B cell compartment with a reduced frequency of 
memory B cells, the absence of antibody-secreting cells and impaired conversion of 
memory cells to antibody-secreting cells during acute IM.  It also showed a dysregulation 
in BAFF signalling which is crucial for B cell survival and increased expression of death 
receptor FAS. This change in phenotype of B cells during acute IM could result in 
increased susceptibility to apoptosis and explain the reduction in B cell subsets. Therefore 
the next aim in this project is to study the impact these apparent B cell defects could be 
having upon the induction of an EBV-specific humoral immune response.  
 
  
 59 
 
CHAPTER 4. GP350-SPECIFIC B CELL 
RESPONSE DURING ACUTE IM 
4.1. ABSTRACT 
Immunity to most pathogens requires the combined effort of both innate and adaptive 
immune responses. During EBV infection, cell-mediated immunity, the CD8 T cell 
response in particular, is primarily responsible for controlling infection. While the T cell 
response to EBV has been well characterized, B cell and humoral immune responses 
have largely been ignored. Antibodies produced against EBV—non-neutralising viral 
capsid antigen (VCA) and EBV nuclear antigen (EBNA1)—are used as diagnostic markers 
for the detection of EBV infection. It is known that the EBV membrane antigen EBV MA-
gp350 is the major target of the virus-neutralising antibody response after natural infection. 
EBV MA-gp350 is the best-characterized vaccine antigen and it has been used in various 
preclinical and clinical vaccine trials. While no protection from primary EBV infection has 
been detected, neutralisation against gp350 has been found to be effective in reducing the 
symptoms of IM. Studies in this chapter showed a defect in global B cell response during 
acute infectious mononucleosis (IM). Sequential analysis of quantity and quality of virus-
specific antibody response were measured using B cell ELISpot and ELISA revealed a 
reduction in memory B cells and reduced gp350 antibody titres. More importantly, IM 
patients also showed a total lack of anti-EBV neutralising antibody response. Taken 
together, these studies suggest that a dysregulation of both global and anti-viral B cell 
responses is a critical factor in high levels of circulating viral load in acute IM patients.    
. 
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4.2. INTRODUCTION 
The immune response to EBV is, by and large, successful in controlling infection and 
ensuring lifelong latency of the virus. However, primary EBV infection can be associated 
with severe disease, and is associated with an increased risk of a number of complications 
during the latent stage of infection. The role of CD8+ T cells in the control of viral infection 
and their contribution to the severity of clinical symptoms during IM are well understood. 
The amplified response of CD8+ T cells to EBV causes IM in some, but could also lead to 
the clearance of EBV-infected cells in others (Hislop, Annels et al. 2002). Although the 
presence of the humoral or antibody response is used in the diagnosis of EBV infection, 
the mechanism of B cell response to EBV infection is not well understood. However, it is 
known that EBV membrane antigen EBV MA-gp350 is the major focus of virus-neutralising 
antibodies after natural infection (Thorley-Lawson and Poodry 1982).  
EBV MA-gp350 is required for efficient infection of B cells by EBV. The virus binds to 
CD21, the complement receptor 2 (CR2) on B cells (Fingeroth, Weis et al. 1984). Until 
recently, CD21 was the only known receptor for gp350, but a recent report stated that 
complement receptor 1 (CR1 or CD35) on B cells also binds gp350 (Ogembo, Kannan et 
al. 2013). This protein is found in abundance on the envelope of viral particles and on the 
surface of EBV-infected cells (Beisel, Tanner et al. 1985). EBV MA-gp350 induces a virus-
neutralising antibody response against EBV after primary infection (Thorley-Lawson and 
Poodry 1982). For this reason, the various preclinical vaccine trials in animal models and 
clinical trials in humans have used gp350 as the immunogen, and it is the best-
characterized vaccine antigen against EBV (Epstein, Morgan et al. 1985, Morgan, Finerty 
et al. 1988, Gu, Huang et al. 1995, Sokal, Hoppenbrouwers et al. 2007). Despite this focus 
on gp350 as a vaccine candidate, very little research has been done to study the role of 
the gp350-specific response during primary infection.  
Interaction between CD4 T cells and B cells in the secondary lymphoid organs is 
required for the development of humoral immunity (Garside, Ingulli et al. 1998). TFH cells 
are specialized CD4+ T cells that reside in secondary lymphoid organs and support the 
development and maturation of B cells (Junt, Fink et al. 2005). Interaction between B cells, 
TFH cells and DCs in response to foreign antigens facilitates the formation of germinal 
centres in secondary lymphoid organs and differentiation of B cells into plasma cells and 
memory B cells (Hardtke, Ohl et al. 2005). Since TFH cells reside mostly in secondary 
lymphoid organs like the lymph nodes, alternative approaches in human subjects has been 
developed to study circulating memory TFH cells in blood, which have been shown to share 
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functional properties with lymphoid TFH cells and correlate with antibody responses 
(Breitfeld, Ohl et al. 2000, Morita, Schmitt et al. 2011, He, Tsai et al. 2013, Locci, Havenar-
Daughton et al. 2013).  
The primary objective of the studies outlined in this chapter was to investigate the 
kinetics of the EBV-specific B cell response in patients undergoing acute IM. To quantitate 
B cell response to EBV, resting memory B cells were induced to convert to antibody-
secreting cells by in vitro stimulation using a mix of polyclonal mitogens. EBV membrane 
antigen gp350 was used as the immunogen (Crotty, Aubert et al. 2004). This assay was 
complemented by ELISA, which measured serum antibody titre during and post infection. 
Together, they showed the response of the two arms of humoral immunity which provide 
protection—circulating memory B cells in blood and long-lived plasma cells in bone 
marrow. In addition, the capacity of antibodies in the plasma of IM patients to neutralise 
the virus was also tested and compared by conventional method (Moss and Pope 1972).   
The data showed reduced gp350-specific memory B cells, low gp350 antibody titre in 
the plasma and no detectable level of neutralising antibody in patients undergoing IM. The 
presence of CXCR5+ TFH cells in peripheral blood was found to be very low while CXCR3 
expressing CD4+ T helper cell response was found to be the predominant CD4+ T cell 
response during IM. EBV membrane antigen gp350 was found to be a very poor T cell 
antigen. 
 
4.3. MATERIALS AND METHODS 
4.3.1. EBV MA-gp350 Protein Purification  
CHO cells secreting truncated EBV MA-gp350 were kindly provided by Prof. Jaap 
Middeldorp (Hessing, van Schijndel et al. 1992). The cells were grown to high density in 
DMEM/Ham’s F12 (Life Technologies) at 1:1 ratio containing 10% heat-inactivated FCS, 
100 units/ml of penicillin and 100 µg/ml of streptomycin. The cells were maintained in 
serum-free DMEM/F12 medium and the secreted protein was collected and concentrated 
using Amicon Ultracel-50K (Millipore).  
The concentrated protein was then purified using con A sepharose 4B column (GE 
Healthcare). It was dialyzed using snake-pleated dialysis tubing (Thermo Fisher) in binding 
buffer (20 mM Tris–HCl pH 7.4, 0.5 M NaCl in water). The con A sepharose column was 
equilibrated overnight and washed with three times the column volume of binding buffer. 
The dialyzed protein in binding buffer was loaded onto the column and the flow-through 
 62 
 
was collected. The protein was reloaded onto the column three more times to facilitate 
maximum protein retention. The column was then washed with six times the column 
volume of wash buffer (binding buffer with 25 mM –D methyl glucoside) and eluted with 
increasing concentration of –D–methyl glucoside (ACROS Organics, Thermo Fisher). 
4.3.2. Dot Blot 
This protocol was used to determine the presence of EBV MA-gp350 protein after its 
expression and purification. On a strip of nitrocellulose membrane, the position of each 
sample was marked as a circle with pencil. 10 µl of different samples from protein 
purification (flow-through, wash and elution samples with different concentration of –D–
methyl glucoside), as well as positive and negative controls, were blotted on the 
nitrocellulose membrane. Using a narrow-mouth pipet tip, 1 µl of the sample was spotted 
each time to the centre of the circle. The membrane was allowed to dry for 1 h at room 
temperature and blocked using 5% dry milk in PBST (PBS with 0.05% Tween–20). After 1 
h of blocking, the membrane was incubated with OT6 mAb to gp350, a gift from Prof. 
Middledorp, at 1:3000 dilutions in PBST at room temperature on a rocker. The membrane 
was incubated with a secondary antibody after washing with PBST. Goat anti-mouse HRP 
(Southern Biotech) was used as the secondary antibody at 1:3000 dilution and incubated 
for 1 h at room temperature. The protein was detected using western lightning plus-ECL 
(Perkin-Elmer), exposed on an x-ray film and developed in the dark. 
4.3.3. SDS–PAGE and Western Blotting 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis was performed to 
confirm the presence of the protein EBV MA-gp350 after its purification by lectin 
chromatography. The purified protein was analysed using a 6% SDS–PAGE based on the 
molecular weight of the protein. A 6% gel (prepared from 30% acrylamide:bisacrylamide 
stock solution, 0.4 M Tris–HCl pH 8.8 ,0.1% SDS, TEMED and ammonium persulphate 
(APS) was loaded with molecular weight marker (Precision Plus Protein Standards from 
Bio-Rad) and different concentration of the protein in reducing buffer (50 mM Tris0HCl pH 
6.8, 50% Glycerol, 5% SDS, 0.05% BromoPhenolBlue and 0.25 M DTT). The samples 
were prepared in reducing buffer and incubated at 95°C for 5–10 min before loading on the 
gel. Electrophoresis was done on a Mini-Protein II cell gel apparatus (Bio-Rad) at room 
temperature at 24 Amp for I h and stained with Coomassie Brilliant Blue (0.25% 
Coomassie Blue, dissolved in 10% acetic acid and 50% methanol). Tris-Glycine buffer (25 
mM Tris, 0.25 M Glycine and 0.1% SDS) was used as running buffer for electrophoresis.  
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After electrophoresis, the protein was transferred to a nitrocellulose membrane, 
Hybond-C (Amersham). The transfer was conducted in the cold room at 100 V for 1 h. The 
membrane was blocked with 5% non-fat dry milk (Bio-Rad) and developed with gp350 
mAb EBV OT6 provided by Prof. Middledorp (Hessing, van Schijndel et al. 1992) with a 
1:3000 dilution for 1 h at room temperature, followed by incubation with secondary 
antibody goat anti-mouse HRP (Southern Biotech) at 1:3000 dilution. The protein was 
visualized by Western Lightning Plus-ECL (PerkinElmer) using an X-ray film.  
4.3.4. Protein Concentration Estimation-Bradford Assay 
The protein concentration was estimated using Quickstart Bradford dye reagent (Bio-
Rad). Protein standards were made from 2 mg/ml BSA (Sigma) and PBS was used as 
blank. In a 96-well flat-bottom plate, seven serial dilutions of protein standards were made 
in duplicate. The measurement was taken in a Spectrophotometer and each sample was 
analysed in duplicate. 
4.3.5. Endotoxin Test 
The protein gp350, both homemade and commercial, were tested for Endotoxin 
using ToxinSensor Endotoxin Detection System from GenScript. The sample pH was 
between 6 and 8. Reagents were prepared in accordance with the manufacturer’s 
instructions. Limulus Amebocyte Lysate (LAL) was reconstituted by adding 1.7 ml LAL 
reagent. The chromogenic substrate was reconstituted similarly. Colour stabilizers 1, 2 and 
3 were reconstituted in 10 ml of Stop solution for 1 and LAL water for 2 and 3. Standard 
endotoxin solution was dissolved in 1 ml LAL water to get 6 EU, from which 1 EU/ml was 
used to make dilutions for making the standard curve. The standard concentrations were 
0.1, 0.04, 0.02, 0.01 and 0.005. 
100 µl of standards, samples and blank were dispensed into endotoxin vials. 100 µl 
of LAL was added to each vial and mixed by vortexing. The tubes were incubated at 37oC 
for 45 min. After incubation, 100 µl of chromogenic substrate was added to each vial, 
mixed gently and incubated for another 6 min at 37°C. This was followed by the addition of 
500 µl of colour-stabiliser #1, followed by 500 µl each of colour-stabilizer #2 and #3, with 
mixing between each addition. The absorbance of each reaction at 545 nm was read on a 
spectrophotometer. 
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4.3.6. B Cell ELISpot  
Memory B cells in PBMC were quantified using the method developed by Crotty et al 
(2004), in which memory B cells are converted to antibody-secreting cells in vitro. PBMC 
were thawed and incubated at 37°C in a 24-well plate at 5x105 cells/ well for six days. The 
cells were suspended in R10 (RPMI1640 with penicillin/streptomycin 100 IU/ml, 10% heat-
inactivated FCS, 50 µM -mercaptoethanol).The medium was supplemented with an 
optimized mix of polyclonal mitogens, which included pokeweed mitogen extract (PWA) at 
1/100,000 dilution, Protein A from Staphylococcus aureus, Cowan strain (SAC) at 1/10,000 
dilution, CpG ODN 2006 at 2.5 µg/ml (Sigma Aldrich) (Crotty, Aubert et al. 2004) and IL-10 
(BD Biosciences) at 25 ng/ml (Weiss, Traore et al. 2010). 
The antigen was immobilized on a 96-well ELISpot plate (Millipore Multiscreen HTS 
IP) and incubated at 4°C overnight. The plate was coated with 25 g/ml of gp350, 
recombinant EBV membrane antigen expressed from CHO cells (Hessing, van Schijndel 
et al. 1992), a control EBV non-neutralising structural antigen VCA (Gen Way Biotech), 
and 10 µg/ml of tetanus toxoid (CSL) as a general antigen control. To estimate total IgG 
secreting cells, 5 µg/ml of capture anti-IgG (Mabtech, Resolving Images) was used. On the 
next day, the plates were washed with PBS and blocked with R10 for 2–4 h at room 
temperature. The in vitro activated cells were washed and plated in triplicate to antigen-
coated wells at 3x105 cells/ well in order to detect antigen-specific antibody-secreting cells 
(ASC). For the detection of total IgG-secreting cells, 3000 cells/well were plated in 
triplicate to the wells containing capture anti-IgG. The plates were then incubated at 37°C 
overnight. The following day, the excess cells were washed with PBS containing 0.05% 
Tween-20 (PBST) and incubated with 1:500 biotinylated anti-IgG (Mabtech) for 2 h at room 
temperature followed by incubation with 1:1000 Streptavidin-AP (Sigma Aldrich) for 1 h at 
room temperature. The plates were then incubated with Sigma Fast BCIP/NBT (Sigma 
Aldrich) at room temperature until spots developed, following which the reaction was 
stopped by washing with water. Spot quantification was done using an ELISpot reader 
(AID Diagnostika). 
4.3.7. Fluorolink Cy5 Labelling  
1 mg/ml gp350 protein was used for labelling with the Fluorolink Cy5 labelling kit from 
GE Healthcare. The protein was mixed with sodium carbonate buffer pH 9.3, followed by 
incubation with the dye, pre-weighed ready to label and supplied in the kit. The reaction 
was incubated for 30 min at room temperature, with additional mixing every 10 min. The 
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unconjugated dye was separated from the labelled protein using a gel filtration system that 
was provided by the manufacturer. 
CD19+ B cells were enriched from the PBMC of EBV sero-positive and sero-negative 
donors by positive selection with an autoMACS separator. 20 µl of CD19 microbead was 
incubated per 107 PBMC for 15 min in the dark in 100 µl buffer (PBS with 2 mM EDTA and 
0.5% FCS) at 4°C. The cells were washed with 2 ml buffer and resuspended in 500 µl 
buffer for magnetic separation using autoMACS separator (instrument and microbeads 
from Miltenyi Biotec). The instrument was prepared and primed according to the 
manufacturer’s instructions. Sample tubes were placed at the uptake port and the fraction 
collection tubes at port pos1 to collect the positive (labelled) fraction and port neg1 for the 
negative (unlabelled) fraction using the positive selection program on the separator. 
Positive fraction which contains the CD19+ B cells were used to incubate with and without 
Cy5 labelled gp350 protein (1 µg/sample well) and with and without unconjugated anti-
CD21 to block gp350 receptor on B cells. Enriched CD19+ B cells were stained with 
Live/Dead fixable aqua, a live dead stain from Invitrogen, followed by anti-CD21 antibody 
and then finally with Cy5 labelled gp350. B cells are then analysed by flow cytometry. 
4.3.8. Biotin Labelling of gp350  
Recombinant gp350 from MedImmune was biotinylated using the EZ-Link 
Pentylamine-Biotin from Thermo Fisher. EZ-Link Pentylamine-Biotin has a terminal 
primary amine which can bind to terminal carboxyl group on a protein. The reaction was 
mediated by EDC, which is a carbodiimide crosslinker that activates the carboxyl group to 
bind to primary amine, forming an amide linkage. 
The protein (5 mg/ml) was dialysed into 25 mM MES buffer, pH 5.5 (Amresco) using 
a Slide-A-Lyzer dialysis cassette (Thermo Fisher) overnight in the cold room. The protein 
in MES buffer was concentrated using a 10 K Ultracel (Millipore) to 500 µl. Pentylamine-
Biotin was dissolved in water at 50 mM in 500 µl. Equal volumes of biotin solution and 
protein were mixed. Just before use, an EDC solution was made in MES buffer at 20 
mg/ml. 50 µl of the EDC solution was added to the protein-biotin mix and incubated at 
room temperature for 2 h with shaking. Non-reacted Pentylamine-Biotin and EDC by-
products were removed by dialysis using Slide-A-Lyzer dialysis cassette. The biotinylated 
protein was stored at 4°C, as recommended by the manufacturer.  
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4.3.9. gp350 Tetramer Preparation 
Biotinylated gp350 was used in the preparation of tetramers using Streptavidin–PE 
(SAPE) premium grade (Molecular Probes, Invitrogen) and Streptavidin-APC (Prozyme-
Phycolink Strep-APC from Prozyme). The amount of protein and streptavidin conjugate 
required for a 4:1 molar ratio was calculated as published in Current Protocols in 
Immunology- Basic Protocol 4. The protocol for preparing MHC tetramer was adapted for 
this purpose. 
The streptavidin conjugate was added to the biotinylated protein in 5 steps of small 
aliquots with 10 min interval between each addition. The tetramerisation was done on ice 
and kept in dark between additions. Before cell staining, the tetramer preparation was 
centrifuged for 5 min at maximum speed to remove aggregates. 
4.3.10. B Cell Labelling Using gp350 Tetramers 
PBMC were thawed and rested for 1 h in RPMI1640 with 10% FCS at 37°C. The 
cells were counted and 200,000 cells were distributed per well in a 96-well V bottom plate. 
The gp350 receptor CD21 on B cells was blocked using anti-CD21 antibody (R&D 
Systems) to avoid the selection of all B cells. The blocking kept non-gp350-specific B cells 
from being labelled. 
The cells were washed twice in PBS with 2% FCS and incubated with and without 
anti-CD21 antibody at a concentration of 10µg/ml. The cells were incubated at 4°C for 30 
min. Then without washing the protein, gp350 (monomer or tetramer) was added to the 
wells at 5 µg/well and incubated for another 30 min at 4°C. The cells were washed once 
and incubated with CD19-eFluor450 to label B cells. The gp350-specific B cells were 
sorted as CD19+, PE or APC positive cells by flow cytometry. The cells were also stained 
with Live/Dead aqua (Life Technologies) to eliminate dead cells, followed by CD3/CD14 
FITC (Beckman Coulter/BD Biosciences) to eliminate T cells and monocytes. The B cells 
were then stained with both Strep-PE and Strep-APC. The gp350-specific B cells were 
then visualized as live cells/CD3-/CD14-/CD19+ cells, which are double positive for PE and 
APC. 
4.3.11. Enzyme Linked Immunosorbent Assay (ELISA) of gp350 
ELISA was done using ELISA plates (EIA/RIA plate from Costar and gp350 antigen 
from MedImmune). 5 g/ml of protein was plated in carbonate buffer, pH 9.4, on ELISA 
plates and incubated overnight at 4°C. The coated plates were washed in PBS containing 
0.05% Tween–20, PBST and blocked with PBS containing 5% non-fat dry milk (blotting 
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grade blocker from Bio-Rad) for 2 h at room temperature. The plates were washed and 25 
µl of serially diluted plasma samples were added in duplicates and incubated for 2 h at 
room temperature on a plate shaker. After further washing in PBST, 25 µl of 1:1000 
dilution of HRP-conjugated goat anti-human IgG (Chemicon, Millipore) or 1:4000 dilution of 
goat anti-human Ig (Southern Biotech) was added and incubated for 1 h. After washing in 
PBST, 25 µl of 1xTMB ELISA substrate solution (eBiosciences) was added for colour 
development and incubated for 15 min at room temperature in the dark, after which the 
reaction was stopped by the addition of 25 µl of 1 M HCL. The absorbance was measured 
using a spectrophotometer at the wavelength of 450 nm.  
4.3.12. Titration of EBV Virus Pool 
To titrate EBV virus pool B95-8, PBMC of an EBV seronegative donor were used. 50 
µl of 1x105 cells/ well was plated in a 96-well plate and 50 µl of 10-fold serial dilution of 
virus was added and incubated at 37°C for 1 h. Each dilution was done in six replicates 
and the virus dilutions started with undiluted and 5 x 10-fold dilutions were used. The 
plates were centrifuged at 300 x g/5 min, the medium removed and resuspended with 
fresh R10. For the next four weeks, 100 µl of the medium was removed and replaced with 
100 µl of fresh R10 and read after one month for the presence of transformation. 
Transformation was indicated by the visible growth of cells in clumps and the TCID50 was 
calculated as the effective dilution of plasma that inhibit 50% EBV transformation of B cells 
and also using the Reed and Muench calculator (Reed and Muench 1938). 
4.3.13. Neutralisation Assay 
EBV seronegative PBMC were used for the assay. Plasma samples from IM patients 
during infection and after recovery, along with age-matched healthy controls, were used 
for the assay. The plasma was heat-inactivated at 56°C for 30 min before the assay. Equal 
volume of 3-fold serially diluted plasma and 10 TCID50 of EBV B95-8 were mixed and 
incubated in 96-well round bottom plates at 37°C for 2 h. Four replicates of 50 µl, each of 
virus-plasma mixture, were then incubated with 50 µl of 1x105 cells/well for 1 h and the 
plates were centrifuged at 300 x g/5 min. The medium was removed and resuspended with 
200 µl of fresh medium (RPMI with 10% FCS) and plated in 96-well flat bottom plates. The 
medium was changed once every week, and after four weeks the effective dilution of 
plasma that inhibits virus transformation by 50% (EDI50) was calculated (Reed and 
Muench 1938, Moss and Pope 1972, Sashihara, Burbelo et al. 2009). 
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4.3.14. Pepmix EBV 
gp350 Pepmix (JPT Technologies GmbH) was dissolved in 40 µl DMSO and diluted 
in PBS as 1 µg/ml final concentration of each peptide, total of 224 peptides, per test for 
stimulating PBMC. The aliquots were made as one single aliquot per test and stored at –
20°C.  
4.3.15. Flow Cytometry of CD4+ T Helper Cells 
The phenotypic analysis of a population of circulating TFH cells in peripheral blood 
has been described by various recent studies. To evaluate the presence of these cells 
during EBV infection, PBMC from different stages of EBV infection were stained with 
surface markers, CD3–PE Cy7; CD4–Pacific Blue; CD45RA–AF700; CXCR5–FITC; 
CXCR3–APC and ICOS–BV421 and PD–1 PE, and the frequency of these cells was 
analysed by flow cytometry.  
4.3.16. Antigen-Specific CD4+ T Cell Expansion and Functional Analysis 
PBMC from healthy asymptomatic virus carriers and donors with a history of IM were 
used to prepare EBV MA-gp350 specific CD4+ T cells. This was done by pulsing 1–2x106 
PBMC with gp350 pepmix (JPT). The cells were incubated for 2 h at 37°C in a CO2 
incubator. The cells were washed once in R10 and mixed with another 2–4x106 cells and 
plated in a 48 well plate (2x106 cells/ well). On days 3, 5 and 7, interleukin (IL) -2 was 
added at a concentration of 20 IU/ml.  
On day 10, functional assay intracellular cytokine staining (ICS) was performed. ICS 
measured the ability of cells to express cytokines IFN-, TNF-and IL-21. The cells were 
stained with CD4-Pacific Blue, CD8- PerCPCy5.5 and CXCR5–FITC surface markers. The 
intracellular staining was performed after re-stimulation with gp350 pepmix in the presence 
of BrefeldinA/monensin (BD Biosciences) for 6 h. The cells were washed, fixed and 
permeabilised with cytofix/cytoperm (BD Biosciences) and stained with IFN--AF700, TNF-
APC, and IL-21 PE. The CD4+ T cell analysis was performed by flow cytometry and 
FlowJo software. 
4.3.17. Intracellular Cytokine Staining (ICS) and Cell Surface Marker Staining 
PBMC from IM patients were thawed and rested for 1 h in RPMI1640 with 10% FCS 
at 37oC. The cells were counted and distributed in a 96-well V bottom plate. The cells were 
stimulated by the addition of gp350 pepmix (JPT Technologies) overnight in the presence 
of golgiplug, Brefeldin A (BD Biosciences) to the final concentration of 1 µl/ml for 4–6 h at 
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37°C. The cells were washed and stained with surface markers, CD8- PerCPCy5.5, CD4-
Pacific Blue and incubated at 4°C for 30 min. The intracellular staining was performed after 
fixing and permeabilizing the cells using cytofix/cytoperm solution. Permeabilizing solution, 
10X solution diluted to 1X with deionized water, from BD Biosciences was used for 
subsequent washes and cells were stained for cytokines using IFN--AF700, TNF-APC 
and IL-21 PE and incubated at 4°C for 30 min. The cells were analysed by flow cytometry 
and FlowJo software. 
4.3.18. Cell Surface Marker Staining of IM Samples 
Phenotypic analysis of B-cells was done on PBMC by Flow Cytometry. Frozen PBMC 
stored in liquid nitrogen were thawed at 37°C, washed once in R10 and rested for at least 
one hour in a 37°C incubator. The cells were then counted and 500,000 cells/ well were 
used for surface antigen staining in a 96-well V bottom plate. The cells were washed twice 
in PBS/2% FCS and incubated with fluorochrome conjugated antibodies diluted in PBS/2 
% FCS for 30 minutes at 4°C. The cell surface markers were CD3-PE Cy7, CD4-Pacific 
Blue, ICOS-BV421, CXCR5-FITC and CXCR3-APC, CD8-PerCpCy5.5 and PD1-PE. The 
cells were washed twice in PBS/2 % FCS and fixed in 4 % paraformaldehyde. Data was 
acquired on FACS LSRII Fortessa and analysed using FlowJo software.  
 
4.4. RESULTS 
4.4.1. EBV MA-gp350 Purification and Quantification 
The recombinant gp350 used to measure B cell responses was expressed from 
Chinese hamster ovary cells grown in serum-free medium. The cells were grown to 80% 
confluence in serum containing DMEM/F12 medium, then moved to serum-free 
DMEM/F12 and cultured for several weeks. Truncated gp350 protein secreted into the 
medium was collected and concentrated using Amicon Ultracel-50K each week. The 
protein was then purified using conA sepharose column and eluted by increasing 
concentration of -D methyl glucoside. The presence of the protein was visualized using 
dot blot analysis, SDS-PAGE and western blotting. The presence of purified protein in 
different eluents after purification was checked first by dot blot analysis, and samples with 
the protein were pooled together and dialysed into PBS, followed by SDS-PAGE and 
western blot (Figure 4.1). 
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Figure 4. 1. EBV-membrane antigen gp350 purification 
SDS-PAGE and Western Blot analysis of the purification of EBV-MA gp350 expressed by CHO 
cells. The gp350 protein was purified using Con A Sepharose 4B column and visualized through 
coomassie blue staining and mAb EBV OT6.  
Panel A: Truncated gp350 expressed by CHO cells was collected from the supernatant and 
concentrated using Amicon Ultracel-50K. Different volume of the supernatant was run on a 6% 
SDS-PAGE gel to confirm the presence of protein. Precision Plus protein standards were used as 
markers and 5 µl (lane 2), 10 µl (lane 3) and 20 µl (lane42) protein were loaded on the gel. After 
electrophoresis, the gel was stained with coomassie blue and the presence and size of protein 
were confirmed. 
Panel B: Purified and concentrated EBV-MA gp350. Both gp350 and splice product gp220 were 
visible.  
Panel C: Western Blot analysis of purified gp350 protein run on a 6% SDS-PAGE with 5 µl (lane 1 
and 4), 10 µl (lane 3) and 20 l (lane 2) of protein loaded on the gel and transferred to a 
nitrocellulose membrane. The blot was then incubated with EBV-MA specific monoclonal antibody 
EBV OT6 and visualized with goat anti-mouse HRP and western lighting ECL.  
Protein concentration was estimated using Bradford assay, with an average yield of 1 
mg/ml per purification. The presence of endotoxin was ruled out by using a Toxin Sensor 
LAL detection kit. The level of endotoxin was found to be less than 0.1 EU/g of protein. 
4.4.2. Frequency of EBV-Specific Memory B Cells 
Observations in the previous chapter suggested that during acute symptomatic EBV 
infection, the B cell compartment is perturbed, with a reduction in total B cells and MBCs in 
PBMC, which was associated with the poor in vitro conversion of MBCs into ASCs.  To 
explore the impact this B cell dysfunction has upon EBV-specific B cell immunity, the 
kinetics of the gp350-specific memory B cell response was assessed. Longitudinal PBMC 
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samples from 15 patients with IM were stimulated for 6 days with the B cell mitogen 
cocktail, and then assessed for gp350-specific memory B cells by ELISpot.  
 
 
Figure 4. 2. B cell ELISpot analysis to EBV-MA gp350 and total IgG 
Representative ELISpot assay using in vitro-activated PBMC from donors at different stages of 
EBV infection.  PBMC were cultured for six days in the presence of an optimized mix of polyclonal 
mitogens. 300,000 cells/well and 3,000 cells/well were incubated overnight on ELISpot plates 
coated in triplicate with gp350 antigen and total IgG capture antigen, respectively. Mitogens induce 
the conversion of memory B cells to antibody-secreting cells, and each individual spot represents a 
single antibody-secreting B cell (gp350/IgG). The frequency of antigen-specific memory B cells 
was calculated as a percentage of total IgG secreting B cells.  
Panel A: PBMC from EBV-seropositive asymptomatic carrier and frequency of gp350 and total 
IgG-specific memory B cells. 
Panel B: ELISpot from EBV seronegative donor and frequency of gp350 and total IgG-specific 
memory B cells. 
Panels C, D, and E:  ELISpot assay using PBMC from longitudinal samples from a donor during 
recovery (20-50 days post infection) and post-IM (six months after infection). 
Figure 4.2 shows a representative ELISpot assay of gp350-specific and total IgG-
specific memory B cells using PBMC from asymptomatic EBV carriers, EBV-seronegative 
donors as controls, and a longitudinal sample from a donor during illness, recovery, and 
post IM. As expected, EBV-seronegative donors did not have EBV-specific memory B 
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cells.  As shown in the previous chapter, MBCs from acute IM displayed poor in vitro 
conversion into ASCs. Similarly, there was a significantly lower frequency of gp350-
specific B cells during acute IM (Figure 4.3A).  
 
 
Figure 4. 3. Frequency of 
EBV-specific memory B cells 
per 106 PBMC  
Compilation of B cell ELISpot data 
using EBV membrane antigen 
(EBV-MA) gp350 which induces 
virus neutralising antibody 
response, EBV viral capsid antigen 
VCA, which is non-neutralising 
viral antigen, and general control 
antigen Tetanus Toxoid TT.  
Panel A: Frequency of gp350-
specific memory B cells per 106 
PBMC with 11 acute IM samples, 
11 post-IM samples and 18 age-
matched asymptomatic virus 
carriers. 
Panel B: Frequency of VCA-
specific memory B cells with 8 
longitudinal samples during and 
post-IM and 15 age-matched 
healthy virus carriers. 
Panel C: Frequency of general 
antigen TT-specific memory B cells 
using 8 longitudinal samples and 
15 age-matched healthy virus 
carriers. 
The data are presented as 
mean+/_ SEM and statistical 
analysis for the longitudinal 
samples were calculated by 
Wilcoxon matched-pair analysis 
and the comparison between 
different groups by non-parametric 
Mann-Whitney analysis. The 
significant p values were **** 
p<0.0001, ** p<0.01 and *p<0.05. 
 
 
To control for potential changes in the total memory B cell compartment, 
commercially-available EBV viral capsid antigen (VCA), another structural antigen with no 
neutralising properties, was used as a control EBV antigen and tetanus toxoid as a general 
control antigen. Although not as significant, VCA and TT-specific ASCs were also reduced 
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during acute IM (Figure 4.3A, 4.3B), suggesting that the reduction in the size of the 
memory B cell compartment and poor in vitro conversion to ASCs was influencing the in 
vitro conversion of gp350, VCA and TT-specific MBCs into ASCs.  
 
 
Figure 4. 4. Frequency of 
EBV-specific memory B cells 
as a percentage of total IgG-
specific memory B cells  
Compilation of B cell ELISpot data 
using EBV antigens, gp350 and 
VCA, and control antigen Tetanus 
Toxoid TT normalised as the 
percentage of total IgG. 
Panel A: Frequency of gp350-
specific memory B cells per total 
IgG secreting memory B cells with 
15 acute IM samples, 15 post-IM 
samples and 18 age-matched 
asymptomatic virus carriers. 
Panel B: Frequency of VCA-
specific memory B cells with 10 
longitudinal samples during and 
post-IM and 15 age-matched 
healthy virus carriers. 
Panel C: Frequency of general 
antigen TT-specific memory B cells 
using 12 longitudinal samples and 
15 age-matched healthy virus 
carriers. 
The data are presented as 
mean+/_ SEM and statistical 
analysis for the longitudinal 
samples were calculated by 
Wilcoxon matched-pair analysis 
and the comparison between 
different groups by non-parametric 
Mann-Whitney analysis. The 
significant p values were **** 
p<0.0001 and *** p<0.001. 
 
The quantification of antigen-specific memory B cells using ELISpot assay is usually 
performed by normalising the antigen-specific memory B cells as the percentage of total 
IgG-secreting cells to account for B cell proliferation during the six day culture (Crotty, 
Aubert et al. 2004). Therefore to further explore changes in the B cell response during IM, 
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the frequency of gp350, VCA and TT-specific T cells was normalized as a proportion of 
total IgG-secreting cells. These observations demonstrated that patients with acute IM had 
a very low relative frequency of gp350-specific memory B cells when compared to age-
matched asymptomatic virus carriers (Figure 4.4A). The frequency of gp350-specific 
memory B cells only reached numbers comparable to asymptomatic virus carriers during 
convalescence. Conversely, the reduced absolute response to VCA and TT did not appear 
attributable to a lower frequency of antigen-specific cells as a proportion of total IgG 
secreting cells (Figure. 4.4B, 4.4C), and were more likely associated with the overall poor 
in vitro conversion of memory B cells. 
 
Figure 4. 5. Absolute count of EBV-
specific memory B cells per litre of 
blood 
Compilation of B cell ELISpot data using EBV 
antigens, gp350 and VCA, and control antigen 
Tetanus Toxoid TT using absolute count per 
litre of blood at the time of harvest.  
Panel A: Frequency of gp350-specific memory 
B cells per litre of blood with 9 acute IM 
samples and 9 post-IM samples. 
Panel B: Frequency of VCA-specific memory B 
cells with 8 longitudinal samples during and 
post-IM. 
Panel C: Frequency of general antigen TT-
specific memory B cells using 8 longitudinal 
samples during and post-IM. 
Statistical analysis for the longitudinal samples 
was calculated by Wilcoxon matched-pair 
analysis. The significant p value ** p<0.01. 
 
To confirm the lower frequency of gp350-specific B cells during acute IM, the 
absolute number of antigen-specific MBCs per litre of blood at the time of harvest was 
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calculated for samples where the whole blood count was available (Figure 4.5).  This 
analysis confirmed the low frequency of gp350-memory B cells during acute IM when 
compared to post IM samples (Figure 4.5A), and demonstrated no significant difference  in  
the frequency of VCA or TT-specific memory B cells during and after acute IM (Figure 
4.5B, 4.5C).  
4.4.3. gp350-Antibody Concentration in Plasma 
While ELISpot allows the quantification of EBV-specific memory B cells in peripheral 
blood, ELISA determines the presence and measures the amount of EBV-specific antibody 
titre in plasma produced by long-lived plasma cells. To see whether the frequency of 
gp350-specific memory B cells correlate with antibody levels in the plasma, the plasma 
samples from the same cohort of IM patients, during and after recovery, were used to 
measure gp350 antibody titre with ELISA (Figure 4.6).  
 
Figure 4. 6. Measurement of gp350-antibody titre 
gp350 ELISA was performed to see whether gp350 antibody titre in the plasma of donors at 
different stages of EBV infection correlated with frequency of memory B cells in their blood as 
measured by B cell ELISpot.  
Panel A: Data from 10 longitudinal IM samples and 10 age-matched healthy virus carriers 
measuring the gp350 total Ig antibody titre, which included IgA, IgM and IgG. 
Panel B: Data from 10 longitudinal samples from IM donors and 10 age-matched healthy virus 
carriers measuring the gp350 total IgG antibody titre which complements the ELISpot analysis. 
The data are presented as mean+/_ SEM. Statistical analysis for the longitudinal samples was 
done using Wilcoxon matched -pair analysis and comparison between different groups by non-
parametric Mann-Whitney analysis. The significant p values were **** p<0.0001 and ** p<0.01.  
Measures of total IgG and total Ig—aggregate of IgM, IgA and IgG—in longitudinal 
plasma samples from 10 patients during and post-IM were compared against those from 
age-matched asymptomatic latent virus carriers. Similar to the results obtained in the 
ELISpot analysis, a significantly lower gp350 response was evident during acute IM in both 
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total Ig titre (Figure 4.6A) and IgG titre (Figure 4.6B) when compared to the antibody titre 
post-IM or in age-matched asymptomatic virus carriers. 
To determine if reduced memory B cell response and plasma antibody levels 
correlated with severity of infection, the cohort of patients was divided based upon a 
clinical score of 4—6 or 0—3, then assessed for the number of gp350-specific memory B 
cells and gp350-specific antibody titre during and following resolution of acute IM. These 
observations revealed that there was no significant difference in the gp350-specific 
memory B cell response during acute IM, in the resolving phase during the first six months 
after IM, or in patients in long term recovery of more than 6 months after IM (Figure 4.7A). 
Similarly, there was no difference in gp350-specific IgG titre in patients with, mild or severe 
symptoms (Figure 4.7B).  
 
Figure 4. 7. Correlation of frequency of gp350-specific memory B cells and antibody 
titre with severity of infection 
SOI scores were assigned from 0–6 with a score between 0–3 classified as mild infection and 4–6 
as severe. The percentage of gp350-specific memory B cells to total IgG+ memory B cells by  
ELISpot (Panel A) and gp350-IgG titre by ELISA (Panel B) was found to be similar in both groups 
with low frequency during  acute IM and higher frequency  with disease resolution Post IM-
Recovery, 20-50 days after symptom starts (Post IM-R) as well as  Post IM long term carrier state, 
more than six months from start of symptom (Post IM-LT).The data are presented as mean +/-
SEM. 
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4.4.4. Quantity and Quality of Antibody Produced During Primary EBV Infection 
The conventional method to study the quality and quantity of neutralising antibody 
produced looks at the ability of antibodies to inhibit transformation of B cells by EBV. This 
assay was performed to confirm the ELISpot and ELISA data. Equal volume of 10 TCID50 
of EBV B95-8 and heat inactivated plasma samples from donors were mixed and 
incubated to let the antibodies in the plasma to neutralise the virus. This mixture was then 
incubated with susceptible PBMC from EBV seronegative donors for 3-5 weeks to 
determine the effective dilution of plasma that neutralise the virus.  
 
Figure 4. 8. Conventional EBV 
virus-neutralisation assay 
Efficiency of antibodies produced during 
and post IM to neutralise virus was 
compared between longitudinal plasma 
samples from IM patients and plasma 
from age-matched healthy virus carriers. 
The assay measures the ability of 
antibodies in plasma to inhibit EBV 
transformation of B cells. 
Panel A:  A representative well from 
neutralisation assay where antibodies in 
the plasma were not successful in 
neutralising the virus, as evidenced by 
EBV transformed B cells. 
Panel B:  representative well where 
antibodies in plasma efficiently neutralised 
virus, resulting in absence of EBV-
transformed B cells. 
Panel C: Compilation of data from all 
assays using 10 longitudinal IM plasma 
samples and samples from 10 age-
matched healthy virus carriers. 
Statistical analysis of the longitudinal 
samples was done by Wilcoxon matched-
pair test and comparison between 
different groups by non-parametric Mann-
Whitney test. The significant p values 
were *** p<0.001 and ** p<0.01. 
Figures 4.8A and 4.8B shows representative wells from the neutralisation assay where 
the antibodies in the plasma failed (Figure 4.8A) or succeeded (Figure 4.8B) in inhibiting 
the virus transformation of B cells, as evidenced by the presence or absence of EBV 
transformed B cells. The neutralisation assay used the plasma samples from 14 acute IM 
samples and 10 post-IM samples of which 10 samples followed patients during IM to their 
recovery > six months post-IM. Plasma samples from age-matched asymptomatic latent 
virus carriers and EBV seronegative donors were used as positive and negative controls in 
the assay. The neutralisation of the virus was below the detection level when using the 
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plasma from acute IM patients while the plasma from both the post-IM samples as well as 
asymptomatic virus carriers neutralised virus efficiently. This shows that the quality of virus 
neutralising antibody made from recovered IM patients and asymptomatic virus carriers 
are equally effective in neutralising the virus while the quality and/or quantity of 
neutralising antibody produced remained poor during acute IM (Figure 4.8C).  
Observations from the acute IM cohort suggest that gp350-specific B cell response in 
patients is poor during acute symptomatic EBV infection. These observations support 
findings from over forty years ago showing the delayed induction of neutralising antibodies 
to EBV and suggest that primary EBV infection is associated with the inefficient priming of 
gp350-specific memory B cells (Hewetson, Rocchi et al. 1973). Recent observations 
during other human viral infections have shown that assessment of the B cell repertoire 
during and post-infection can provide significant insight into the maturation of the antigen-
specific B cell response. These studies typically sorted either total ASCs, shown to be 
enriched for antigen-specific cells during acute infection, or cells stained with fluorescently 
labelled antigen, and then performed downstream B cell receptor and functional analysis 
on recombinant monoclonal antibodies. As outlined in the previous chapter, there was no 
evidence of an increase in ASCs during acute EBV infection, which would have provided a 
potential source of gp350-specific B cells during acute IM. Additionally, as determined by 
ELISpot assay, the frequency of gp350-specific B cells in both acute IM patients and 
healthy virus carriers was found to be very low, constituting typically < 0.1% of the total B 
cells. Since the frequency of gp350-specific B cells was so low, attempts were made to 
develop a protocol for the enrichment of the gp350-specific B cell population in order to 
isolate gp350-specific memory B cells to assess BCR usage and to generate monoclonal 
antibodies. From the literature, two methods to enrich rare memory B cells were obtained 
and tried (Figure 4.9). These methods involve labelling and sorting antigen-specific B cells 
by flow cytometry using fluorescently labelled or biotinylated antigen. The method to 
fluorescently label the antigen using Fluorolink Cy5 labelling Kit from GE (Potzsch, 
Spindler et al. 2011) was tried first.  
The CD19+ B cell population was sorted from the PBMC of healthy EBV seropositive 
and seronegative donors using CD19 microbeads and autoMACS separator, both from 
Miltenyi Biotec. To avoid selection of all B cells by labelled gp350 protein, the gp350 
receptor CD21 on the B cells was blocked by unconjugated anti-CD21 antibody before 
labelling with Cy5 labelled gp350 protein (Figure 4.9A). Panel 9A shows representative dot 
plot of control where no protein or no anti-CD21 antibody was added, B cells labelled with 
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Cy5 labelled gp350 without CD21 receptor block and B cell labelled with Cy5 labelled 
gp350 with CD21 receptor blocked with anti CD21 antibody respectively. The frequency of 
live cells that are Cy5+/CD19+ B cells was then quantified. While blocking with anti-CD21 
antibody reduced the gp350 binding to CD21 on B cells a significant amount of non-
specific binding was still evident. To improve on this protocol, a technique was developed 
using biotinylation of gp350 using the EZ-Link Pentylamine-Biotin from Thermo Scientific 
and using dual fluorescently labelled Streptavidin for flow cytometry. 
 
Figure 4. 9. Enrichment of gp350-specific memory B cells for generation of 
monoclonal antibodies. Structure of gp350 (Szakonyi, Klein et al. 2006) 
Two methods for labelling rare memory B cells are shown.  Panel A: First, fluorescently-labelled gp350 
protein was used to enrich gp350-specific memory B cells using fluorolink Cy 5 labelling kit. Representative 
FACS plot of PBMC with 5A as control without the addition of gp350 protein, with Cy 5 labelled gp350 
added, which resulted in all B cells being labelled since B cells express gp350 receptor CD21, and where 
unconjugated anti-CD21 was used to block CD21 receptor so that only gp350-specific memory B cells will be 
labelled by Cy5 labelled gp350 respectively.  
Panel B: Next, biotinylated gp350 protein was tetramerised using Streptavidin-PE, as well as Streptavidin-
APC. Frequency of gp350-specific memory B cells were gated as CD3
-
/CD14
-
/CD19
+
 B cells which are 
double positive for PE and APC. PBMC from both EBV seronegative and seropositive donors were used to 
evaluate the success of labelling. 
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Previous comparison of tetrameric and monomeric antigens showed tetramers to be 
more sensitive than monomers as the frequency obtained by tetramer labelling was larger 
than from monomers (Franz, May et al. 2011). Biotinylated gp350 was used to make 
tetramers using Streptavidin-PE and Streptavidin-APC. Tetramerisation of biotinylated 
gp350 was done on the same day as labelling to avoid degradation of the tetramer. The 
PBMC were stained by Live/Dead aqua followed by anti-CD21 antibody to block gp350 
receptor and stained with gp350 tetramers and surface markers, CD3, CD14 and CD19 for 
flow cytometry. The gp350-specific B cells were then analysed as live cells/CD3-/CD14-
/CD19+ B cells that are double positive for PE and APC. The aim of using dual colour for 
tetramers was to enrich the gp350-specific B cells and avoid non-specific binding. Analysis 
of EBV seropositive and seronegative donors showed that even though the blocking with 
anti-CD21 antibody worked it is not complete and significant non-specific binding can still 
be noticed with both fluorescent labelling and tetramer staining of B cells. This was made 
clear by the presence of double positive B cells in both seropositive as well as 
seronegative donors (Figure 4.9B). The low frequency of gp350-specific memory B cells 
and the added complication of gp350 receptor CD21 being expressed on all B cells made 
it difficult to specifically isolate gp350-specific memory B cells and this protocol was not 
pursued further.  
4.4.5. Circulating Memory CD4 Helper T Cells 
One of the classic features of IM is a temporary reversal of the CD4/CD8 ratio during 
acute IM (Hornef, Wagner et al. 1995, Maini, Gudgeon et al. 2000). This change is evident 
in the cohort of patients investigated in this study as shown in Figure 4.10.   
 
Figure 4. 10. CD4/CD8 ratio 
Characteristic temporary reversal 
of CD4/CD8 ratio during acute 
IM and the restoration of T cell 
homeostasis after disease 
resolution. Statistical analysis 
was done by one-way ANOVA, 
Tukey’s multiple comparison 
with *** p<0.001, ** p<0.01 and 
* p<0.05. 
 
These observations have suggested that the inflammatory response during IM is 
primarily mediated by CD8+ T cells, with a reduced contribution by CD4+ T cells and NK 
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cells (Tomkinson, Wagner et al. 1987, Balfour, Odumade et al. 2013). However, CD4+ T 
cells play an important role in regulating the induction and maturation of both the cellular 
and humoral immune response during viral infection (Hale, Youngblood et al. 2013). While 
T helper (Th1) cells are critical for the induction of cellular immunity, the humoral immune 
response is regulated by T follicular helper cells (TFH), a subset of CD4 T cells that help B 
cells (Nakayamada, Kanno et al. 2011, Whitmire 2011). Therefore to explore their role 
during EBV-infection, the frequency of TFH in the cohort of IM patients was assessed 
during and after IM. Although TFH are classically found in germinal centres in secondary 
lymphoid tissue, recent observations in a number of infectious settings have demonstrated 
populations of circulating memory TFH cells in peripheral blood, characterised by the 
expression of CXCR5, ICOS and PD1 (Haynes, Allen et al. 2007).  
 
Figure 4. 11. Frequency and 
phenotype of CD4+ T cell 
subsets during acute IM 
The frequency of CD4+ T cell 
subsets during and post IM were 
analysed. PBMC from donors at 
different stages of EBV infection 
was analysed by staining with 
surface markers CD4, CXCR5, 
CXCR3, ICOS and PD-1.   
Panel A: The data from donors 
during and post IM showing the 
percentage of CD4+/CXCR5+ T 
cells that express ICOS and/or 
PD1. 
Panel B:  The data from donors 
during and post IM evaluating the 
frequency of CD4+/CXCR3+ T 
cells that express ICOS and /or 
PD1. 
Statistical analysis was done by 
non-parametric Mann-Whitney 
test and the p value correspond 
to *** p<0.001. 
To assess the presence of circulating TFH during EBV infection (both primary and 
persistent), PBMC from donors during and post-IM were stained with CXCR5, ICOS and 
PD1.  PBMC were also stained with CXCR3 to characterise Th1 cells (Groom, Richmond 
et al. 2012). These observations revealed that during acute EBV infection there was no 
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increase in the frequency of circulating CD4+/CXCR5+/ICOS+/PD-1+ TFH cells (Figure 
4.11A), although there was a dramatic increase in the proportion of CXCR3+ICOS+PD1+ 
cells, which likely correspond to a population of activated Th1 cells (Figure 4.11B). These 
observations support the findings in the previous chapter showing no obvious induction of 
circulating ASCs during acute IM, and suggest that the induction of TFH cells may also be 
dysregulated during acute IM.   
4.4.6. Presence of gp350-Specific CD4+ T Cells 
To more specifically investigate the induction of CD4+ T cells responses during IM, 
next, the presence of gp350-specific CD4+ T helper cells in blood was investigated. 
Preliminary observations suggested that whole gp350 induced the non-specific 
proliferation of CD4+ T cells in both EBV-seropositive and EBV-seronegative donors, which 
supports previous studies by Hsiao, Lin et al that the binding of gp350 to CD21 receptor on 
the B cell activates the human endogenous retrovirus HERV–K18 env, which encodes a 
super antigen that can strongly stimulate T cells (Hsiao, Lin et al. 2006). Therefore, the 
study of CD4+ T helper cells during primary and persistent infection was performed using a 
gp350 pepmix of 15 mer peptides with 11 amino acid overlap. Intracellular cytokine 
analysis was performed to investigate the induction of IFN-, TNF- and IL-21 producing 
gp350-specific T cells.  
 
Figure 4. 12. gp350-specific CD4+ T 
cell response during acute IM 
Data from intracellular cytokine (ICS) staining 
of gp350-specific CD4 T cells. The cytokines 
produced after stimulation with gp350 pepmix 
(Panel A) and after stimulation with PMA and 
ionomycin (Panel B) for 12–16 h was studied 
in donors undergoing acute IM. The 
frequency of CD4 T cells that produce IFN-, 
TNF- and IL-21 are shown. 
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Acute IM samples showed very low expression of IFN- and TNF- from CD4+ T cells 
following stimulation with the gp350 pepmix (Figure 4.12A), suggesting poor induction of 
gp350-specific Th1 cells despite evidence of a dramatic expansion of Th1 cells during IM, 
which was also reflected in the strong IFN- and TNF- response following stimulation with 
PMA and Ionomycin (Figure 4.12B). Similarly, stimulation with gp350 showed very little 
activation of IL-21 production.  To determine if the poor CD4+ T cell response to gp350 
was also reflected in the gp350-specific CD8+ T cell response, CD8+ T cells from acute IM 
patients were also assessed for IFN-, TNF- and IL-21 production following stimulation 
with the gp350 pepmix.  Similar to CD4+ T cells, the response of CD8+ T cells to gp350 
was very low when compared to PMA and Ionomycin activated cells (Figure 4.13A &B).  
 
 
Figure 4. 13. gp350-specific 
CD8+ T cell response during 
acute IM 
Data from intracellular cytokine 
(ICS) staining of gp350-specific 
CD8+ T cells. The cytokines 
produced after stimulation with 
gp350 pepmix (Panel A) and 
after stimulation with PMA and 
ionomycin (Panel B) for 12–16 h 
was studied in donors 
undergoing acute IM. The 
frequency of CD8+ T cells that 
produce IFN-, TNF-α and IL-21 
are shown. 
To determine if the poor response to gp350 was preferentially associated with IM, the 
response in latent virus carriers with and without a history of IM was assessed. Due to the 
inability to detect ex vivo responses in PBMC, cells from donors with and without the 
history of IM were stimulated with the gp350 pepmix, cultured for 10 days in the presence 
of IL-2, and then analysed on day 10 after re-stimulation with and without gp350 pepmix 
for the production of IFN-, TNF- and IL-21. While there was evidence of a CD4+ T cell 
response to gp350, latent virus carriers with and without a history of IM showed very little 
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expansion of a gp350-specific T cell response, with a low frequency of IFN- TNF- and 
IL-21 producing CD4+  T cells detected after 10 days in culture (Figure 4.14A).  
 
 
Figure 4. 14. Characterisation 
of gp350-specific CD4/CD8 T 
cells during persistent EBV 
infection  
Data from intracellular cytokine 
(ICS) staining of gp350-specific T 
cells. The cytokines produced 
after stimulation with gp350 
pepmix was studied in healthy 
virus carriers, with (Post IM) or 
without (healthy carriers) 
symptomatic EBV primary 
infection. PBMC from donors with 
and without a history of IM were 
cultured for 10 days in presence 
of gp350 to expand gp350-
specific T cell lines. These cells 
are used to study the cytokine 
profile of gp350-specific 
CD4+/CD8+ T cells by flow 
cytometry. The frequency of 
CD4+/CD8+ T cells that produce 
IFN-, TNF- and IL-21 are 
shown. 
Panel A: shows the response to 
gp350 by CD4+ T cells using 
PBMC from donors post IM and 
asymptomatic virus carriers.  
Panel B: shows the response to 
gp350 by CD8+ T cells using 
PBMC from donors post IM and 
asymptomatic virus carriers. 
 
Additionally, no significant difference in the response from volunteers with and 
without a history of IM was evident. A similar response was also seen in CD8+ T cells; 
where the response to gp350 was even lower (Figure 4.14B). These observations suggest 
that gp350 is a poor immunogen for both CD4+ and CD8+ T cells, inducing very low 
frequency CD4+ and CD8+ T cell responses during acute EBV infection, which did not 
appear to improve in latent virus carriers.  
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4.5. DISCUSSION 
Study of humoral immune response during EBV infection has received very little 
attention. Neutralising antibodies provide protective immunity after most infections and 
vaccinations. They help control viral load during an active viral infection. In this chapter, 
our study of humoral immunity—the virus-neutralising antibody response during acute 
IM—showed a reduction in frequency of gp350-specific memory B cells, low gp350 
antibody titre in the plasma and a complete lack of virus-neutralising capabilities for 
antibodies produced during acute IM.  Our findings also revealed a lack of circulating CD4+ 
TFH cells during acute EBV infection, and demonstrated that gp350 appears to be a poor 
immunogenic target for CD4+ and CD8+ T cells. Lack of circulating TFH cells and poor 
immunogenicity of gp350 potentially contribute to the ineffective induction of a gp350-
specific neutralising antibody response during IM, and thus poor control of the virus during 
primary infection. 
EBV membrane antigen gp350 is found on the outer coating of the virus, as well as 
on the surface of EBV-infected cells (Pearson and Qualtiere 1978). gp350 is found in 
abundance during EBV infection and antibodies against it have the capacity to neutralise 
the virus (Hoffman, Lazarowitz et al. 1980, Moutschen, Léonard et al. 2007). Observations 
as far back as 40 years ago showed that EBV-neutralising antibodies are slow to appear 
during acute IM, with levels increasing and stabilising during convalescence, in contrast to 
non-neutralising responses to the viral capsid antigen that peak during the first few weeks 
of IM (Hewetson, Rocchi et al. 1973, Svedmyr, Ernberg et al. 1984).  We found evidence 
of very low gp350 response during acute IM, global dysfunction in the B cell 
compartment—as outlined in the previous chapter—and likely poor immunogenicity of 
gp350 contributing to inefficient virus neutralisation. Although it remains to be fully 
explained, the poor immunogenicity of gp350 may explain the differential kinetics of 
gp350-specific and VCA-specific B cell responses.  While some early efficient processing 
of the VCA antigen could promote an early antibody response to the EBV VCA, the poor 
processing of gp350 may restrict the induction of a virus neutralising response.  This 
delayed neutralising antibody response could be an immune evasion mechanism of EBV 
that facilitates the establishment of EBV persistence in the early stages of infection.  This 
lack of virus-neutralising antibody response also likely contributes to the increased viral 
load that ultimately leads to symptomatic IM and a global dysfunction in B cell response 
that may further complicate the induction of a neutralising antibody response.  This is 
supported by our findings and others that the establishment of an efficient neutralising 
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response does not occur well into convalescence, often many months after exposure.  
Unlike the massive expansion of CD8+ T cells during acute IM, CD4+ T cells do not 
increase in number but still play an important role in the control of EBV infection. CD4+ T 
helper cell subsets are reported to play a role in the control of early EBV infection and also 
during persistent infection (Nikiforow, Bottomly et al. 2001, Mackay, Long et al. 2009). 
CD4+ T cell subset (TFH cells) are also directly involved in humoral immune responses 
(Breitfeld, Ohl et al. 2000). These cells influence the formation of germinal centres, signal 
antigen-activated B cells via CD40L and provide cytokines IL-4, IL-10 and IL-21 to facilitate 
the growth and differentiation of B cells (Bryant, Ma et al. 2007, King and Mohrs 2009). 
Since TFH cells are mostly found in the secondary lymphoid organs, circulating memory 
TFH cells in blood were studied instead.  TFH cells (CXCR5
+ CD4+ T cells, (Haynes, Allen et 
al. 2007) were found to occur with low frequency, with resting phenotype and no 
detectable level of activated TFH cells as measured by the expression of ICOS and PD1 in 
the blood of IM patients. This is in agreement with the results from Aim 1 studies that 
showed no increase in ASCs and decreased number of memory B cells during acute IM. 
This suggests that despite the presence of high EBV viral loads, TFH cells do not persist, at 
least in the blood during acute IM, unlike during other human viral infections (Breitfeld, Ohl 
et al. 2000, Feng, Lu et al. 2011, Locci, Havenar-Daughton et al. 2013). This could also 
impact the efficiency of B cell differentiation into memory cells and ASCs.  
The majority of CD4+ T cell subsets found during acute IM were activated 
CXCR3+CD4+ cells, previously reported to be Th1 cells (Groom, Richmond et al. 2012). 
The frequency of activated Th1 cells decreased significantly with disease resolution, while 
a low frequency of resting memory Th1 cells remained during and post IM. Despite the 
obvious activation of a Th1 response, our data also showed that gp350 is a very poor T 
cell immunogen. There was very little cytokine production by CD4+ T cells when stimulated 
by gp350 as compared to control PMA and Ionomycin stimulation, and even in latent virus 
carriers there was very little activation of a gp350-specific response. Although the 
presence of gp350-specific Th1 cells has been reported (Adhikary, Behrends et al. 2006), 
this analysis required repeated in vitro stimulation with recombinant  protein to generate a 
gp350-specific response. Our data suggest that while gp350-specific responses are 
detectable they are sparse, even during the priming phase.  This could also be part of the 
immune evasion mechanism employed by EBV that makes gp350, abundant during EBV 
infection, a poorly-recognised antigen to host immune cells. This data further support the 
hypothesis that there is a defect in gp350-specific immune control during early infection. 
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CHAPTER 5. PERIPHERAL BLOOD DENDRITIC CELL (DC) 
DYNAMICS DURING ACUTE EBV INFECTION 
5.1. ABSTRACT 
Dendritic cells (DCs) are essential for the proper functioning of antiviral immunity and 
the development of the humoral immune response. They promote B cell differentiation 
directly through DC–B cell interaction and indirectly by providing cytokines and promoting 
the development of TFH cells, which are specialized CD4+ T cells that help B cells. 
Dendritic cells in blood are divided into two subsets: myeloid DCs or mDCs, and 
plasmacytoid DCs or pDCs. These DCs are activated by a different set of Pattern 
Recognition Receptor (PRR) ligands. Activated pDCs have the capacity to produce large 
quantities of type I interferons, especially IFN-, which is a key cytokine in the initiation of 
both innate and adaptive immune responses. Since dendritic cells and type 1 interferons 
are both directly involved in humoral immune response, studies in this aim sought to 
understand whether the impaired humoral immune response during acute EBV infection is 
due to a dysregulation of peripheral blood DC subsets. Ex vivo analysis revealed that the 
impairment of B-cell immunity during acute IM was coincident with a dramatic loss of 
circulating myeloid and plasmacytoid DCs, which recovered to baseline following 
convalescence.  Furthermore, in vitro studies showed that the loss of circulating DCs may 
be mediated by IL-10 which is consistently elevated in the plasma of acute IM patients. 
Most importantly, we demonstrated that the loss of circulating DCs is intrinsically linked to 
the impaired activation and maturation of antibody-secreting B-cells. Our findings show 
defective innate immune control during acute infectious mononucleosis, which could have 
an effect on humoral immune response. 
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5.2. INTRODUCTION 
Dendritic cells (DCs) belong to a group of antigen presenting cells (APCs) that 
include B cells and monocytes. They provide a link between the innate and adaptive 
immune systems. DCs reside in blood and peripheral tissues, constantly monitoring 
incoming pathogens. They are activated upon directly sensing pathogens, or by other 
innate lymphocytes (Kadowaki, Ho et al. 2001, Leslie, Vincent et al. 2002, Mocikat, 
Braumüller et al. 2003). The activation of DCs is known to both initiate and stimulate innate 
and adaptive immune responses (Lanzavecchia and Sallusto 2001, Ferlazzo, Pack et al. 
2004). DCs are unique in their ability to induce a primary immune response in naïve T cells 
and activate memory T cells by presenting processed antigens (Liu and MacPherson 
1993, Klechevsky, Morita et al. 2008, Banchereau, Thompson-Snipes et al. 2012). They 
present unprocessed antigens to naïve B cells and in so doing trigger humoral immune 
response (Wykes, Pombo et al. 1998, Huang, Han et al. 2005). They produce B cell 
activation factor BAFF, which is critical for B cell survival and growth (Schneider, MacKay 
et al. 1999, Liu, Stacey et al. 2012). DCs also promote immune tolerance and 
immunological memory (Brocker, Riedinger et al. 1997, Ludewig, Oehen et al. 1999).  
Blood dendritic cells are divided into two subsets: myeloid DCs (mDCs), also known 
as conventional DCs, and plasmacytoid DCs (pDCs). These two subsets have different 
origins, phenotypes and functions. Myeloid DCs develop from a myeloid progenitor, 
express CD11c and other myeloid markers, and secrete IL-12 when activated (Olweus, 
BitMansour et al. 1997). More recent studies have shown that mDCs and pDCs have both 
lymphoid and myeloid origins, and show flexibility in their development (Shigematsu, 
Reizis et al. 2004). Plasmacytoid DCs express CD123 and CD303; when activated they 
show a high capacity to produce Type I IFNs, especially IFN- (Siegal, Kadowaki et al. 
1999). Both subsets express different toll-like receptors (TLRs) and vary in their responses 
to different TLR ligands (Jarrossay, Napolitani et al. 2001, Kadowaki, Ho et al. 2001). 
While mDCs express many TLRs and can respond to a variety of ligands from pathogens, 
pDCs only express TLR 7 and 9 and specialize in recognizing bacterial and viral ligands 
(Kadowaki, Ho et al. 2001). 
The mDC and pDC populations are reduced during HIV, Hepatitis B and malaria 
infections (Feldman, Stein et al. 2001, Pacanowski, Kahi et al. 2001, Duan, Wang et al. 
2004, Pinzon-Charry, Woodberry et al. 2013). Chronic infection by HIV, hepatitis B and C, 
and human papilloma viruses also result in lowered production of IFN-by pDCs because 
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of impaired TLR signalling (Hasan, Caux et al. 2007, Gondois-Rey, Dental et al. 2009, Xie, 
Shen et al. 2009). HIV and malaria infection also cause an accumulation of immature DCs, 
which in HIV stimulates T cell tolerance rather than immunity (Krathwohl, Schacker et al. 
2006, Pinzon-Charry, Woodberry et al. 2013). Infection of DCs with influenza A virus can 
induce apoptosis. However, while mDCs are susceptible to influenza infection, pDCs 
exhibit resistance and may secrete large amounts of IFN- in response to infection 
(Thitithanyanont, Engering et al. 2007). It has been reported that in malaria infection a 
decrease in DCs expressing BAFF results in decreased memory cell differentiation to 
antibody-secreting cells (Liu, Stacey et al. 2012). 
Although the impact of EBV on DC numbers and function in vivo has not been 
thoroughly investigated, recent in vitro observations do suggest an interaction between 
DCs and EBV. DCs are known to cross-present EBV antigens from infected B cells to 
naïve T cells (Bickham, Goodman et al. 2003). EBV infection has been shown to result in 
increased apoptosis of monocytes and inhibit development of dendritic cells (Li, Liu et al. 
2002); and direct EBV infection of pDCs through MHC class II molecules is reported to 
impair cell maturation (Severa, Giacomini et al. 2013). Other observations reveal that the 
interaction of EBV with dendritic cells causes the production of large quantities of IFN- 
from pDCs in in vitro culture and also in the humanized NOD/SCID mouse model (Lim, 
Kireta et al. 2007, Quan, Roman et al. 2010). However, in contrast to these in vitro 
observations, studies of cytokines in the plasma of infectious mononucleosis patients have 
consistently found type I interferon IFN- to be absent, but other cytokines—including the 
other type I interferon IFN-—to be elevated (Linde, Andersson et al. 1992, Hornef, 
Wagner et al. 1995, Prabhu, Michalowicz et al. 1996, Balfour, Odumade et al. 2013). This 
led us to hypothesize that blood dendritic cells, pDCs in particular, are involved in 
symptomatic EBV primary infection IM since pDCs are the main producers of IFN- We 
concluded that studying dendritic cells in acute IM patients would provide insights into 
immune response during the early stages of EBV infection.  
Studies in this chapter investigated the role of dendritic cells during EBV infection, 
specifically during symptomatic primary EBV infection. The phenotype and frequency of 
peripheral blood dendritic cell subsets during and post IM were compared to the DC 
population in age-matched asymptomatic virus carriers. The data show a severe reduction 
in dendritic cell subsets during acute IM and their gradual recovery upon disease 
resolution. Since pDCs and the IFN- they produce are critical for the generation of 
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plasma cells and Ig production, this aim also provided insights into factors that could affect 
humoral immunity during EBV infection.  
5.3. MATERIALS AND METHODS 
5.3.1. Flow Cytometry 
The frequencies of DC subsets during EBV primary and persistent infections were 
measured using the four-colour dendritic value bundle from BD Biosciences. The DC 
subsets were stained in accordance with the manufacturer’s instructions. Lineage cocktail 
(lin1) in FITC included antibodies to surface markers CD3, CD14, CD16, CD19, CD20 and 
CD56. The two different subsets of peripheral blood dendritic cells (mDCs and pDCs) were 
identified. mDCs were characterized as populations expressing high levels of HLA-DR 
(PerCp) and CD11c (APC), while pDCs were characterized as HLA-DR high cells which 
express CD123 (PE) or CD123 (BV421). The data were acquired and analysed using flow 
cytometry and FlowJo software. 
5.3.2. In Vitro DC Culture 
For the in vitro culture of DCs, 1x106 PBMC were cultured in FACS tubes (BD Falcon, 
BD) to avoid cells adhering to the tissue culture plates. The cells were incubated in serum-
free OpTmizer medium from Invitrogen in the presence of IL-3 (20 ng/ml) and LPS (10 
ng/ml), both from R&D systems. The cells were grown for 24 h and used in various in vitro 
assays. 
5.3.3. In Vitro Infection 
PBMC (1x106) were cultured in FACS tubes (BD Falcon) to avoid cells adhering to 
the tissue culture plates. The cells were incubated in serum-free OpTmizer medium from 
Invitrogen in the presence of IL-3 (20 ng/ml) from R&D systems and EBV B 95-8. The cells 
were grown for 24 h and stained for DC subsets and apoptosis. 
5.3.4. Apoptosis (Annexin V Binding Assay) 
Annexin V binding assays were performed using the Annexin V kit from BD in order 
to determine the percentage of apoptotic dendritic cells. A live/dead marker—Live/Dead 
Fixable Aqua Dead Cell Stain (Life Technologies)—was used to distinguish between dead 
and apoptotic cells. PBMC were washed with 1X Annexin binding buffer (working 
concentration made by diluting one part of 10X Annexin V binding buffer provided in the kit 
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with nine parts distilled water), following staining with dendritic cell-specific surface 
markers. The cells were incubated with 1 µl Annexin V (PE) in 100 µl Annexin binding 
buffer for 15 min at room temperature in the dark. After incubation, 200 µl of 1X binding 
buffer was added to each tube and analysed by flow cytometry within 1 h of staining. 
5.3.5. Cytokine Influence 
To test the role of cytokines in the reduction of dendritic cells during infectious 
mononucleosis, PBMC from healthy donors were cultured in serum-free OpTmizer 
medium in the presence of IL-3 and LPS. First, cells were incubated with 50% vol/vol 
plasma from acute IM patients and age-matched asymptomatic virus carriers for 24 h, after 
which the frequency of DCs and percentage of apoptotic DCs were measured by flow 
cytometry. Next, various cytokines that are upregulated in infectious mononucleosis 
samples were added individually at concentrations of IL-4 (10 ng/ml), IL-6 (10 ng/ml), IL-10 
(500 pg/ml), IL-12 (10 ng/ml), IFN-  (100 u/ml), TNF-(50 ng/ml) and TGF- (10 ng/ml). 
Cytokines (R&D Systems) were added and the tubes incubated for 24 h in a 37oC 
incubator, then analysed by flow cytometry with dendritic cell-specific surface markers and 
Annexin V staining, both from BD. 
5.3.6. Migration to Lymphoid Organs 
The possibility of increased migration of blood DCs to lymphoid organs was tested by 
studying the expression of lymphoid homing marker CCR7.  The cells were incubated with 
CCR7 (AF 700) for 10 min at 4oC before incubating with DC-specific surface markers for 
another 20 min. DCs were then analysed for increased expression of CCR7 by flow 
cytometry.   
5.3.7. DC-B Cell Interaction  
PBMC (1x107) from healthy donors were used to confirm the requirement of dendritic 
cells for the conversion of memory B cells to antibody-secreting cells. Dendritic cells were 
depleted using DC-specific microbeads from Miltenyi Biotec following manufacturer’s 
instructions. The microbeads included CD304 (BDCA–4/Neuropilin–1) to deplete pDC and 
CD1c (BDCA–1), and CD141 (BDCA–3) to deplete mDC subsets. 10 µl of each antibody 
conjugated to biotin was incubated per 107 PBMC for 10 min in the dark in 100 µl buffer 
(PBS with 2 mM EDTA and 0.5% FCS). The cells were washed with 2 ml of buffer, after 
which 30 µl of anti-biotin microbeads were added before incubation for another 10 min. 
The cells were washed with 2 ml buffer and resuspended in 500 µl buffer for magnetic 
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separation using an autoMACS separator (the instrument and antibodies from Miltenyi 
Biotec).  
The instrument was prepared and primed in accordance with the manufacturer’s 
instructions. The sample tubes were placed at the uptake port, while fraction collection 
tubes were placed at port pos1 for the positive fraction (labelled) and port neg1 for the 
negative fraction (unlabelled) using the deletes program on the separator. The cells were 
then washed and resuspended in R10 containing an optimized mix of polyclonal mitogens 
for the conversion of memory B cells to antibody-secreting cells using whole PBMC, DC-
depleted PBMC, and DC-depleted PBMC with DCs reconstituted.  The conversion of 
memory B cells to antibody-secreting cells, with and without dendritic cells, was analysed 
by B cell ELISpot assay and flow cytometry after in vitro culture for six days. 
5.4. RESULTS  
5.4.1. Frequency & Phenotype of Blood Dendritic Cells during EBV Primary Infection 
In order to study the impact of EBV infection on circulating DC populations, 
phenotypic characterization was performed using the human DC four-colour assay kit as 
described in the Materials and Methods section. The blood DC population was identified in 
primary and persistent EBV infection as lineage-HLA-DR+ cells, which can be further 
divided into the two major DC subsets—the CD11c+ myeloid (mDC) and the CD123+ 
plasmacytoid (pDC) dendritic cells. The lineage cocktail included CD3, CD14, CD16, 
CD19, CD20 and CD56 antibodies conjugated to FITC for the elimination of T cells, 
monocytes, B cells and NK cells. PBMC from asymptomatically-infected latent virus 
carriers and individuals during and post-IM were analysed. Figure 5.1 shows the 
longitudinal analysis of a donor undergoing acute IM (top panel) and after recovery, post-
IM (> six months later, middle panel). Figure 5.1 also shows the gating strategy for human 
peripheral blood DCs (bottom panels) from a latent EBV carrier. 
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Figure 5. 1. Peripheral blood dendritic cells during EBV infection 
Seen here are representative dot plots obtained by flow cytometry of the gating strategy of 
peripheral blood dendritic cells from donors at different stages of EBV infection. The lineage-HLA-
DR+ DCs are further divided as its major subsets as defined by the expression of CD11c+ myeloid 
DCs (mDCs) and CD123+ plasmacytoid DCs (pDCs). Lineage markers eliminate T cells, B cells, 
NK cells and monocytes. Top panels show the frequency of dendritic cells in a longitudinal sample 
from a donor during and post IM, while the bottom panel shows the frequency of DCs from an 
asymptomatic virus carrier. DCs and their subsets are shown as the percentage of PBMC. 
A compilation of the data analysed from all volunteers at different stages of EBV 
infection is shown in Figure 5.2.  A significant reduction was noticed in the frequencies of 
both blood DC populations during acute IM. Gradual recovery in both pDC (Figure 5.2A) 
and mDC (Figure 5.2B) numbers was evident during convalescence, with numbers in long-
term patients similar to those seen in asymptomatically-infected individuals. Interestingly, a 
more profound loss was evident for pDCs, which was associated with a slower recovery in 
numbers during resolution of the infection.   
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Figure 5. 2. Frequency of DC subsets at different stages of EBV infection 
Panels A and B show the compilation of all data analysed from donors at different stages of EBV 
infection — 20 acute IM patients, 12 donors recovering from IM (20–50 days from the start of 
symptoms), 16 donors post IM (> 6 months from the start of symptoms), and 10 age-matched 
asymptomatic virus carriers. Panel A shows the frequency of pDCs, and Panel B shows the 
frequency of mDCs. The box plot shows mean, range and data points; statistical analysis was 
done by one-way ANOVA, Tukey’s multiple comparison with p values represent **** p <0.0001, ** 
p<0.01 and * p<0.05. 
Analysis of the absolute number of pDCs and mDCs also confirmed a significant 
reduction in peripheral DC populations during acute EBV infection (Figure 5.3A, 5.3B). The 
number of pDCs (A) and mDCs (B) was estimated based on the total PBMC count per litre 
of blood at the time of harvest. 
Next, the severity of illness (SOI) was correlated with reduction in dendritic cell 
frequency. Acute IM samples were scored for severity of illness. As mentioned in Chapter 
3, the SOI scores assigned to acute IM patient donors ranged from zero to six, with 
asymptomatic infection receiving a score of zero and severe symptoms requiring 
hospitalization or confinement to bed a score of six. The samples were grouped according 
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Figure 5. 3. Frequency of DC subsets 
in whole blood and correlation to 
severity of infection 
Acute EBV infection is associated with an 
absolute loss in the number of peripheral 
dendritic cell populations that is associated 
with the severity of disease. The number of 
pDCs (A) and mDCs (B) was estimated 
based upon the total PBMC count per litre of 
blood at the time of harvest. Panel C shows 
correlation between frequency of DCs and 
severity of infection. Acute IM patient 
samples from collaborators at the University 
of Minnesota were grouped according to 
severity of infection, with 0–3 classified as 
mild and 4–6 as severe, where a score of 0 
was assigned to donors with asymptomatic 
infection and a score of 6 to completely bed-
ridden patients. Statistical analysis was done 
by non-parametric Mann Whitney test and 
the p values correspond to ** p<0.01 and * 
p<0.05. 
to severity of infection, with scores 0–3 characterized as mild and 4–6 as severe. Samples 
from six donors with mild symptoms and nine donors with severe IM symptoms were 
analysed. The frequency of dendritic cell subsets in the samples was plotted against 
severity of illness of the respective patients. A direct correlation was observed, with loss of 
DCs, especially pDCs (Figure 5.3C), increasing as SOI scores increased. The number of 
circulating pDCs was significantly lower in patients with an SOI of 4-6. Although not at 
statistically significant levels, there was a trend towards a more severe reduction in mDC 
populations in patients with an SOI of 4-6. 
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5.4.2. Migration to Lymphoid Organs 
Circulating blood DCs are either immature DCs migrating from the bone marrow to 
peripheral tissue, or mature antigen-activated DCs migrating to lymphoid tissue to initiate 
an immune response (de la Rosa, Longo et al. 2003). One possible explanation for the 
loss of blood DC populations during acute IM is increased migration of DCs from blood to 
lymphoid tissues where they are required to initiate adaptive immune response during an 
acute infection. The expression of lymphoid homing marker CCR7 on blood DC subsets 
was used to determine whether these cells showed evidence of enhanced migration. 
Longitudinal samples from six donors during and post IM were analysed, along with six 
age-matched asymptomatic virus carriers. No significant difference in the level of CCR7 
expression on both pDCs (Figure 5.4A) and mDCs (Figure 5.4B) was evident during acute 
IM when compared with levels in the latent carrier state. This does not rule out the 
possibility of increased migration of blood DCs into lymphoid organs as the DCs 
expressing high CCR7 could have already migrated to lymphoid organs when symptoms 
first appeared. 
 
Figure 5. 4. Migration to lymphoid 
organs 
Differential expression of lymphoid 
homing marker CCR7 is measured as 
MFI in six longitudinal IM samples and 
six asymptomatic virus carriers in DC 
subsets. Panel A compares the MFI of 
CCR7 expression in pDCs. Panel B 
compares the MFI of CCR7 expression 
in mDCs. 
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5.4.3. Effect of Cytokines on the Survival of DCs 
As with many acute infections, IM is associated with increased plasma levels of many 
inflammatory and suppressive cytokines. Previous observations have suggested that some 
of these cytokines have a detrimental effect on the survival of DC populations during acute 
infection (Pinzon-Charry, Woodberry et al. 2013).  Therefore, to assess the impact of 
circulating plasma cytokines in IM patients on their DC subsets, PBMC from healthy 
donors were incubated with plasma from acute IM patients and with plasma from age-
matched asymptomatic virus carriers for 24 h. The cells were cultured in serum-free 
medium in the presence of IL-3, which is required for pDC survival, and the DCs were then 
induced to mature using LPS. Incubation with plasma from acute IM patients caused a 
marked loss of DCs in PBMC as compared to plasma from asymptomatic carriers (Figure 
5.5A). Furthermore, these cells also showed down-regulation of surface HLA-DR 
expression following incubation with acute IM plasma, which was more pronounced for lin-
CD123+ pDCs (Figure 5.5B) than in lin-CD11c+ mDCs (data not shown). A summary of 
data based on 10 acute IM patients and five latent virus carriers is shown in Figure 5.5C.  
 
Figure 5. 5. Effect of IM plasma on DC survival 
Blood DCs in the PBMC of healthy donors were cultured in serum-free medium and induced to 
mature with the addition of LPS and IL-3, which are required for pDC survival. The cells were 
incubated with 50% v/v of medium alone, plasma samples from asymptomatic virus carriers, or 
plasma from acute IM patients. The percentages of lineage-HLA-DR+ cells were then compared. 
HLA-DR expression and percentage of apoptotic cells were analysed by flow cytometry. 
Panel A shows the frequency of blood dendritic cells when incubated with medium alone, with 
plasma from asymptomatic virus carriers, and with plasma from acute IM patients. 
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Panel B shows comparison of HLA-DR expression between medium alone with acute IM plasma 
and medium alone with asymptomatic virus carrier plasma. 
Panel C is a summation of all data analysed from 10 acute plasma samples and 5 asymptomatic 
plasma samples comparing the MFI of HLA-DR expression on lin-CD123+ pDCs. 
Analysis by non-parametric Mann Whitney test; p values correspond to ** p<0.01 and * p<0.05. 
 
 
Figure 5. 6. Effect of cytokines in the survival of blood DCs  
Various cytokines upregulated in acute IM plasma were tested for their effect on the survival of 
DCs. Representative dot plots of a few cytokines tested are shown in Panel A. The cells were 
cultured in serum-free medium with LPS and IL-3, and various cytokines tested were added 
individually and incubated for 24 h, after which the frequency, HLA-DR expression, and percentage 
of apoptotic cells were analysed by flow cytometry. The frequency of DCs is represented as 
percentage of lymphocytes. 
Panels B and C show the percentage of apoptotic cells in mock (medium-alone) and hIL-10 added 
blood DCs, with Panel B showing percentage of annexin-positive pDCs and Panel 6C showing 
 99 
 
annexin-positive mDCs from 10 donors. Statistical analysis was done by non-parametric Mann 
Whitney test and the p values correspond to ** p<0.01 and * p<0.05. 
Panel 6D shows the representative histogram of HLA-DR expression when pDCs are incubated 
with hIL-10 and a representative histogram of HLA-DR expression when incubated with vIL-10, as 
a representative for all other cytokines that were tested, both compared to HLA-DR expression 
when cultured in medium-alone. 
Next, we tested the influence of individual cytokines elevated during acute IM to see 
whether any one of these cytokines, or a combination of them, could have caused 
dendritic cell loss. Antiviral, inflammatory and suppressive cytokines found elevated during 
acute IM were chosen for in vitro testing based on previously published findings by Balfour 
and colleagues (Balfour, Odumade et al. 2013). PBMC from healthy volunteers were 
cultured in serum-free medium in the presence of IL-3 and LPS, followed by incubation 
with IL-4, IL-6, IL-10 (human and viral), IL-12, IFN-, TNF-, and TGF-. Figure 5.6A 
shows a representative dot plot of the effect of a select cytokine on blood DCs. Of all the 
cytokines tested, the addition of hIL-10, but not viral IL-10, was found to result in the loss 
of dendritic cells (Figure 5.6A). An Annexin V binding assay was performed to determine 
whether the loss was due to apoptosis. While there was increased apoptosis with the 
addition of hIL-10 in both mDCs and pDCs, the loss of pDCs was greater than that of 
mDCs (Figure 5.6B, Figure 5.6C). A reduction in HLA-DR expression was also evident on 
pDCs with the addition of hIL-10. Figure 5.6D shows representative histograms of HLA-DR 
expression comparing hIL-10 treated PBMC versus mock-treated PBMC. 
5.4.4. Requirement of Dendritic Cells for Plasmablast (ASC) Formation 
Previous studies have shown the importance of both pDCs and mDCs in the efficient 
generation of ASCs (Jego, Palucka et al. 2003). Given the importance of dendritic cells in 
promoting humoral immunity, and the findings that global and EBV-specific B cell immunity 
are impaired during acute IM, the impact of DC depletion on the generation of ASCs was 
tested in vitro. PBMC were depleted of dendritic cells using microbeads specific for 
dendritic cell subsets: CD141, CD1c and CD303 (while CD141 and CD1c deplete mDCs, 
CD303 depletes pDCs). Figure 5.7A shows the efficiency of DC depletion using PBMC 
from a healthy donor. Then 1x106 untouched PBMC, PBMC depleted of DCs, and DC-
depleted PBMC with reconstituted DCs were cultured for six days using polyclonal 
stimulators. On the sixth day, total IgG-secreting cells were quantitated using ELISpot 
assay. Representative data from the ELISpot assay is shown in Figure 5.7B. The in vitro 
cultured cells were also assessed for the presence of CD3-/CD19+/CD20lo/CD27hi/CD38hi 
ASCs.  
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Figure 5. 7. Dendritic cell depletion and its effect on B cells 
Blood dendritic cells from the PBMC of healthy donors were depleted using DC-specific 
microbeads from Miltenyi Biotec. Panel A shows the DC population in PBMC from a healthy donor, 
top half, and effective depletion of DCs in the bottom half. 
In Panel B, a representative ELISpot analysis shows the conversion of memory cells to antibody-
secreting cells. PBMC, DC-depleted PBMC, and PBMC with DC reconstituted from a healthy donor 
were cultured with an optimised mix of polyclonal mitogens that convert memory B cells to 
antibody-secreting cells after six days (B-stim).  The frequencies of total IgG-secreting cells were 
analysed in these three PBMC. 
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A representative flow cytometric analysis is shown in figure 5.8.  These observations 
showed that the conversion of memory B cells to antibody-secreting cells and production 
of IgG were severely reduced in DC-depleted PBMC.  
 
 
Figure 5. 8. Phenotypic analysis of in vitro-activated PBMC with and without the 
presence of DCs  
In vitro activated PBMC, in the presence and absence of dendritic cells, were subjected to 
phenotypic analysis by flow cytometry. The frequencies of total B cells (CD3-/CD19+) and 
antibody-secreting cells (CD3-/CD19+/CD20lo/CD27hi and CD38hi) were calculated as a 
percentage of lymphocytes. The lymphocyte gate was extended to include the activated B cell 
blasts.   
The percentages of lymphocyte activation and total B cell numbers were significantly 
reduced in DC-depleted PBMC when compared to untouched PBMC and DC-depleted 
PBMC in which DCs were reconstituted (Figure 5.9A). The percentage of ASCs was also 
reduced significantly in DC-depleted cultures (Figure 5.9B), which was associated with a 
significant reduction in the number of IgG-secreting cells in DC-depleted populations 
(Figure 5.9C). DC reconstitution restored IgG-secreting cells following in vitro stimulation. 
To determine if B cells stimulated in the absence of DC showed evidence of increased 
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apoptosis, an Annexin V binding assay was performed. The percentage of apoptotic B 
cells in DC-depleted PBMC in culture was significantly higher when compared to 
untouched PBMC and PBMC in which DCs were reconstituted (Figure 5.9D). This data 
shows that DCs are required not only for the generation of antibody-secreting cells but 
also for B cell survival in culture.  
 
Figure 5. 9. Requirement of dendritic cells for antibody-secreting cell formation 
Compilation of total B cells (Panel A), antibody-secreting cells (Panel B) by flow cytometry, and 
total IgG-specific memory B cells as measured by ELISpot assay (Panel C) were quantified using 
PBMC, with and without dendritic cells. PBMC were cultured in the presence of polyclonal 
mitogens for 6 days (B-stim). The percentages of annexin positive B cells were compared between 
the different PBMC to quantify apoptotic cells by flow cytometry in Panel D. Statistical analysis was 
done by one-way ANOVA, Tukey’s multiple comparison and the p values correspond to 
****p<0.0001, ***p<0.001,  ** p<0.01 and * p<0.05. 
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5.5. DISCUSSION 
The role of dendritic cells during the early stages of EBV infection and during acute 
IM, is not well understood. The aim of this chapter, therefore, was to investigate the 
potential role of DC in the immune dysfunction that is evident during acute IM. The 
observations seen in this chapter demonstrated that in addition to dysfunction in the B cell 
compartment during acute EBV infection, patients show a dramatic loss in circulating DC 
populations. There was no evidence that this loss in circulating DCs was due to an 
increase in the expression of lymphoid homing signals, though it did appear to be 
associated with increased inhibitory cytokine levels, particularly of IL-10, which is known to 
affect DC function and survival. Importantly these observations also suggest a potential 
mechanism of B cell dysfunction in IM patients, by demonstrating a critical role for DCs in 
promoting B cell maturation into ASCs.  
The interaction of antigen-presenting cells with pathogens results in the initiation of 
both innate and adaptive immune responses (Banchereau and Steinman 1998). In vitro 
experiments and in vivo humanized mouse models show that pDCs and mDCs, the two 
blood dendritic cell subsets, are activated when dendritic cells interact with EBV (Lim, 
Kireta et al. 2006, Iwakiri, Zhou et al. 2009). This then leads to the production of Type I 
interferons, mainly IFN- from pDCs.  IFN- is a key cytokine in the initiation of both innate 
and adaptive immune responses. Various studies measuring cytokines upregulated during 
acute IM consistently show an absence of IFN- in the plasma of IM patients, although the 
levels of other antiviral, inflammatory and immune-suppressive cytokines appear elevated 
(Balfour, Odumade et al. 2013). Since pDCs are the main producers of IFN-, and 
considering the importance of IFN- in the development of humoral immunity, the 
frequency and phenotype of peripheral blood dendritic cells during primary EBV infection 
was studied.  
This is the first study to explore the fate of dendritic cells during EBV primary 
infection. Longitudinal comparisons during acute infection and after recovery with age-
matched controls showed a severe reduction in dendritic cell population, both pDCs and 
mDCs, during acute IM, with gradual recovery as the disease resolved. This loss of DCs, 
especially pDCs, likely accounts for the lack of IFN-found in the plasma of IM patients. 
Interestingly, the loss of pDCs was significantly greater and took longer to recover from 
than the loss of mDCs. This could suggest some prolonged dysfunction in the DC 
compartment following IM, although this possibility was not explored. However it is evident 
that disease severity is associated with the loss of circulating pDC populations, suggesting 
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that either the level of pDC loss is critical in the development of disease or that the 
increased viral load and other inflammatory changes that occur during IM impact upon 
pDC survival.  
Various studies have reported a decrease in the frequency of dendritic cells during 
viral infection. Viruses like HIV, HSV, measles and dengue can directly infect DCs and 
affect their frequency and function (Feldman, Stein et al. 2001, Marovich, Grouard-Vogel 
et al. 2001, Bosnjak, Miranda-Saksena et al. 2005, de Witte, Abt et al. 2006). A direct 
cytopathic influence of EBV on the survival of dendritic cells has not been found, even 
though in vitro experiments have shown that EBV can infect and impair pDC maturation 
(Severa, Giacomini et al. 2013). It has also been shown that EBV infection of monocytes 
results in their increased apoptosis and inhibits the development of monocyte precursors 
to dendritic cells (Li, Liu et al. 2002). While the mechanism responsible for the loss of DCs 
during acute IM has not been fully explained, it is evident that cytokines do play a role, as 
shown by in vitro observations that incubation with IM plasma and hIL-10 results in the 
loss of DCs. The effect of IL-10 on the survival of DCs has been reported in malaria as 
well, where prolonged exposure to IL-10 resulted in the loss of DCs by apoptosis (Pinzon-
Charry, Woodberry et al. 2013). In vitro experiments in this study, too, showed a reduced 
expression of HLA-DR when incubated with the plasma of IM patients or when incubated 
with hIL-10. However, this phenomenon of low HLA-DR expression was not seen in ex 
vivo experiments where the phenotype of blood DCs was studied in the PBMC of IM 
patients. 
Finally, to connect all three aims of this project, the requirement of dendritic cells in B 
cell activation and generation of antibody-secreting cells was assessed. The requirement 
of IFN- secreted by pDCs was reported to be essential for the production of Ig (Le Bon, 
Schiavoni et al. 2001, Jego, Palucka et al. 2003) while mDCs provide BAFF and APRIL as 
well as the IL-12 required for B cell survival and plasma cell differentiation respectively 
(Dubois, Massacrier et al. 1998, Litinskiy, Nardelli et al. 2002). Since both DC subsets 
were affected during acute IM and both are required for B cell survival and function, the 
DC-depletion study was done by depleting total blood DCs. DC-depleted PBMC showed 
less B cell activation and a reduction in ASC when compared to untouched PBMC, or 
when DC-depleted PBMC were reconstituted with DC. These findings indicate that 
dendritic cells are required for humoral immune response and that a defect in the DC 
population results in a reduction in the generation of antibody-secreting cells. Contrary to 
other published findings that  depletion of pDCs led to the cessation of Ig production but 
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not the death of B cells (Jego, Palucka et al. 2003), our results indicate  that depletion of 
both blood DC subsets affect Ig synthesis and the survival of B cells. Thus, defects in both 
innate and humoral immune responses could contribute to the immune dysregulation 
noticed in acute infectious mononucleosis.  
 The findings of this aim suggest that a loss of DC during the early stages of EBV 
infection contributes to symptomatic IM. Dendritic cells are important in the control of viral 
infection, as they are found in the periphery where pathogens enter the host. They can 
sense pathogens and alert the immune system. Because of this, many pathogens target 
dendritic cells as part of their immune evasion mechanism, but none has been found to be 
as profound as during symptomatic EBV primary infection IM. Since dendritic cells play 
both direct and indirect roles in humoral immune response, this defect could alter the 
humoral immune response to EBV. Further studies on the mechanism of the loss of 
dendritic cells could give insights into the dysregulation observed during acute IM and the 
role played by peripheral blood dendritic cells in this disease. 
 
  
 106 
 
CHAPTER 6. DISCUSSION AND FUTURE DIRECTION 
Delayed EBV infection causes infectious mononucleosis (IM) in more than 50% of 
infected adolescents and young adults. IM is an immunopathological disease, in which the 
symptoms result from an uncontrolled expansion of EBV-specific CD8+ T cells in some 
individuals. It is not known why some individuals are more likely than others to develop IM. 
The risk of developing IM increases with age, as does the severity of symptoms. The 
reasons for this age-specific severity of IM are not known. One possible explanation for 
this phenomenon is a concept termed heterologous immunity. This refers to T cell cross-
reactivity, where memory T cells specific to one virus get activated by an unrelated virus 
and in doing so alters the host’s immune response (Selin, Varga et al. 1998). CD8+ T cells 
specific to EBV lytic proteins have been found to cross-react with influenza-specific 
proteins (Clute, Watkin et al. 2005). Another possible explanation is the difference in the 
amount of virus received during primary infection. It is possible that a larger dose of virus 
is transferred between young adults during kissing compared to less invasive methods of 
infection during childhood. There is also a recent report that shows an imbalance in the 
CD8+Tcell differentiation during early life of mice. CD8+T cells predominantly differentiate 
into short lived effector cells with impairment in memory CD8+T cell formation (Smith, 
Wissink et al. 2014).  If this is true in humans, that could also explain the lack of 
immunopathology in young children during primary EBV infection.  
Although the disease is typically self-limiting, a history of IM is associated with an 
increased risk of developing EBV-associated Hodgkin’s Lymphoma and certain 
autoimmune disorders, including Multiple Sclerosis. Due to improved standards of living 
the incidence of IM is increasing, especially in developed countries (Tattevin, Le Tulzo et 
al. 2006). Certain similarities have been reported between IM and EBV-associated 
diseases. The presence of multinucleated cells, Reed-Sternberg cells, and increased 
susceptibility of individuals with HLA class 1 polymorphism was found in both IM and HL. 
Similar B cell profiles with loss of naive and memory B cells and an overexpression of V4-
34 encoded Ig, which is associated with autospecificity, were found in IM and autoimmune 
disease systemic lupus erythematosus (Mockridge, Rahman et al. 2004). The risk of MS 
was reported to last for 30 years after IM, and persistent immunological changes caused 
during IM were thought to be among the reasons for this increased risk (Nielsen, 
Rostgaard et al. 2007). Thus, primary EBV infection could be a factor that determines the 
risk of developing more serious EBV-associated diseases.  
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Protection against most pathogens requires the induction of long-lived plasma cells 
and memory B cells, the two arms of humoral immunity. The study of B cells during EBV 
infection so far focused on the establishment and maintenance of persistent latent EBV 
infection. So the objective was to understand humoral immune response to EBV, 
especially during IM. We first examined global B cell response to EBV infection. We found 
that unlike other acute infections—including malaria, dengue, hepatitis B and influenza, 
which are accompanied by an increase in memory B cells and ASCs (Bocher, Herzog-
Hauff et al. 1999, Weiss, Traore et al. 2010, Wrammert, Koutsonanos et al. 2011, 
Wrammert, Onlamoon et al. 2012)—acute IM causes a significant loss of MBCs and no 
increase in the frequency of ASCs. Similar to the published findings on one IM patient 
during incubation, acute IM and recovery (Svedmyr, Ernberg et al. 1984), our data show 
that the ability of memory B cells to respond to mitogen activation and Ig production are 
severely diminished during acute IM. The ability of memory B cells to convert to antibody 
secreting cells and/or the survival of plasmablast seem to be compromised during acute 
IM. This defect was not found to be a direct consequence of EBV infection, for in vitro 
infection with EBV followed by mitogen activation showed normal conversion efficiency 
and IgG synthesis. This suggests that other factors, such as virus-induced differential 
expression of cytokines, contribute to the survival and functioning of B cells. Increased 
expression of IL-6 and IFN- during acute IM has been reported to correlate positively with 
severity of infection (Balfour, Odumade et al. 2013, Dunmire, Odumade et al. 2014). 
Dunmire and colleagues also reported the lack of induction of nine interferon response 
genes during IM that are upregulated during various other viral infections. Other studies, 
too, have found a lack of IFN- production during acute IM (Hornef, Wagner et al. 1995, 
Prabhu, Warwick et al. 1996), which is important for the generation of  ASCs (Jego, 
Palucka et al. 2003). 
We next explored factors that could impact upon the survival of B cell subsets 
during acute IM. BAFF, B cell activation factor, and its receptor expression on B cells are 
crucial for the survival of B cells. Studies conducted in mice have shown that BAFF-BAFF-
R signalling is crucial to B cell homeostasis because it prevents apoptosis through various 
signalling pathways (Rauch, Tussiwand et al. 2009). The reduced expression of BAFF-R 
on IM B cells could have an effect on the survival of B cells. Similar to IM, other diseases 
that result from B cell dysfunction—like autoimmunity—show a significant increase in 
BAFF concentration in the plasma of patients (Sellam, Miceli-Richard et al. 2007, 
Kreuzaler, Rauch et al. 2012). The presence of excess BAFF in the plasma of patients 
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could be a marker for B cell dysfunction. BAFF homolog APRIL, which is reported to be 
important for the survival of long-lived plasma cells in bone marrow (Belnoue, Pihlgren et 
al. 2008), was reduced during acute IM; which could be a factor that affects plasma cell 
survival. During acute infection, B cells also were found to express increased levels of 
death receptor FAS and, in combination with BAFF dysregulation, this could compromise 
B cell survival.  
After studying global B cell function, our investigations turned to the quantity and 
quality of virus-neutralising antibody response during acute IM. Humoral immune response 
during acute IM showed a complete lack of virus-neutralizing antibodies, as measured by 
the ability of antibodies in the plasma of IM patients to neutralise the virus. The frequency 
of EBV-MA gp350-specific memory B cells, which could induce virus-neutralizing antibody 
response and gp350-antibody titre, was extremely low in patients with IM. The poor 
neutralising antibody response during acute IM could result in defective humoral immune 
control and increased viral load, as seen in IM patients. In addition, there was no 
detectable level of circulating memory TFH cells or gp350-specific TFH cells in the blood of 
IM patients.  EBV-MA gp350 was also found to be a very poor immunogen for both CD4+ 
and CD8+ T cells. While studies of peripheral blood have provided compelling evidence of 
dysfunction in the humoral immune response during acute EBV infection, the tonsils are 
the primary site of EBV infection and also one of the secondary lymphoid organs where 
the initiation of immune response occurs. Therefore, analysis of the humoral immune 
response, including the induction of gp350 immunity and TFH cells in tonsils, will likely 
provide further insight into the dysregulated responses during IM. Despite its abundance 
during acute infection, the lack of both a virus-neutralising antibody response and poor 
induction of gp350-specific T cell responses suggest that inefficient handling of the gp350 
antigen for presentation to both T and B cells may be an immune evasion mechanism of 
EBV that promotes the successful establishment of a persistent infection.  
The last aim of the project was to describe the function of dendritic cells during IM. 
DCs have long been known to play a critical role in the induction of both cellular and 
humoral immunity. Our data revealed a severe reduction in dendritic cell populations in 
acute IM patients compared to DCs in latent virus carriers. Among the two DC subsets, 
pDC loss was found to be far more severe than mDC loss, and pDC levels recovered at a 
much slower rate than mDCs. The direct correlation between frequency of DC subsets and 
severity of infection suggests a role for DC subsets in the development of IM. One 
mechanism by which DC loss may be contributing to immune dysfunction during IM is by 
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suppressing IFN- production, which is primarily produced by pDCs. Previous 
observations have shown that IFN-produced by pDCs is critical for the efficient 
differentiation of B cells into antibody-secreting plasmablasts (Le Bon, Schiavoni et al. 
2001, Jego, Palucka et al. 2003). Indeed, the observations in this study support this 
hypothesis, whereby it was demonstrated that DC depletion prevents the efficient 
generation of antibody-secreting cells and Ig production. It has been reported that IFN- 
secretion is required for the survival of pDCs in an autocrine manner (Kadowaki, 
Antonenko et al. 2000). Various proteins encoded by EBV have been shown to target the 
production of IFN-. EBV tegument protein LF2 and BZLF1 are two such proteins that 
inhibits the function of IRF7 which is required for the production of type I interferons (Hahn, 
Huye et al. 2005, Wu, Fossum et al. 2009). It is not clear whether the activities of these 
EBV proteins results in the reduced secretion of IFN- that contributes to the loss of pDCs 
or the reduced pDC number results in the reduced secretion of IFN-.  Although 
speculative, a plausible explanation is that the profound loss of DCs during acute IM may 
be contributing to the lack of efficient maturation of B cells into ASCs during acute IM in 
vivo, as evidenced by an absence of notable change in ASCs numbers in the peripheral 
blood of IM patients.  
Even though DCs influence the development of cellular and humoral immune 
response, the loss of DCs does not seem to diminish antibody response to VCA during 
acute IM, and the massive expansion of EBV-specific CD8+ T cells. It could be that the DC 
loss observed during acute IM is confined to the blood DC population and that tissue-
resident DCs are not affected to the same extent. Our data does not address the impact of 
the loss of blood DCs on the tissue specific DC pool during acute IM. It could also mean 
that the blood DC loss occurs after the initiation of both humoral and cellular immune 
response and is attributable to virus-induced environmental changes like prolonged 
exposure to elevated cytokine levels as found during malaria infection (Pinzon-Charry, 
Woodberry et al. 2013).   
 This study explored various reasons for the loss of pDCs. There was no evidence of 
increased migration of blood DCs to lymphoid organs, or cytopathic effects of EBV, either 
of which could have explained reduced blood DCs. We also tested, in vitro, the effect of IM 
plasma and various cytokines that are elevated during acute IM. The results showed DC 
loss when PBMC were incubated with IM plasma and a similar effect when they were 
incubated with hIL-10. There was also a decrease in HLA-DR expression on pDCs, which 
may not be relevant to IM as it was not found during ex vivo analysis of PBMC from IM 
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patients. Further studies are required to elucidate the mechanism responsible for pDC loss 
during acute IM. EBV infection could also result in other factors that affect the survival of 
DCs. EBV-encoded protein BARF1 could be one such factor that could play a role in the 
loss of DCs during IM (Cohen and Lekstrom 1999). The protein is produced during the 
early stages of EBV infection and was found to inhibit IFN- secretion by blocking colony-
stimulating factor 1 (CSF-1). Whether this protein could also block type I interferon 
regulatory genes and affect IFN- production remains to be explored. Studies into the role 
of BARF1 protein during EBV infection could shed light into the lack of IFN- secretion and 
DC loss.  
Different models have been proposed over the years to explain symptomatic EBV 
infection in adolescence and adults. Size of the viral load acquired during the initial 
infection was suggested as one factor that could cause IM. This was found to be validated 
in later studies where high viral load was found to correlate with severity of symptoms 
(Williams, Macsween et al. 2004). Genetic differences with polymorphism in cytokine 
genes such as IL-10 and IL-1 complex and variations in T cell response with HLA-A1 and 
HLA-DR polymorphism were also suggested as possible factors contributing to developing 
IM (McAulay, Higgins et al. 2007, Ramagopalan, Meier et al. 2011). Defective NK cell 
control in the early stages of EBV infection has been suggested as another factor for 
susceptibility to symptomatic EBV infection. A humanized mouse model depleted of NK 
cells was found to have severe IM symptoms and was prone to EBV-associated 
tumorigenesis (Chijioke, Muller et al. 2013, Azzi, Lunemann et al. 2014). 
The above models provide alternate explanations for the cause of IM. Based on the 
data from this study, we propose another possible model for immune dysregulation during 
acute IM. IM causes a severe loss of blood DCs especially pDCs which, in turn, results in 
the lack of IFN-, a key cytokine in the initiation of immune response. The absence of IFN-
, along with dysregulation in BAFF signalling, results in a poor virus neutralizing antibody 
response, reduces memory B cell formation, and no increase in antibody-secreting cells 
during acute IM. The outcome is an increase in viral load and uncontrolled expansion of 
CD8+ T cells, which contribute to the clinical symptoms of IM. A few steps in this model 
need clarification. The requirement of DC subsets for the survival and differentiation of B 
cells was confirmed by our findings during the DC depletion study and also in research 
undertaken by Jego and colleagues (Jego, Palucka et al. 2003). But the environmental 
changes taking place during incubation and in the early days of IM—which influence 
phenotypic changes in blood DCs and B cell subsets, and so affecting their survival—need 
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further study. Also requiring study are the differential expression of neutralising and non-
neutralising antibody responses, which cause the high viral load, and the massive CD8+ T 
cell expansion, which leads to symptomatic infection.   
This study was able to bring forth the defects in the innate and humoral immune 
responses that could contribute to symptomatic primary EBV infection, but the factors that 
bring about this change need to be identified. Future work arising from this study should 
include elucidating the mechanism of loss of dendritic cells, especially pDCs, during IM. 
The factors that affect the phenotypic changes in B cells, which result in very poor 
antibody production and reduced survival during acute IM, also need to be explained. 
These insights will give a complete picture of the immune dysregulation that causes IM.  
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